Asthma in electronic health records: validity and phenotyping by Nissen, FW
LSHTM Research Online
Nissen, FW; (2019) Asthma in electronic health records: validity and phenotyping. PhD
(research paper style) thesis, London School of Hygiene & Tropical Medicine. DOI:
https://doi.org/10.17037/PUBS.04653375
Downloaded from: http://researchonline.lshtm.ac.uk/4653375/
DOI: https://doi.org/10.17037/PUBS.04653375
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
   
 
 
Asthma in electronic health records: 
validity and phenotyping 
Francis Willem Nissen 
 
Thesis submitted in accordance with the requirements for the degree of 
Doctor of Philosophy of the University of London 
April 2019 
Department of Non-communicable Disease Epidemiology 
Faculty of Epidemiology and Population Health 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE 
 
Scholarship funding by GSK 
Affiliated to the LSHTM EHR research group  
Advisors: Dr Ian Douglas, Prof Dr Liam Smeeth, 
Dr Jennifer Quint and Dr Hana Müllerova 
2  
  
  
3  
  
Declaration page  
  
I, Francis Nissen, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been clearly 
indicated in the thesis.  
  
  
Francis Nissen 
Signature 
Date 
 
 
 
Use of published work 
 
Three papers have been published based on work undertaken for this thesis, the 
fourth paper is in press and the fifth paper is under peer review at the time of 
submission. Work for these papers were carried out as part of the PhD and took 
place during the period of registration for the PhD. For these papers, Francis Nissen 
was the lead and corresponding author, and prepared all protocols and drafts of the 
papers. The contributions of the co-authors were restricted to providing study 
advice and comments on the drafts prepared by FN.  
4  
  
Abstract  
This PhD thesis explores the validation of asthma in electronic health records (EHR) 
and the characteristics of asthma phenotypes in the UK using CPRD GOLD, HES and 
ONS data. The absence of a universal case definition, the overlap with other diseases 
and the incomplete recording of diagnostic markers makes the identification of 
asthma patients in EHR challenging. Furthermore, asthma phenotypes have 
previously been established based on cluster analysis in small populations, but their 
prevalence, treatment and outcomes in the general population have not been 
investigated. 
Firstly, I conducted a systematic review to understand how past epidemiological 
studies have validated asthma recording in EHR, including a critical appraisal and list 
of test measure values for the selected studies. 
Secondly, I validated algorithms to reliably ascertain the asthma status of patients in 
CPRD GOLD. This validation study identified multiple algorithms with PPV greater 
than 80%. The most practical algorithm (presence of a specific asthma diagnostic code) 
had a PPV of 86.4 (95% CI:77.4-95.4). 
Thirdly, I quantified the concomitant occurrence of asthma in COPD patients and vice 
versa in CPRD GOLD. After detailed case review, concomitant asthma and COPD was 
concluded in 14.8% of validated asthma patients and in 14.5% of validated COPD 
patients. However, asthma diagnoses may be unreliable in COPD patients, as over 
50% of COPD patients had received an asthma code.  
Finally, I examined the prevalence, treatment, outcomes and characteristics of 
established asthma phenotypes in CPRD GOLD. Only a minority of patients (37.3%) 
were classified into these phenotypes using stringent inclusion criteria. Exacerbation 
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rates/1000PY were lowest for benign asthma (106.8 [95% CI:101.2-112.3]), and highest 
for obese non-eosinophilic asthma (469.0 [95% CI:451.7-486.2]). 
In conclusion, this thesis provides information on the validation of asthma diagnoses 
in EHR and the prevalence, treatment, outcomes of predefined asthma phenotypes in 
the UK primary care population. 
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The only true wisdom is in knowing you know nothing.  
Socrates (470–399 BC) 
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Foreword  
This thesis is structured as follows: the first chapter describes the thesis background 
with an overview of asthma, electronic health records and asthma phenotypes, while 
the second chapter outlines the data sources used and the rationale for using them. 
The next four chapters are presented as a series of research papers, and the last 
chapter summarises and discusses the overall results. The research papers are 
presented as pre-print versions for ease of reading, and all references are numbered 
and presented at the end of each chapter. Code lists are included in the appendix of 
this thesis, and other supplementary information specific to a chapter is included at 
the end of each chapter. All included studies are or will be published using Open 
Access. 
All research papers presented in this thesis are my work (Francis Nissen). I designed 
the research protocols, obtained the ethical approvals and the data, and performed the 
data management, analysis and interpretation. I wrote the first draft of the 
manuscripts, and the final draft after incorporating the comments from the co-authors 
and advisors. The inclusion and bias assessment of the studies in the systematic 
review was simultaneously carried out by the author of this thesis and a second PhD 
student as the second reviewer (Samantha Wilkinson). The assessment of asthma and 
COPD status based on the questionnaires was carried out by one respiratory physician 
and one general practitioner familiar with the CPRD GOLD (Jennifer K Quint and 
Daniel Morales, respectively). The list of codes used in this thesis were developed by 
the author or, in the case of covariates, by collaborators at the London School of 
Hygiene and Tropical Medicine and Imperial College. Four papers included in this 
thesis have been published or are in print, the fifth is under peer review. 
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Chapter 1: Introduction  
Summary 
This chapter provides the background for the thesis, including an overview of asthma 
and electronic health records.  
The definition, history, diagnosis, epidemiology, treatment and pathophysiology of 
asthma are described, followed by an overview of asthma characteristics and 
phenotypes. Asthma is a complex multicomponent syndrome which involves the 
interactions between the individual patient and their exposure to the environment. 
The development and symptoms of asthma are affected by a myriad of different risk 
factors and protective factors, which are described in this chapter. Asthma can 
therefore not simply be defined or described, despite the considerable investments in 
asthma research. Asthma phenotyping by grouping patients according to 
characteristics can offer the opportunity to target specific therapies at patients who are 
most likely to benefit and develop appropriate therapies for patients who remain 
poorly controlled.  
Electronic healthcare records (EHR) and their use and limitations for asthma research 
are discussed in detail. The lack of a standard case definition for asthma, the absence 
of specific symptoms and the overlap with many other diseases render the 
ascertainment of asthma status in EHR difficult. 
The chapter closes with the overall aim and objectives of this PhD project. 
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1.1 Asthma: disease background 
1.1.1 Definition of asthma 
The Global Strategy for Asthma Management and Prevention 2018 guidelines from 
the Global Initiative for Asthma (GINA) define asthma as follows:(1) 
“Asthma is a heterogeneous disease, usually characterised by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough that vary over time and in intensity, 
together with variable airflow limitation.” 
Asthma constitutes one of the most prevalent non-communicable diseases in children 
and adults and affects people of all ages, all ethnicities and both sexes. The core 
symptoms (cough, wheeze, breathlessness and chest tightness)(2) are non-specific, 
and asthma is characterised by the pattern of these symptoms and their timings, the 
response to treatment, asthma triggers, and a variable expiratory airflow limitation 
which is generally reversible. The disease ranges in severity from milder attacks which 
can interrupt daily life and work productivity, to more severe and life-threatening 
attacks,(3) in which case it can greatly hinder the patient’s life and ability to perform 
regular activities and can even cause death. The few signs of asthma are also non-
specific: the clinician can look for expiratory wheezing and comorbidities such as 
obesity, bronchiectasis, eczema and allergic rhinitis to aid with the diagnosis of 
asthma. Asthma is innately variable, and therefore asthma patients can experience 
fluctuating symptoms. Figure 1 shows the difference between a normal airway and an 
airway during asthma symptoms. 
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Figure 1: Asthma pathophysiology. A shows the location of the lungs and airways in the body. 
B shows a cross-section of a normal airway. C shows a cross-section of an airway during asthma 
symptoms. www.nhlbi.nih.gov/health-topics/asthma. Work of the US Federal government; 
(public domain free from copyright restriction) 
There is widespread consensus that people who suffer from asthma should be offered 
medication based on a step-wise approach if they require pharmacological treatment 
and are under regular medical care. Mild asthma might only require few medications 
on a low dose, while severe disease will require more medications, often at higher 
doses. The current guidelines of the Global Initiative for Asthma,(3) British Thoracic 
Society (4) and National Asthma Education and Prevention Program(5) provide 
direction on the diagnosis and management of asthma. 
1.1.2 Asthma in history 
Asthma has been recognised before modern times, and the symptoms have been 
described in multiple ancient civilisations.(6,7) The word asthma itself is derived from 
the Greek ασθμα which translates as hard breathing, panting or death rattle.(8) In the 
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earliest records, asthma was used as a term to describe symptoms rather than a disease 
entity. Aretaeus of Cappadocia, an ancient Greek clinician living in the fourth century 
BC, attributed asthma to a “thick and viscid phlegm caused by coldness and humidity 
of the pneuma”.(9) He also noted that women were more susceptible to asthma, men 
were more likely to die of it, and children had better recovery chances.(10) 
Over the centuries, other authors have provided additions to the concept of asthma. 
Moses Maimonides (1135–1205) stated the need for clean air in asthma patients (11) 
and Gerolamo Cardano (1501–1576) noted the relationship between a lack of air 
quality and asthma.(8) 
Sir John Floyer (1649–1734) authored the first modern publication on asthma in 1698 
and documented the symptoms, triggers, treatment, and prevention of asthma.(12) 
Henry Hyde Salter (1823–1871) described key features of asthma and gave a more 
formal definition: ”paroxysmal dyspnoea with intervals of healthy respiration 
between attacks”.(13) He also stated that severe asthma can inflict permanent injury 
to the lungs.(14) However, Salter also viewed asthma as a psychosomatic disorder.(13) 
Towards the end of the nineteenth and the beginning of the twentieth century, 
clinicians started to recognise that asthma was associated with allergens and 
inflammation, and differentiated asthma from hyperventilation.(15–17) 
Francis Rackemann was one of the first to recognise the heterogeneity of asthma based 
on a series of studies conducted at the beginning of the twentieth century. He 
categorised asthma as either extrinsic (exposure to allergens, younger age) or intrinsic 
(associated with infection or stress, older age).(18–20) In the 1840s, Hutchinson,(21) 
used spirometry to show the association between asthma and a variable airflow 
obstruction in the 1840s while the FEV1/FVC (Forced Expiratory Volume in 1 second 
over Forced Vital Capacity) ratio as a measure for lung function was introduced by 
Tiffeneau in the 1940s.(22)  
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In 1958, Harry Morrow-Brown was the first to notice that systemic corticosteroids had 
efficacy in patient with clear eosinophils in their sputum smear, but that these 
corticosteroids were not effective in patients with less eosinophils in their sputum.(23) 
These finding were largely ignored over the following decades, but have resurfaced 
with the renewed interest in the heterogeneity of asthma.(24) 
In the mid-1960s, the treatment of asthma began to focus on airway 
hyperresponsiveness through the introduction of selective inhaled β2 agonists.(24)  
The use of these bronchodilators offered asthma patients more control over their 
symptoms and improved their quality of life. However, it was also associated with an 
increase in mortality and acute hospital admissions due to asthma(25,26); this was as 
a result of the over-reliance on inhaled β2 agonists and lack of anti-inflammatory 
medication such as corticosteroids.(27) 
This led to a treatment shift in the late 1980’s towards a more aggressive use of inhaled 
corticosteroids. Between 1990 and 2005, the increased use of anti-inflammatory 
medication led to a decrease in fatalities and hospital admissions due to acute asthma, 
in particular in children.(28) The combination of inhaled long-acting β2 agonists 
(LABA) and inhaled corticosteroids (ICS) has resulted in better outcomes for many 
patients.(29,30) However, there is no clear evidence of a correlation between airway 
hyperresponsiveness and inflammation.(31,32) Recently, new medications have 
become available, such as monoclonal antibodies.(33) However, there has not been a 
great deal of progress in key asthma outcomes including preventable deaths since 
2002 as the combination of LABAs and ICS is still the basis of most guidelines.(28) The 
current treatment guidelines are expanded upon in a later section of this chapter. 
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1.1.3 Diagnosis of asthma 
The diagnosis of asthma depends on the identification of a pattern of symptoms and 
the absence of an alternative explanation for those symptoms. There is no universal 
case definition for the diagnosis of asthma. Asthma diagnosis is based on probability, 
symptoms and a variable expiratory airflow limitation. When asthma is suspected, the 
variable expiratory airflow limitation should be confirmed by use of spirometry and 
a trial of treatment.(4) In asthma patients, the expiratory airflow typically falls outside 
the normal range and the FEV1/FVC should be less than 75-80% of the value predicted 
taking into account the patient’s age, sex, height and race in at least one measurement 
to confirm a diagnosis of asthma in adults.(4) For children, the FEV1/FVC should be 
less than 90% of the predicted value. A reversibility test is positive if the FEV1 
increases by more than 12% or 200mL after administration of a short-acting β2 agonist 
in adults, or more than 10% in children. The reversibility of airflow obstruction after 
bronchodilator treatment is the most commonly used test; however, the validity of 
this test has never been addressed, and it provides no information on the underlying 
inflammation.(34) Other tests are the bronchial challenge test and exercise challenge 
test, but they are difficult to do correctly in primary care, and a negative test does not 
rule out asthma.(35) The use of exhaled nitric oxide (FeNO) to diagnose asthma is 
controversial. The current British Thoracic Society (BTS) and Global Initiative for 
Asthma (GINA) guidelines do not recommend using FeNO measurements to 
diagnose asthma, while the National Institute for Health and Care Excellence (NICE) 
guidelines endorse it.(3,4,36,37)  
FeNO and blood eosinophilia are independent markers of preventable risk in 
asthma,(38) but these markers cannot predict the severity of the underlying asthma 
on their own, unlike markers in many other chronic diseases. Some degree of 
inflammation is present in mild intermittent asthma, and asthma exacerbations can 
continue even when the inflammation is suppressed (see section 1.1.7 for a more 
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detailed discussion of exacerbations).(39) Uncontrolled symptoms increase the risk of 
exacerbation, but several other common non-symptom risk predictors exist.(40) These 
predictors encompass short-acting β2 agonist (SABA) overuse, a lack of inhaled 
corticosteroid use, smoking, low lung function, allergies and allergen exposure, viral 
infections of the upper airways, psychological or socioeconomic troubles, drug abuse, 
comorbidities including obesity and rhinitis, and high eosinophil counts in blood or 
sputum. 
1.1.4 Epidemiology of asthma 
According to the current estimates of the Global Burden of Disease Study 2015, 358 
million people worldwide had asthma and 400,000 people died due to asthma in 2015, 
with a wide variation in prevalence between different countries around the world.(41) 
However, the prevalence of asthma also depends strongly on the exact asthma 
definition that was used. The International Study of Asthma and Allergy in Children 
(ISAAC) and the European Community Respiratory Health Survey have developed 
questionnaires to assess asthma in the early 1990s.(42–44) These studies showed very 
large fluctuations in asthma prevalence around the world, with a high prevalence in 
English-speaking countries and a lower prevalence in developing countries. 
Asthma prevalence is lower in girls than in boys, but is 20% higher in women than in 
men.(45) The high prevalence in boys is thought to be partly due to smaller airways 
at a young age, genetic and hormonal factors, and differing comorbidities between the 
sexes.(46) Most commonly, asthma emerges during childhood, but it can also arise 
during adulthood. Therefore, adult asthma in adults can be either persistent/relapsed 
childhood disease or true incident adult disease. With the right treatment, symptoms 
can usually be managed and asthma patients can lead their lives without 
disruption.(2) 
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The prevalence of asthma is probably underestimated in developing countries, as 
patients do not have easy access to healthcare and asthma medications might not be 
available. Migration studies examining migrants from low-prevalence to high-
prevalence countries have been conducted.(47) Asthma prevalence is lower in 
migrants than in natives of the host country, but it rises with increasing length of 
residence. 
The prevalence of asthma is stable or decreasing in most developed countries with a 
high socio-demographic index such as those in Western Europe, but increasing in 
most low-to-middle socio-demographic index countries such as those in Sub-Saharan 
Africa.(48) Asthma  continues to impose a high burden on healthcare systems in both 
primary and secondary care.(41,48) While the global prevalence of asthma has 
increased, the global mortality rate of asthma has decreased between 1990 and 
2015.(41) Asthma places a significant cost on society through loss of productivity, both 
because workers are themselves affected by asthma, and because workers might be 
caring for children suffering from asthma.(49) Frequent exacerbations generally reflect 
poor asthma control, which is reflected in a lower quality of life and in loss of 
productivity in the workplace.(50) 
Asthma is a major public health issue in the UK, and has a high impact on patients, on 
healthcare resources and on the wider economy. In the UK, 5.4 million people are 
currently receiving treatment for asthma of whom 4.3 million are adults,(51) and each 
year 12.7 million working days are lost due to illness. The direct NHS healthcare 
expenditure on asthma is more than 1 billion GBP annually,(52) and each day three 
people die in the UK due to their asthma.(51) The condition accounts for over 65,000 
hospital admissions and 1,000 deaths annually.(53) 
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1.1.5 Pathophysiology of asthma 
Asthma results from a chronic inflammation that narrows airways. This narrowing 
follows a contraction of the smooth muscles around the airways and a build-up of 
mucus. In some people, asthma attacks happen while they are exposed to a certain 
trigger, while there is no obvious cause in other people. Common triggers are tobacco 
smoke, dust mites and pollen.(4) Asthma is often worse at night and during the 
morning.(3) While most asthma episodes are relatively benign, there is a serious risk 
when the required oxygen cannot be supplied to the tissues, which results in 
hypoxaemia.(54) Prevalence of comorbidities (among which gastro-oesophageal 
reflux, recurrent respiratory infections and psychological disorders) are particularly 
high in patients with severe asthma, and may be detrimental to asthma control in 
those individuals.(55,56) 
The causes of asthma are a combination of complex and incompletely understood 
genetic and environmental factors.(57) The endotypes (underlying mechanisms) and 
phenotypes (observable characteristics) of asthma are complex and result from 
multiple interactions between host and environment. These interactions occur 
between genes, cells, tissues and organs at different times. The endotypes describe a 
subtype of the disease based on intrinsic distinct pathogenic mechanisms, on a cellular 
and molecular level. Many different genes have been implicated using genome-wide 
association studies, including polymorphisms for IL33, HLA-DQ, SMAD3 and 
IL2RB.(58) The endotypes and genetics of asthma fall beyond the scope of this project, 
whilst the phenotypes are described further in this chapter. The environmental factors 
include allergens, air pollution and other airborne chemicals.(59) The hygiene 
hypothesis attempts to explain the increasing rates of asthma as a result of the reduced 
exposure to bacteria and viruses during childhood due to societal development;(60) 
however, this hypothesis is controversial and largely superseded.(61) 
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1.1.6 Treatment of asthma 
The main goal of asthma treatment is to attain asthma control: to minimise both the 
symptom burden and the risk of adverse outcomes (exacerbations, airflow limitation 
and side-effects of the medication).(62) The treatment of asthma is personalised and 
includes pharmacological treatment, education, a written asthma management 
plan,(63) inhaler training,(64) minimisation of risk factors, management of 
comorbidities and further non-pharmacological treatment.(3) The treatment should be 
regularly assessed and adjusted based on symptom control, risk factors, 
comorbidities, side-effects and patient satisfaction. Asthma attack prevention through 
a healthy diet, exercise, smoking abstinence and trigger avoidance are non-
pharmacological interventions that may be enough for patients with mild asthma. 
There is some evidence for further non-pharmacological treatment of asthma 
including nocturnal temperature-controlled laminar flow and add-on allergen 
immunotherapy.(65,66) The decision-making process should be shared with the 
patient to improve outcomes.(67) 
BTS guidelines 
The pharmacological treatment recommended by the British Thoracic Society (BTS) 
and the Global Initiative for Asthma (GINA) is stepwise.(3,4) The exact treatment 
steps differ slightly by guideline; however, for the purposes of this thesis, the BTS 2016 
guidelines for adults are used. The treatment steps in the figure below (Figure 2) are 
included in the BTS 2016 guidelines and are used for the cohort study included in 
Chapter 6 of this thesis.  
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Figure 2: Summary of asthma management in adults. This figure is reproduced from BTS/SIGN British Guideline on the management of asthma by 
kind permission of the British Thoracic Society. British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN). British 
Guideline on the management of asthma. Edinburgh: SIGN; 2016. (QRG 153). [cited 13 08 2018]. Available from URL: http://www.sign.ac.uk 
 
In adults, treatment step 1 is defined by either no maintenance treatment or non-
regular treatment with inhaled corticosteroids (ICS). Step 2 includes repeat low-dose 
ICS, step 3 adds an inhaled long-acting β2 agonist. Step 4 introduces a trial of 
leukotriene receptor antagonists, theophylline or long-acting muscarinic antagonists 
(LAMA). Step 5 increases the ICS dose. Step 6 includes the usage of oral 
corticosteroids, which should be minimised due to their systemic side effects. 
Additional treatment that can be considered in step 6 are add-on anti-
immunoglobulin E (anti-IgE) treatment such as omalizumab, anti-interleukin-5 (anti-
IL5) treatment such as mepolizumab/reslizumab, or bronchial thermoplasty. 
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Asthma medication classes 
Inhaled corticosteroids and β2 agonists are the pillar of the pharmacological treatment 
of asthma. Bronchial inflammation is managed by ICS to prevent exacerbations and 
breathlessness is relieved by β2 agonists through bronchodilatation. Prescribed β2 
agonists are either short-acting (SABA) or long-acting (LABA). SABA use is for quick 
relief and is not included in the maintenance treatment steps. On the other hand, 
LABAs tend to act slower and are included in these treatment steps. 
Leukotriene receptor antagonists are considered less effective than ICS to treat 
inflammation, but may be an option for patients unable or unwilling to use ICS.(68) 
Theophylline in sustained-release medications has only weak efficacy and side effects 
are common.(69,70) Chromones such as nedocromil sodium and sodium 
cromoglycate have weak efficacy and are burdensome to use, but have a safer profile 
compared with theophyllines.(71) LAMA can be used as an add-on therapy in patients 
at risk of exacerbations, as it modestly improves lung function and increases time to 
severe exacerbation.(72) Anti-IgE treatments or anti-IL5 treatments are reserved for 
patients with refractory asthma, partly due to their costs.(32,73–78) Oral 
corticosteroids may be effective for adults with severe asthma, (36) but often have 
severe side-effects.(79,80) Other immunosuppressant medications, including 
ciclosporin or methotrexate, are not recommended.(36) There is only limited evidence 
on the effectiveness of bronchial thermoplasty.(36) The roles of macrolide antibiotics 
and antifungal therapy in asthma remain unclear, as there is no conclusive 
evidence.(36,81,82)  
There are some emerging therapies that show promise, including benralizumab (an 
anti-IL5 antibody) (83) and fevipiprant, a prostaglandin D2 type 2 receptor 
antagonist.(84) Studies on IL-13 antibodies have been discouraging,(85,86) but a 
monoclonal antibody targeting both IL-4 and IL-13 (dupilumab) has shown potential 
in a clinical trial.(87) In general, new medications for refractory patients are considered 
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the greatest unmet need in asthma. However, from a public health perspective, 
effective preventative treatment would be more beneficial.(62) 
Many controversies in the optimal treatment of asthma persist, such as whether 
SABA-only treatment should be the initial treatment for asthma, what the criteria for 
ICS start-ups are and how seasonal asthma should be treated.(62) 
1.1.7 Asthma exacerbations 
Asthma exacerbations, also known as asthma attacks or flare-ups, are (sub)acute 
episodes with increased symptoms. Patients with an acute exacerbation show 
increasing shortness of breath, wheezing, chest tightness, cough, and reduced lung 
function. The onset time varies and an exacerbation can develop for over more than a 
week in adults. Asthma exacerbations are expensive to treat, affect quality of life (88) 
and can be lethal in rare cases.(89) Asthma exacerbations are triggered by multiple 
different contributing factors, including infections, allergens, atopy, pollution, 
environment and comorbidities. In about 80% of exacerbations, a respiratory virus 
infection is one of the causes.(90) 
There is some controversy on the use of the word exacerbation, as it allows for 
multiple different interpretations.(76,77) It has been suggested that the word 
exacerbation should only be used to describe asthma with poor prognosis that 
requires immediate attention.(62) 
1.2 Asthma phenotypes 
1.2.1 Background 
Asthma is a heterogeneous disease, this heterogeneity is evident by the existence of 
observable clusters called asthma phenotypes. A phenotype is defined as the set of 
observable characteristics of an individual resulting from the interaction of its 
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genotype with the environment.(93) These phenotypes refer to a pattern of observable 
characteristics, without regard to the underlying pathophysiology. There are many 
characteristics that can construct asthma phenotypes including inflammatory 
profiling based on leucocyte counts (eosinophils, neutrophils and paucigranulocytic), 
age-of-asthma onset, and airflow measurements.(94–100) Some characteristics may be 
clinically recognised, for example asthma may be induced by infection, exercise or 
might be caused by obesity or menstruation. They can also be defined by the 
frequency of exacerbations, or be more complex and only definable in laboratories or 
specialised secondary care. 
The exact demarcation of potential phenotypes is not well defined in the literature, as 
there is no universally accepted asthma phenotype categorisation. There have been 
multiple studies describing asthma phenotypes, involving populations with asthma 
alone (101–110), or as part of an entity called “obstructive airways disease” together 
with COPD.(111,112) Classifying asthma into phenotypes can allow one to 
deconstruct the disease into separate identifiable traits (94) and better understand the 
disease progression and its response to treatment, which further enables the practice 
of precision medicine.(113) In particular, phenotyping may be useful in providing 
long-term prediction of outcomes and determining the effects of specific treatments 
for selected phenotypes.(113)The classification by eosinophil levels can be particularly 
meaningful due to a difference in treatment response.(114–116)  
 Patients with asthma can present with a range of different clinical histories, 
physiological changes on spirometry and airway inflammation. There are multiple 
ways to define these phenotypes. For example, it is possible to determine them based 
on the severity of asthma (103) or to use cluster analysis on a cohort to identify related 
groups for analysis.(101) 
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1.2.2 Characteristics associated with asthma 
Currently, there is no consensus on the classification of asthma phenotypes. In this 
thesis, the term phenotype is used to describe a set of characteristics that can be 
observed in the population. Regardless of how phenotypes are defined, phenotypes 
consist of a set of characteristics which can be divided in specific clinical, demographic 
and pathophysiological characteristics. For the purposes of this PhD project, 
phenotypes are constructed based on the characteristics for asthma in the table below. 
Some of these characteristics could be defined as phenotypes themselves (like 
eosinophilia), while others can be regarded as essential components of larger 
phenotypes. The next section will focus on the specific characteristics which shape the 
different phenotypes, regardless of the exact delimitations of these phenotypes. 
   
Clinical Potential relation to asthma Prevalence(117) References 
Severity Asthma severity is mostly based on received treatment.  (1) 
Atopic eczema Similar aetiology 13.4% (118–120) 
Rhinitis Similar aetiology  (121,122) 
COPD Common symptoms, potentially same aetiology 13.4% (111,123) 
GORD Increased acid reflux, micro-aspirations, reduced sphincter pressure 
 pressure 
10.9% (124–126) 
Anxiety Asthma can give rise to anxiety and vice versa 6.9% (127,128) 
Depression Asthma can give rise to depression and vice versa 17.3% (117,129,130) 
Allergies Similar aetiology  (62) 
Sleep apnoea Potentially through obesity  (127,131) 
    
Demographic/Lifestyle    
Age-of-onset Potentially different aetiology between early and late onset  (96) 
Sex-related More common in boys than girls, but more common in women than men  (132,133) 
Obesity Altered lung dynamics, inflammatory process or common predisposition  (134,135) 
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Socio-economic status Different exposures, health status and access to treatment and   (136,137) 
Ethnicity Different genetic predisposition  (138) 
Family history Different genetic predisposition  (139) 
Occupational Different exposures  (140,141) 
Smoking Exposure to toxic substances 24.7% (142–144) 
    
Pathological    
Early life infections Influence on the immune system development  (99,145) 
Leucocyte levels Classification based on eosinophil, neutrophil and pauci-granulocytic 
level 
 (120,146) 
Th2 cytokine levels TH2 helper cells orchestrate immune response  (147,148) 
    
Table 1: Asthma characteristics. GORD=Gastro-Oesophageal Reflux Disease Th2=Type 2 helper cell. Prevalence rates from Weatherburn et al: 
Comorbidities in adults with asthma: Population-based cross-sectional analysis of 1.4 million adults in Scotland were reported. Estimates from 
other populations were not included, as comparing would be more difficult. 
 
   
These characteristics can be aetiological, provoke deterioration of 
symptoms/exacerbations, or both. In the following paragraphs, the asthma 
characteristics that form the basis of phenotype categorisations are further described. 
Clinical characteristics 
An asthma diagnosis requires careful assessment of comorbidities or potential 
alternative diagnoses. Under-treatment of comorbidities can influence asthma control 
and quality of life greatly.(127) 
Asthma, atopic eczema and chronic rhinitis often appear together,(149) and asthma 
and allergic rhinitis are often preceded by atopic eczema. This observation has been 
seen in multiple longitudinal studies and has been designated the “atopic 
march”.(150,151) Not all atopic patients will develop asthma, however.(152,153) 
Atopy is the sensitisation followed by the generation of specific IgE antibodies against 
environmental allergens or can indicate a predisposition to produce increased levels 
of IgEs after exposure to allergens and develop allergic reactions (type 1). Atopic 
eczema can be assessed though skin prick tests or serum measurements of allergen-
specific IgE.(118,154) Fifty to sixty per cent of asthma patients have atopy,(119) but the 
prevalence is higher in children with severe asthma and adults with early-onset 
asthma.(120) Rhinitis, even in the absence of atopy, is a strong predictor of adult-onset 
asthma.(121) Inflammation is an important factor in both rhinitis and asthma, which 
can be caused by exposure of the nose and lung to allergens. Anti-inflammatory 
strategies targeting both anatomic sites could be beneficial.(122)  
Asthma and Chronic Obstructive Pulmonary Disease (COPD) share many symptoms. 
(28)(111,123) It has been proposed that the two conditions are just components of the 
same airway disease.(59) The idea that asthma and COPD are different components 
of the same airways disease was first postulated in 1961 as the Dutch hypothesis,(155) 
and remains controversial.(111,148,156) The term for the overlap syndrome is ACOS 
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(Asthma-COPD Overlap Syndrome). The viewpoint that asthma and COPD are two 
distinct disease entities that can co-exist is sometimes called the ‘British 
hypothesis’.(148,157) Asthma also shares inflammatory features with COPD such as 
neutrophilia, which complicates the differential diagnosis. The airflow limitation is 
generally less reversible in COPD compared with asthma and there is a reduced elastic 
recoil and hyperinflation at rest.(158) However, partially reversible or even 
irreversible airways obstruction has also been described in asthma,(159) and COPD 
patients may show some degree of reversibility of airways obstruction.(160–162)  
COPD is more common among older people and smokers. A recent study suggests 
that asthma can contribute as much as smoking to the development of chronic 
bronchitis in middle age.(163) The obstructive form of chronic bronchitis is included 
within the definition of COPD.(164) Outcomes of concomitant asthma and COPD are 
worse than either disease alone.(165,166) 
Most patients with asthma report symptoms related to Gastro-Oesophageal Reflux 
Disease (GORD) or have an abnormal 24h oesophageal pH test.(124,125) There is a 
strong association between asthma and GORD, but there is not much known on the 
direction of causality, if indeed any exist.(126) The mechanisms might include 
increased acid reflux during exacerbations, micro-aspirations, and β2 agonists 
reducing oesophageal sphincter pressure. 
Psychological disorders such as anxiety and depression are more frequent in people 
with asthma compared with the general population.(127,128,130) Asthma symptoms 
may be triggered by psychological factors or influence the patient’s perception of 
asthma symptoms. Reverse causality, in which asthma gives rise to anxiety or 
depression, is also possible and these factors can influence medication 
adherence.(167). Anxiety symptoms can also mimic asthma exacerbations.  
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While allergens are triggers for exacerbations in those with asthma, their role in 
development is not crystal clear. How exactly exposure leads to sensitisation, and how 
sensitisation leads to asthma, is not well understood.  
Obstructive sleep apnoea may be associated with asthma, perhaps through obesity 
as an intermediary variable.(131,168) Fatigue, irritability and decreased concentration 
are symptoms of obstructive sleep apnoea that are typical in children who also have 
poorly controlled asthma.(169) 
Demographic and lifestyle characteristics 
The age-of-asthma onset is often used as a determinant of different asthma 
phenotypes. It has been suggested that early-onset adult asthma, which originates in 
childhood, is more attributable to atopy and genetic factors, while late-onset adult 
asthma is more related to environmental risk factors.(96) 
Asthma is almost twice as common in boys as in girls,(3) while both sexes have the 
same rates of severe asthma in childhood.(170) In adulthood, the prevalence of asthma 
is greater in women than men.(132) A possible hormonal influence has been 
suggested.(133) 
People with a Body Mass Index higher than 30kg/m² have a higher incidence and 
prevalence of asthma, particularly in women.(134) The underlying mechanisms are 
uncertain, but various hypotheses have been proposed. These hypotheses include a 
common genetic predisposition, altered lung mechanics because of obesity, the 
presence of a systemic inflammatory process, and an increased prevalence of 
comorbid conditions such as GORD or sleep apnoea.(135) 
Asthma was historically thought to have a higher prevalence in groups with higher 
Socio-Economic Status (SES), which was an argument in support of the hygiene 
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hypothesis.(136) However, this might have been due to a difference in diagnosis and 
reporting of asthma and this view has now been reversed. Asthma prevalence in 
young adults is higher in individuals living in a low-educational area according to the 
European Community Respiratory Health Survey.(137) 
A family history of asthma in first-degree relatives was consistently identified as a 
risk factor for childhood asthma in a systematic review.(138) 
A UK study revealed that there is a ethnic difference in the prevalence of asthma, with 
Caribbean and white populations having a higher prevalence than African or South 
Asian populations.(139) 
Asthma can also be caused by exposure to an agent in the work environment. In a 
large population-based study in young adults in Europe, the highest risk was shown 
for cleaners, farmers, painters and plastic workers.(140) The proportion of asthma 
attributable to occupation was 5-10% in this study. This cause of asthma can be missed 
as GPs may not routinely explore the role of occupation.(141) 
Exposure to environmental tobacco smoke is associated with an increased reported 
prevalence of asthma, wheezing and chronic bronchitis.(142) Maternal smoking 
during pregnancy has been shown to increase the occurrence of physician-diagnosed 
asthma and wheezing during childhood.(143) Asthma incidence during adulthood 
has been found to be strongly associated with active cigarette smoking in a UK 
prospective study using a longitudinal birth cohort.(144) Tobacco smoking could 
deteriorate the prognosis of people living with asthma.(171) 
Pathological characteristics 
Exposure to infections in early life influences the immune system development. The 
controversial hygiene hypothesis proposes that this exposure could lead to a reduced 
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risk of asthma and other allergic diseases.(61,145) Some studies show an increased risk 
of asthma following infection, while others show a decreased risk. 
The heterogeneity of immunology in asthma has been used to better understand the 
different clinical presentations of asthma. The cytology of sputum or blood can 
provide evidence of eosinophilic, neutrophilic and pauci-granulocytic 
inflammation.(146) Around 50% of adult asthma patients have eosinophilic airway 
inflammation. T helper 2 cells aid the survival and maturation of eosinophils through 
the production of Interleukin-5. The pathways in non-eosinophilic asthma remain 
poorly understood.(120) Papi et al. have described the inflammatory pathways in 
asthma in detail.(62)  
The eosinophilic phenotype of asthma is defined by the central role that eosinophils 
play in the pathophysiology of the condition. It is characterised by elevated sputum 
and/or blood eosinophils and by a significant response to treatments that suppress 
eosinophilia.(172) The  eosinophils are quite rare in serum, but can be common in the 
airways of asthma patients.(173) They are often considered as effector cells, but also 
play a role in the regulation of immunity, remodelling and modulating other 
leukocytes.(174) 
Cytokines derived from T helper type 2 cells (TH2) play a critical role in orchestrating 
and amplifying the inflammatory response in asthma.(175) There is a group of asthma 
patients in which TH2 cytokines predominate and which can be defined by 
biomarkers and response to therapies targeting this type of immunity.(147) 
Protective factors 
There are also factors which protect against asthma including certain 
infections,(176,177) farm and animal exposure (178–180),and vitamin D 
intake.(181,182)  
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Many of the characteristics, including allergen exposure in childhood, family history, 
occupation, early life infections, maternal smoking and TH2 cytokines, cannot be 
measured reliably in the datasets used for this PhD project, so are not discussed in 
detail. The implications of this lack of data are further discussed in the last chapter of 
this thesis. 
1.2.3 Phenotypes identified using cluster analysis 
Cluster analysis can help reveal hidden arrangements of entities, in this case patients, 
with similar attributes into groups and differentiate groups of patients with 
heterogeneous characteristics.(183,184) Patients can be grouped together based on 
characteristics that make them similar (high intra-class similarity) and separate them 
from different groups (low inter-class similarity).(185) The patients within a cluster 
are geometrically grouped together, and the distance between patients in different 
clusters is greater than the distance between patients within the same cluster. In the 
context of health data, cluster analysis can be used to identify which patient belongs 
to which group, and to identify the ideal number of clusters and thus reveal a latent 
structure within a dataset or group of patients.(186) 
There are several different methods of cluster analysis, including k-means, 
multivariate Gaussian mixture, hierarchical clustering, spectral and nearest neighbour 
method.(187)(188) 
 
One of the most influential studies using cluster analysis in asthma in order to identify 
distinct phenotypic groups was conducted by Haldar et al. using cluster analysis of 
multiple clinical variables.(101) Among 184 patients managed in primary care, three 
clusters were found: one group with benign asthma, one group with obese non-
eosinophilic asthma, and one group with early-onset atopic asthma. Further cluster 
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analysis of two other asthma populations which were managed in secondary care and 
were mostly refractory (N=255 total), added an early symptom predominant cluster 
and an inflammation predominant cluster.  
The study by Haldar et al. used the k-clustering algorithm.(101) This algorithm has 
been used widely and requires the number of groups (k) and a distance metric as 
inputs.(189) The first step is to associate each data point with one of the k clusters, 
depending on the distance to the cluster centers (centroids) of each cluster. 
The next step is to calculate new centroids and reclassify the data points for the new 
centroids. This process can then be repeated until there are no more significant 
changes in centroid position observed at each new step. 
One of the main limitations of the k-means algorithm is the a priori setting of the 
number of clusters, as the final classification of clusters can strongly depend on the 
choice of number of centroids. The k-means is also not indicated if the clusters have 
very different sizes,(190,191) and is sensitive to the initial seed selection which 
determines the initial cluster centres. The advantage of the k-means are the low 
computational cost ( easy to implement and can be faster than alternatives such as 
hierarchical clustering) and the good results in practical situations such as detection 
of anomalies within a dataset or grouping patients likely to benefit from a certain 
intervention through data segmentation(192),  
The specific limitations of using clustering analysis on health data is that disease and 
health is a continuous spectrum, and separating the population into discrete clusters 
may not be realistic. The study by Haldar et al further mentions that other methods 
with a more probabilistic approach to cluster grouping could be valuable.(193) In 
addition, the choice of variables remains subjective as well as the number of clusters 
chosen for the population.  
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The authors aimed to choose variables that were measured and could contribute to 
the clinical evaluation, variables that were considered important in the definition of 
phenotype definition and avoid variables that would in effect measure the same 
characteristic twice. The variables were categorised as either symptoms, atopy/allergy, 
eosinophilic inflammation, psychological status or variable airflow obstruction. 
Not all variables were recorded and not all etiologic factors could be explored. The 
number of clusters in Haldar’s study were estimated from the dendrogram plots 
obtained using Ward’s method. Further limitations reported by the study are the 
question of stability in cluster membership over time and changes in treatment. There 
was no significant difference in treatments between the clusters. Differences in 
clusters may have been due to a difference in disease profile and differences in 
response to treatment. 
 
Other phenotyping studies using similar clinical characteristics found comparable 
phenotypes.(103,106,194–196) The identified clusters can be found in the figure below. 
As this categorisation forms the basis for the study included in Chapter 6 of this thesis, 
these phenotypes are explained in further detail. 
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Figure 3: Clinical phenotypes of asthma by Haldar P. Reprinted with permission of the American Thoracic Society. Copyright 
© 2018 American Thoracic Society. Haldar P et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care 
Med. 2008;178(3):218–24. The American Journal of Respiratory and Critical Care Medicine is an official journal of the 
American Thoracic Society 
The early-onset atopic phenotype includes primary care patients with airway 
obstruction reversibility and eosinophilic inflammation and asthma onset in 
childhood. Obese non-eosinophilic asthma includes mostly female overweight 
primary care patients with less eosinophilic inflammation. The benign asthma 
phenotype is mostly composed of primary care patients with good control of 
symptoms and inflammation, and a favourable prognosis. The early symptom 
predominant asthma phenotype includes secondary care patients with less 
inflammation and reversibility, but strong symptom expression. Inflammation 
predominant asthma is a secondary care phenotype with clear eosinophilic 
inflammation, but few symptoms. 
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Another influential study on asthma phenotypes was undertaken by Moore et al. 
based on the Severe Asthma Research Program (SARP).(94) The defining criteria of 
these phenotypes were the lung function based on the maximum FEV1 and the age of 
onset, in which five clusters were found that broadly corresponded to the clusters 
found in Haldar’s study. These clusters were mild atopic asthma, mild to moderate 
atopic asthma, late-onset non-atopic asthma, severe atopic asthma, and severe asthma 
with fixed airflow. Moore et al. used Ward's minimum-variance hierarchical 
clustering method as an unsupervised modelling approach to identify asthma 
phenotypes within the SARP cohort.(103)  
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1.3 Electronic healthcare records  
1.3.1 Overview 
An electronic health record system contains information on the health of an individual 
and is an electronic version of a patient’s medical history. It may include all key 
administrative and clinical data that are relevant to that person’s care, including 
demographics, medications, past medical history, immunisations, laboratory data, 
and secondary care reports.(197,198). A clinician or healthcare professional can 
consult these records for patient care.  
The clinical records can be used to access patient information or can be used to 
improve the efficiency of the clinical practice by generating medication prescriptions 
or requesting clinical tests.(199) EHR can improve patient safety,(200) but 
implementation of EHR remains heterogeneous across general practices, healthcare 
systems and countries. As the pace of implementation differs, this can lead to 
differences in patient safety outcomes.(201–203) Routinely collected EHR are the 
predominant setting for pharmacoepidemiological studies, but these EHR are 
typically not primarily constructed for research purposes. Another kind of health data 
are the administrative databases; these are used for non-clinical purposes and often 
exist to facilitate remuneration for care costs. 
Strengths of EHR for research 
EHR data have an enormous potential for epidemiological and clinical research. Due 
to their immense size, they can offer high statistical power and can often be 
representative of a population. Linkage between different EHRs can further improve 
the completeness of the data.  
One of the main benefits of using EHR for research compared with, for example, tailor-
made cohort studies is the financial cost, as these databases do not have to be 
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constructed for the purpose of one study. Other advantages of EHR databases for 
research include their relatively complete recording of drug prescriptions and 
diagnoses, minimisation of observer and participant bias, information on potential 
confounders, and the ability to assess drug effects in the routine clinical care 
population where the medication is used (often different to the conditions under 
which randomised trials are conducted). EHR also hold information on the health 
status of a specific population, which can be used to estimate disease prevalence and 
incidence or provide additional arguments to support or reject a clinical diagnosis. 
Limitations of EHR for research 
A major limitation of the use of EHR for research is that the primary goals of EHR are 
for clinical, administrative or audit purposes. This means that important information 
can either be missing or wrongly classified. In cohort studies where the data are 
collected solely for the purpose of epidemiological research, stricter definitions can be 
used for exposures, covariates and outcomes, and a specific test that is not part of 
routine clinical practice can be requested or looked into at greater detail than in EHR. 
In addition, contact with the patient is rarely possible, and contact with the treating 
physician is only possible in specific cases (such as a validation study). Identification 
of patients with specific diagnoses or covariates depend on specific algorithms or 
codes which can be difficult to construct.  
The record consists of the results of clinical and administrative appointments between 
a healthcare provider and a patient during the patient care. As such, the EHR reflects 
the skill, know-how and job function of the healthcare provider. Due to the nature of 
EHR, information on potential confounders can also be missing or incomplete. In 
addition, studies using these databases should be carefully designed to avoid time-
related biases such as immortal time bias.(204,205) 
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Examples of EHR databases 
Worldwide, there are several EHR databases that have been proven to be reliable data 
sources for research purposes. The first two papers, included in Chapter 3 of this 
thesis, outline different non-claims databases that have been used to identify asthma 
diagnoses and their validity. 
In Europe, the Scandinavian countries are known for the completeness of their 
databases due to their welfare systems and complete registration. For example, the 
Danish National Patient Registry contains information on all secondary care for all 
patients in Denmark,(206) but this database lacks some information on primary care 
variables. Another well-known database is the Dutch Integrated Primary Care 
Information (IPCI) database, which was constructed with the primary purpose to 
conduct pharmacoepidemiologic studies. It contains data on diagnoses in primary 
care, prescriptions, lifestyle factors and hospitalisation events. 
There are several EHR databases containing primary care data in the UK. These 
databases include THIN (The Health Improvement Network),(207) ResearchOne  and 
CPRD GOLD.(208) They differ in size and availability of linkage to other databases 
but contain similar data on primary care. Linkage to secondary care of the UK 
databases varies by UK nation; for example, in England the Hospital Episodes 
Statistics (HES) contain information on hospitalisations, outpatient and Accident and 
Emergency attendances. 
A separate kind of health data are administrative claims data, whose main purpose is 
administration of reimbursements to healthcare providers for their services. This 
contrasts with EHR, which are a digital reflection of the paper medical chart. The 
quality measures between the two types of data can be markedly different.(207,209)  
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In general, USA and Canadian databases tend to be more administrative and used for 
claims and insurance purposes. An issue with this type of data is that the primary 
purpose of this data is financial and is not always constructed or used by the treating 
clinician. As a result, these databases might include more diagnoses that maximise 
profit for the healthcare providers. In addition, they do not contain much information 
on lifestyle factors such as smoking and BMI, which limits access to confounders. An 
example are the Kaiser Permanente medical care programmes, a private health 
insurance scheme covering 8 million people which is based in the US.(210)  
Three studies in this thesis use CPRD GOLD data, linked to HES and ONS (Office of 
National Statistics) data. These databases are described in further detail in the next 
chapter. 
1.3.2 Asthma identification in electronic health records 
Identifying patients with asthma in epidemiological studies can be complicated. The 
absence of a universal case definition for asthma, partly due to the heterogeneity of 
asthma, remains an issue. The variability of symptom severity, the fact that asthma 
symptoms are non-specific, and the differential diagnosis with other diseases such as 
COPD, further convolute the identification of asthma patients. Both bronchodilator 
reversibility and airway hyperresponsiveness have been used to define asthma in 
research, but there is no consensus on the cut-off, which can result in noncomparable 
asthma populations between studies.(95)(211) Asthma medications are commonly 
prescribed in primary care without assessing lung function, while tests may not even 
be available. As such, asthma diagnoses in primary care may be inaccurate in up to 
30% of cases.(212,213) The evolution of guidelines for the diagnosis and management 
of asthma further complicates asthma research.(214) 
In a review published in 2010, 60 different definitions of childhood asthma were used 
in 122 epidemiological studies. This variation in case definitions of asthma can lead to 
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misclassification in research studies. On one hand, if too few inclusion criteria are 
needed some included patients might not have asthma, while, on the other hand, if all 
possible inclusion criteria are used to increase the specificity of an asthma diagnosis, 
people who really have asthma might not be identified as having asthma.(215) 
Furthermore, if specific criteria or test results (such as sputum eosinophilia) that are 
not always available are required for the inclusion of a patient in a research study, the 
study population might not be representative of the general asthma population.  
There are several diseases that share symptoms with asthma and can, therefore, be 
confused with asthma at clinical assessment, including COPD, eosinophilic 
bronchitis,(216) vocal cord dysfunction,(217) bronchiectasis, anxiety and 
dysfunctional breathing.(218) Asthma, by its very definition, is variable and patients 
may present with few symptoms,(219) inflammation (220) or airway 
hyperresponsiveness at the time of assessment. In addition, inflammation and 
hyperresponsiveness show only a weak association with each other.(221–223) In 
clinical and epidemiological research, original asthma diagnoses recorded in patient 
notes cannot always be verified at a later time due to the inherent variability of asthma, 
successful treatment, or differing asthma criteria between the clinician and researcher. 
These issues are all present when aiming to identify asthma patients from EHR for 
epidemiological studies. Being able to reliably and transparently identify the asthma 
status of patients in EHR is vital to conduct asthma research using these EHR. As 
discussed in this subchapter, there are multiple reasons why this is not 
straightforward. The ascertainment of the asthma status of patients in EHR is a major 
part of this PhD thesis, as described in the thesis objectives. 
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1.4 Thesis aim, rationale and objectives 
1.4.1 Aim 
The aim of this thesis is to find reliable ways to identify asthma patients from de-
identified UK electronic health records and study predefined asthma phenotypes, 
including patient characteristics and outcomes. 
1.4.2 Rationale 
Asthma is a common heterogeneous disease that carries a high morbidity and notable 
mortality worldwide. The identification of asthma patients from electronic health 
records (EHR) in primary care can be challenging, as there is no universal consensus 
on what constitutes asthma, asthma shares many symptoms with other diseases such 
as COPD, and asthma diagnostic tests and markers are not always well recorded. 
Different asthma phenotypes have previously been established based on cluster 
analysis in small populations; this categorisation may allow for specific treatment 
strategies. The prevalence and outcomes of distinct phenotypes are not known. 
1.4.3 Objectives 
• Understand how past epidemiological studies have identified asthma 
patients in EHR through a systematic review. 
• Validate the recording of the diagnosis of asthma in CPRD GOLD. 
• Quantify the concomitant occurrence of asthma in COPD patients and vice 
versa in CPRD GOLD. 
• Identify established asthma phenotypes in CPRD GOLD by studying 
characteristics and explore the variation of asthma severity (defined by 
treatment steps) by phenotype. 
• Examine the difference in asthma control by asthma phenotype, stratified 
by treatment step. 
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1.4.4 Thesis organisation 
• Chapter 1 provides the background to the thesis, including an overview of 
asthma and electronic health records. 
• Chapter 2 describes the databases used in this project in detail: the CPRD 
GOLD, HES, ONS and the questionnaire designed as a reference standard for 
asthma diagnosis. 
• Chapter 3 describes ways in which asthma researchers have identified asthma 
patients from EHR databases worldwide and test values through a systematic 
review. 
• Chapter 4 provides the results of a validation study of asthma in the CPRD 
GOLD. 
• Chapter 5 quantifies the prevalence of concomitant asthma and COPD in 
patients with a validated diagnosis of either disease. 
• Chapter 6 outlines the results of a study to detect pre-identified asthma 
phenotypes from CPRD GOLD. 
• Chapter 7 summarises and discusses the overall findings of this PhD project. 
In conclusion, this thesis provides information on the validation of asthma and the 
prevalence and control of asthma phenotypes in electronic health records. 
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Chapter 2: Data sources  
Summary 
In this chapter, the data sources used in this thesis are described, and their respective 
advantages and weaknesses are discussed. These data sources include the Clinical 
Practice Research Datalink GOLD, Hospital Episode Statistics and Office of National 
Statistics mortality and deprivation data. This chapter also discusses the asthma 
questionnaire designed as part of this PhD thesis that was applied as reference 
standard for an asthma diagnosis in the CPRD GOLD. In addition, this chapter reports 
on the coding system and the data flow from the healthcare provider’s practice to the 
researcher. 
  
54  
  
2.1 EHR databases and front-end software systems in the UK 
Large routine health care databases have been considered as a means of addressing 
research questions of interest for many years. There are several different primary care 
EHR databases available in the UK, and multiple front-end software systems that 
deliver their data into the databases.  
The CPRD GOLD is the oldest research database of primary care electronic health 
records in the UK (224) and has generated the highest number of peer-reviewed 
publications.(225) Recently, the CPRD Aurum dataset supported by the EMIS front-
end software has become available,(226) but this dataset was not available at the start 
of this PhD programme. There are several different software systems (the front-end 
systems) available in the UK to record clinical data, for example Vision or EMIS 
(Egerton Medical Information System), which are used by general practices to record 
the information that is subsequently uploaded to their respective databases. Published 
studies in this thesis were included as they were printed and may refer to the CPRD 
GOLD as “CPRD”. This terminology has become more ambiguous with the advent of 
CPRD Aurum and should be avoided in future studies. Other examples of UK primary 
care databases include Q-research and THIN (The Health Improvement Network) The 
data content of these databases is generally comparable with the CPRD GOLD, but 
their size and linkage availabilities can differ. 
Data on secondary care are available in Hospital Episode Statistics (HES), while data 
on mortality and an area-based socio-economic status are made available by the Office 
of National Statistics (ONS). 
The CPRD GOLD was the main data source for this PhD project, and is supported by 
the Vision software system. The following subchapter describes how the data are 
coded, recorded, uploaded, de-identified and made available for research in the CPRD 
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GOLD database using the Vision front-end software system. The data flow in other 
EHR databases is comparable, but may have different features (such as the coding 
system used). The sections thereafter describe HES, ONS and the asthma 
questionnaire for the study described in Chapter 4. 
2.1 Clinical Practice Research Datalink GOLD (CPRD GOLD) 
2.1.1 Background 
The main database used in this thesis was the UK Clinical Practice Research Datalink 
GOLD. The Clinical Practice Research Datalink (CPRD) is a governmental, not-for-
profit research service for observational and interventional research. It is jointly 
funded by the NHS National Institute for Health Research (NIHR) and the Medicines 
and Healthcare products Regulatory Agency (MHRA) and operates as a part of the 
UK Department of Health.(227) This primary care database is composed of de-
identified data on patients from over 650 NHS primary care practices in the UK. In 
total, there are data on over 11 million patients, of whom 4.4 million were active (alive 
and currently registered) in 2015.(208) 
The database includes data on patient demographics, coded diagnoses using Read 
codes, prescriptions using Gemscript codes, laboratory test results, and referrals made 
by general practitioners.(208) The database has been providing de-identified primary 
care records for public health research since 1987.(208) Over 1,500 articles have been 
published using CPRD GOLD data, which have led to improvements in drug safety, 
best practice and clinical guidelines.(227) CPRD GOLD has been used for extensive 
epidemiological research (208) and is representative of the UK population regarding 
age and sex.(228) As data are entered for clinical rather than research purpose, data 
quality can be variable, although the validity of many disease definitions in the CPRD 
GOLD has proven high.(229) In order to check the data quality for asthma research, 
the study included in the Chapter 4 of this PhD thesis tests the validity of asthma 
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recording in the CPRD GOLD. There are two sets of criteria to ensure data quality in 
the CPRD GOLD. The first criterion is patient acceptability based on registration 
status, completeness of patient records, age and gender. The second criterion is up-to-
standard (UTS) time for practices, which ensures the suitability of the data for research 
purposes, ensuring or flagging the practice as ‘up-to-standard’ (UTS).(229) The UTS 
date is given on practice level and based on the continuity of recording and the 
number of recorded deaths.(208) The data contain mainly primary care data, but some 
secondary care data that has been sent to primary care practices may also be recorded 
in CPRD GOLD through manual entry by clinicians. CPRD was previously called the 
GPRD (General Practice Research Database).(208) 
2.1.2 Data architecture 
Coding 
Most of the clinical information is registered in Vision using a dictionary known as 
Read terms with corresponding Read codes. The Read codes are hierarchically 
structured and are arranged into separate chapters, which broadly correspond to 
International Classification of Disease (ICD) chapters. The Read terms dictionary has 
many synonyms and different terms for one specific diagnosis, and it is up to the 
clinician to choose which one to use. Read codes are also used to record referrals to 
secondary care and may include specialty, urgency and the distinction between 
inpatient or outpatient referrals, but this information is not always recorded. Results 
of tests are also associated with Read codes. These codes can either be uploaded by 
the pathology department, or manually entered by healthcare providers in primary 
care.(227) Lifestyle factors and other measured variables such as weight or blood 
pressure are also coded using Read codes and are directly entered by primary care 
providers.  These Read codes were developed in the early 1980s by Dr James Read and 
are a standard terminology for describing the care and treatment of patients.(230) The 
Read coding system has superseded the Oxford Medical Information System 
(OXMIS), which was developed in the 1970s based on the ICD 8.(231) Read codes are 
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a predecessor to the newer internationally unified coding system SNOMED CT, which 
was developed by the International Health Terminology Standards Development 
Organisation.(232) The Read codes correspond to medcodes in CPRD GOLD, which 
are ordered by frequency of use to reduce data size (the new codes are added at the 
end) and are a practical way to identify events in the CPRD GOLD. 
Prescriptions of medications are recorded using product codes, based on a Gemscript 
dictionary in which Gemscript codes are the unique identifiers. The dictionaries can 
be modified depending on the local prescribing practices. Each Gemscript item 
includes the product name, administration route, strength, formulation and BNF code. 
A prescribing clinician can enter the dose, duration and patient advice, or can auto-
populate these fields, and print prescriptions directly from the Therapy module. The 
vast majority of prescribing is electronic and therefore automatically captured. 
Immunisation records are separate from other therapies. 
Data entry 
Data entry in the Vision system is performed during clinical practice. Healthcare 
workers enter clinical information in Vision during consultations. These consultations 
include different activities which include not only direct patient contacts and 
attendances, but also telephone calls, administrative duties, repeat prescriptions of 
medications, information entry from secondary care, or emergency visits.  
The data on patients are recorded during routine clinical care by general practitioners 
or healthcare workers. The clinician can either enter clinical terms as “Read terms” 
directly into a patient’s medical history, or into a structured data area (for example, 
when the results of a test need to be filled in). The Vision system links Read terms to 
specific Read codes. Furthermore, the Vision system can be tailored to the preferences 
of a healthcare professional. One way to do this is to auto-populate preferred terms in 
the Read term box. Each Read code has a specific date. By default, this is the date of 
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recording, but can be changed by the clinician to record historical diagnoses or events. 
In addition to the Read code, a clinician can enter extra information as comments for 
each Read code, but this free text information was not available for this PhD project.  
Figure 1 presents the data flow from the GP practices and hospitals to public health 
researchers. 
 
Figure 1: Data flow in CPRD GOLD. Adapted from www.cprd.com/researchpractice/researchgppractice.asp 
 
 The data are then uploaded to databases specified by the system in use; in the case of 
Vision, this is the CPRD GOLD. These de-identified data can then be linked to other 
data sources such as HES and are made available to researchers as de-identified raw 
data. There are multiple primary care EHR databases available in the UK with similar 
data flow schemes.  
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Research in practice 
The practice data are regularly uploaded to the CPRD servers, after which they are 
processed, go through quality checks (acceptable patient status and practice-level UTS 
dates), de-identified and made available for research purposes.  
Dictionaries of the Read and drug codes are available and searchable within a code 
browser. The electronic health records from patients who received either a diagnostic 
code or drug prescription code can be obtained using the codes and a period of 
interest.  
Study approval for studies using CPRD GOLD data should be sought through a 
protocol submission to the Independent Scientific Advisory Committee (ISAC) for 
Medicines & Healthcare products Regulatory Agency (MHRA) Database Research, in 
addition to institutional ethical committees such as the LSHTM Research Ethics 
Committee. 
After study approval has been obtained, the study data can be downloaded in two 
stages. The patients are uniquely identified by a patient identifier (patient id or patid). 
The first stage is the definition of the study population and construction of a list of 
patids that meet the inclusion criteria. The second stage is the extraction of all records 
of the patients included in the patid list. All records for the included patients are 
extracted, even records outside of the study period, to be able to define co-variates. 
Some variables such as ethnicity, gender, BMI or smoking status might not be 
recorded in the study period. In some cases, the values of recordings outside the study 
period can be used if there are no further entries on these variables. In this case, the 
assumption must be made that the values do not fluctuate greatly. After data 
extraction, the data from patients are presented in separate data files (including 
different types of data).  
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The data are organised in several files as follows: 
• Index list: The master list for the specified cohort, which contains one 
unique patid per patient and date of the clinical diagnosis or medication of 
interest that led to the selection of the patient. 
• Patient file: Demographic data on sex, year of birth, practice id and death 
date. 
• Clinical file: Clinical diagnoses of the patient, including diagnostic Read 
codes and dates. 
• Therapy file: Drug prescriptions of the patient, including therapy code, 
dates, quantity, dose, indication and formulation. 
• Test file: Test records of the patient, including test type, date and result. 
• Referral file: Referral records for the patient, including referral date and 
diagnosis associated with referral. 
• Additional file: Records which provide data or measurements on variables 
such as patient height, weight, BMI and smoking status. 
In addition, important medical events occurring prior to registration in a CPRD centre 
are also recorded. 
In order to capture all events of a clinical concept (such as asthma), code lists with all 
Read codes that correspond to that event should be created. All records of a patient 
can then be searched using this code list. As such, there are multiple ways of defining 
a clinical concept in CPRD GOLD and EHR in general. It is useful to reconsider or 
update a previously used code list for each study as new codes may have been added. 
The Read code lists for this thesis were either developed by searching for all synonyms 
of a clinical concept in a code browser and exploring the codes hierarchically above 
the found codes, or shared with colleagues in the LSHTM and Imperial College for co-
variates. All code lists which were used in this thesis are included in the appendix. 
Figure 2 depicts an example of a strategy to create a code list for asthma. 
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The CPRD GOLD database can be linked with other data, including Hospital Episodes 
Statistics (HES) database for inpatient hospitalisations, Office for National Statistics 
(ONS) data for mortality data and Index of Multiple Deprivation (IMD) data for 
deprivation indices.  
Patients are generally followed up from either the current registration date or date at 
which the practice was UTS and censored at last collection date or transfer out of 
practice or death. 
 
2.1.3 Strengths and limitations 
Strengths 
There are multiple advantages to using the CPRD GOLD for epidemiological research, 
including the breadth of coverage, the size and long-term follow-up, its 
representativeness and data quality.(208) The database has data on morbidity and 
 
 
 
 
Figure 2: Strategy for identifying codes for asthma in the CPRD GOLD 
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lifestyle variables, linkage to secondary care via HES and mortality via ONS. It has a 
median follow-up of 5.1 years, which facilitates long-term epidemiological 
studies,(129,233) and is broadly representative of the UK population.(208,234,235) 
Furthermore, validation studies of some diagnoses have shown high positive 
predictive values (PPVs),(229) and studies on incidence rates have shown similar 
results to other UK data sources.(236,237) Another advantage of the CPRD GOLD is 
that the data quality is promoted by the Quality Outcomes Framework (QOF). 
Quality Outcomes Framework 
The QOF encourages recording of key data by GPs in England through an incentive 
payment, and therefore influences data quality in the CPRD GOLD.(238) It is an 
annual reward and incentive programme which gives more information on GP 
practice achievement results. This programme aims to reward practices for the 
administration of quality care and helps standardise advancement in the delivery of 
primary medical services (65). It is a voluntary process for all surgeries in England 
and was introduced in 2004, so this year was chosen as the index for most work 
included in this document. The indicators for the QOF are set annually. The QOF 
awards practices achievement points for the management of common chronic diseases 
(including asthma since 2006), the management of public health concerns and the 
implementation of preventative measures. This programme has enhanced aspects of 
the data in English General Practice.(208) The QOF indicators for asthma include 
sleeping difficulties, symptoms during the day and interference with daily activities. 
Limitations 
The primary purpose of the data in CPRD GOLD is to facilitate clinical care rather 
than research, so the data quality can be variable. The weaknesses of the CPRD GOLD 
include variability in completeness of data (for example, full blood counts are not 
conducted for every patient), sparse standard definitions (the need for code lists), 
missing information from secondary care (these are only available in CPRD GOLD if 
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the clinician manually records discharge or referral letters) and non-captured data 
(such as household information or age of disease onset).(208) In detail, if a Read code 
for a disease is absent in a patient, the disease must be considered as absent in the 
patient which might not necessarily be the case. There are no standardised definitions 
of diseases, so Read code lists and algorithms are needed. If secondary care 
information is not entered manually, this information is not recorded in CPRD GOLD, 
which might be the case if the information is not directly relevant for patient care. Free 
text data was not available for the purposes of this PhD project. Finally, some data 
may be missing, including some lifestyle data, family composition and over-the-
counter medication. In addition, the data only provide information on medication 
prescriptions, not on medication dispensing or adherence to medication. 
The CPRD GOLD records prescriptions of medication, which does not guarantee that 
patients also used their medication. The studies included in this PhD thesis did not 
directly study at the effects of medication, so the implications of this are limited. The 
validation study (Chapter 4) defined some of the algorithms using medication use, but 
the most practical algorithm only used a specific asthma code. 
The outcome of the cohort study described in Chapter 6 are asthma exacerbations, and 
an asthma exacerbation can be defined by the prescription of oral corticosteroids. The 
medications a patient takes by BTS step were used as measurement of asthma severity. 
The healthcare practitioner who prescribed the medications assessed the exacerbation 
or severity of asthma, so the prescription records would be a good proxy for both 
regardless of whether the patient used the medication.  
While the direct adherence cannot be measured in EHR, it is possible to estimate it by 
studying the percentage of time for which patients at least had medication to cover. 
For example, if a patient has a prescription every 45 days but the amount prescribed 
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only covers 30 days, the patient would be covered for 30/45 of the time (the medication 
possession rate). 
Prescription records and patient’s self-reported drug exposure were compared in the 
French PGRx database (Pharmacoepidemiologic General Research eXtension). Self-
reported drug exposure itself is not a perfect measure, as it can be affected by memory 
errors and other biases. The agreement between the two data sources was kappa = 
0.83, (95% CI: 0.81-0.85).(239) 
Another way to study adherence is estimating the percentage of issued prescriptions 
that are obtained from the pharmacy, in which case pharmacy-level data are needed. 
Treatment adherence can also be defined as missing one or more scheduled 
appointment if recorded, or coding indicating medication non-compliance.(240) 
 
A cohort of asthma patients containing primary and secondary care information can 
be obtained by using a linked cohort from patients attending practices in England and 
linking their CPRD GOLD and HES records. Linkage from CPRD GOLD to patient-
level datasets, including HES and ONS is only available for consenting English 
practices. These linkages are present in about 70% of English practices and 55% of all 
UK practices contributing to the CPRD GOLD.(241,242) 
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2.2 Hospital Episodes Statistics (HES) 
Background 
The second data source of this study was the UK Hospital Episodes Statistics database 
(HES). HES is a data warehouse which holds details of admissions, outpatient 
appointments and A&E attendances at NHS hospitals in England.(243) This database 
enables health care providers to be paid for the care that they deliver. The system 
covers all NHS trusts in England, including primary care and mental health trusts, 
and emergency care hospitals. HES is an administrative database which is composed 
of data on patient demographics, clinical diagnoses and procedures performed in the 
hospital for every NHS hospital admission. Most hospital activity in the UK is funded 
by the NHS (98-99%).(244) 
The Health and Social Care Information Centre prepares and makes the HES 
databases available for secondary purposes, including service planning, 
commissioning and academic and pharmaceutical research. The practices 
contributing to CPRD GOLD located in England have their data linked to HES (not 
the practices in Wales, Scotland and Northern Ireland). The linkage from CPRD GOLD 
to HES is available from April 1997 onward and is generally available in bi-annual 
builds. This affects study designs of epidemiological studies using HES because the 
data only becomes available twice each year, and the HES data are distributed over 
several databases. The HES Admitted Patient Care (HES APC) was the main data 
source on secondary care for this project. Accident and Emergency attendances (HES 
A&E) and outpatient services (HES outpatient) are held in separate databases. 
HES Admitted Patient Care (APC) 
The HES Admitted Patient Care (APC) database includes data on hospital admissions 
including any secondary care-based activity that requires a hospital bed. As such, it 
includes both emergency and planned admissions, day care and childbirths. The 
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admission diagnoses in HES APC are coded using a modified ICD-10 (International 
Classification of Diseases) system. The procedures are coded using standard code for 
hospital procedures: the OPCS4 codes (Classification of Interventions and 
Procedures). 
The data files in HES APC are first structured by financial year, then by 
hospitalisations or “spells” (spell is defined as a single stay in the hospital), which can 
consist of one or more episodes (episode defined as the care under one 
consultant).(244) Each episode can contain multiple diagnoses. In addition to the data 
on diagnoses and medical procedures, HES APC also holds data on 
admission/discharge dates, admission methods, care provider and the individual 
patient’s postcode.(244) 
The advantages of using HES APC for epidemiological research are its universal 
coverage, availability of linkage to other databases, and standardised ICD-10 
coding.(244) It is frequently used in health economics, as the information on costs of 
care are readily available.(245). There are several limitations to the use of HES APC. 
These include the variation of coding between different hospitals, the sensitivity to 
admission thresholds (if this differs between hospitals or guidelines) and the patients 
that opt out of data recording for research purposes (2.3% of episodes).(244) Clinical 
coders rely on discharge summaries in order to enter data correctly, and as such, data 
quality can vary between hospitals. In addition, financial incentives exist in order to 
improve coding.(246) Some conditions have a higher remuneration than others, so 
hospitals have an incentive to code multiple and specific comorbidities. 
HES A&E and HES outpatient databases 
The HES A&E and HES outpatient databases add information on patient attendances 
that do not result in a hospitalisation. However, their data content is lacking compared 
with HES APC, which limits their usefulness for epidemiological studies.(244) HES 
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A&E data contain only a limited number of different codes, and HES outpatient data 
frequently only contain information on the healthcare provider. These databases were 
not used for the research presented in this thesis. 
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2.3 Office of National Statistics (ONS) 
The third data source of this thesis is the Office of National Statistics database.  
The ONS is the executive office of the UK Statistics Authority. Its purpose is to collect 
and publish statistics related to the economy, population and society of the UK.(247) 
As the ONS collects death statistics of the UK, the data it provides can be linked to 
CPRD GOLD to obtain more accurate data on mortality. For areas in Scotland, 
Northern Ireland and Wales the responsibility for some fields of statistics is 
transferred to the devolved governments and their ONS data is not readily linkable, 
so the linked data is only available for England.  
A list of the causes of death (as coded on the individual’s death certificate) for linked 
patients can be obtained from the database by providing CPRD headquarters with a 
list of patient ids. Cause of death is coded according to the WHO ICD-10 standard. 
Index of Multiple Deprivation (IMD) 
The ONS also provides data on socio-economic status through the IMD. The IMD is a 
measure of relative deprivation for small English areas, and is available for different 
time points.(248) I chose the IMD 2015 for the studies in this thesis. The English indices 
of deprivation measure the relative levels of deprivation in small areas of England, 
which are called “lower layer super output areas”. The indices of deprivation are 
assigned based on the postal code of residence. Deprivation is described as the decile 
or quintile of the deprivation index of the patient postcode. The deciles have been 
calculated by ranking the 32,844 small areas in England from the most deprived to the 
least deprived area, and subsequently dividing them into 10 equal groups.  
The IMD mainly uses seven indicators: income, employment, education, health and 
disability, barriers to housing and services, living environment and crime. 
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Deprivation can then be categorised into quintiles or deciles, with 1 being the least 
deprived and 5 or 10 the most deprived. There is no definitive threshold above which 
an area can be described as deprived, as the indices form a continuous scale of 
deprivation. 
2.4 Asthma questionnaire 
A possible way to ascertain asthma status is by using asthma questionnaires. In large 
epidemiological studies without EHR, questionnaires on asthma symptoms and 
history are frequently used.(42,249,250) Questionnaires on symptoms correlate well 
with a clinical diagnosis of asthma and can provide repeatable results.(251,252)  
A two-page questionnaire based on the NICE and BTS guidelines was designed to 
construct an independent reference standard for the validation of asthma patients in 
the CPRD GOLD (Chapter 4). The full questionnaire is included in the appendix of 
Chapter 4. This questionnaire was sent out to the GPs of 684 potential asthma patients 
and is included in the appendix of Chapter 4. The information by the GP was then 
reviewed by two study physicians to construct the reference standard. 
This questionnaire included several questions in order to ascertain or reject an asthma 
diagnosis. The first section of the questionnaire requested to confirm whether the 
patient had asthma, whether this diagnosis was confirmed by a respiratory physician 
and whether the patient had evidence of reversible airway obstruction. The second 
section sought information on additional factors that supported the diagnosis, such as 
history of atopic disorder, wheeze, spirometry results and FeNO measurements and 
the QOF indicators (including sleeping difficulties, usual asthma symptoms and 
interference with daily activities). The questionnaire also asked for the patient’s 
smoking status and comorbidities. 
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A questionnaire was sent to the general practitioners of a random sample of patients 
who fit in a certain algorithm to obtain information for the gold standard. The 
questionnaire is based on the “British guideline on the management of asthma” by the 
British Thoracic Society and Scottish Intercollegiate Guidelines Network 2014 and the 
asthma QOF indicators.  
The main aim of the questionnaire was to allow the study physicians to differentiate 
individuals with asthma from individuals without asthma. The first question (A) asks 
the GP’s evaluation of the asthma status. If the evaluation was either positive or 
uncertain, we asked additional questions to check asthma status. These include the 
confirmation by a respiratory physician (B1), evidence of reversible airway 
obstruction (B2) and the year of diagnosis (B3). 
The BTS 2014 guidelines specify an asthma diagnosis is predominantly based on the 
recognition of a characteristic pattern of symptoms and signs and the absence of an 
alternative explanation for those symptoms. Features that increase the probability of 
asthma include the classic asthma symptoms (wheeze, breathlessness, chest tightness 
and cough), a family history of asthma and/or atopic disorder, widespread wheeze 
heard on auscultation of the chest, otherwise unexplained low FEV1 or PEF and 
otherwise unexplained peripheral blood eosinophilia. We added FeNO 
measurements due to the scientific interest in these measurements at the time. These 
additional features were explored in part B4 of the questionnaire.  
Question B5 of the questionnaire refers to the QOF indicators. Question B6 asks the 
smoking status of the patient, as that was important information to be able 
differentiate asthma from COPD patients who were likely to be picked up with the 
less stringent algorithms, as the treatment of both diseases overlaps. Question B7 
identifies patients with other respiratory conditions that could be identified with the 
asthma validation algorithms. Question C asks if the patient had a history of asthma, 
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if they did not have a current asthma diagnosis. This information was useful to assess 
whether past diagnoses were frequently picked up in the recordings of the last 2 years. 
There were some slight changes to the questionnaire on advice from CPRD regarding 
the remuneration of the GP’s after the ISAC protocol. There were also some minor 
amendments to the questionnaire to clarify the procedure for returning the 
questionnaire and to insert the patient identifier tables we use. The sentence “To 
answer this questionnaire, please refrain from using the data recorded in CPRD as the 
aim of this study is to see how reliable CPRD is.” was removed to avoid confusion. 
 
2.5 Data management 
The data were stored on a secure server with a backup copy on an encrypted external 
hard disk and the data required for ongoing research will be kept in line with CPRD 
and institutional guidance. 
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Chapter 3: Systematic review: Validation of 
asthma recording in electronic health records 
Summary 
• This systematic review found 13 studies with details on their methods for 
asthma validation and reported test measures. 
• Asthma validation studies using EHRs are very varied in their approach to the 
validation, which seems driven by the nature of the data, the study questions 
to be answered and the reference standards used. 
• There were 3 main reference standard types used for validation: manual 
validation, comparison with an independent database and comparison with a 
questionnaire. 
• Identifying asthma cases in electronic health records is possible using each of 
the discussed validation methods with high sensitivity, specificity or positive 
predictive value, by combining multiple data sources, or by focussing on 
specific test measures. 
• Different case definitions within a single data source have different validity 
highlighting the importance of testing a range of case definitions.  
• Validated case definition algorithms are often specific to the database they were 
developed in, limiting their generalisability. 
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3.1 Preface 
This chapter reports on a systematic review of validation methods of asthma recording 
in electronic health records. The primary objectives of this systematic review were to 
provide an overview of the methods used in the literature for validating asthma 
diagnosis in EHR and to provide the corresponding estimates of the validation test 
measures. To do this, I synthesised and appraised the current evidence and test values 
of strategies to identify asthma patients in electronic health records. 
The motivation for this systematic review was to prepare for the subsequent 
validation study of algorithms to identify asthma patients in the CPRD GOLD 
(Chapter 4). The first paper describes the protocol of the systematic review and the 
second paper contains the systematic review itself. The search algorithms for this 
systematic review are included in the appendix. 
Previously to this systematic review, two systematic reviews had been conducted with 
similar study questions. The first review by Sharifi et al was published in 2013 and 
contained a review of validation methods to capture acute bronchospasm in 
administrative or claims data.(253) This study found two validation studies of 
bronchospasm codes.(254,255) However, the study was limited to administrative and 
claims databases which originated in either the United States or Canada and only 
included a symptom (bronchospasm) rather than asthma itself. The second study was 
published in 2017 by Al Sallakh et al. The authors explored approaches to defining 
asthma or assessing asthma outcomes using electronic health record-derived data in 
the literature from 2014 and 2015 and examined the clarity of reporting.(256) This 
review focussed solely on how asthma was defined and did not include an overview 
of test measures or validation statistics such as positive predictive values (PPVs), 
negative predictive values (NPVs), sensitivity or specificity and was published shortly 
before the systematic review included in this thesis. 
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In epidemiological studies using electronic health records, the validity of codes and 
algorithms are quantified using diagnostic accuracy measures: the positive predictive 
value, negative predictive value, sensitivity and specificity. Several test measures 
were reported as different study types need to focus on various database measures to 
identify asthma diagnoses. For example, studies of risk factors for asthma need high 
sensitivities and PPVs, while studies on asthma prevalence need high sensitivities and 
Youden indices.(257) PPVs tend to be higher when derived from databases using both 
diagnosis and prescription data when compared with databases relying only on 
diagnosis data.(258) 
The PPV is the proportion of positive results that are true positive results, while the 
NPV is the proportion of negative results that are true negative results. Sensitivity 
measures the proportion of actual positives that are correctly identified as such, and 
the specificity measures the proportion of actual negatives that are correctly identified 
as such. The sensitivity and specificity can be combined to form the Youden’s index 
or Youden’s J statistic, which is defined as (J= sensitivity +specificity -1).(259) Another 
measure of validity is face validity, in which researchers compare the prevalence of a 
disease within a population with the prevalence in the data. This method can only 
provide rough estimates and is not exact. For example, If the over-and underdiagnosis 
rates of a disease are similar, the face validity will not be able to measure any of 
those.The PPV is the most reported test statistic in the CPRD GOLD and EHRs in 
general,(229) and useful to determine the percentage of patients with asthma codes 
who actually have asthma. The fourth chapter of this thesis describes a study to find 
the optimal algorithm to identify asthma patients from the CPRD GOLD using 
questionnaires to GPs, based on PPVs. 
Quality assessment of the studies included in the systematic review was done using 
the QUADAS-2 tool. The QUADAS-2 tool was constructed to allow for more 
transparent rating of bias and applicability of primary diagnostic accuracy studies 
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and is available from the QUADAS website (www.quadas.org). This tool is included 
in the appendix of this chapter. 
In conclusion, the primary objectives of this systematic review were to provide an 
overview of both the methods with which asthma diagnosis recording has been 
validated in EHR and the estimates of the validation test measures. Specifically, I 
listed the EHR databases, algorithms, diagnostic criteria and estimate values of the 
PPVs, NPVs, sensitivities and specificities. 
The protocol of the systematic review was originally published in BMJ Open, and is 
available here:  
Nissen F, Quint JK, Wilkinson S, Mullerova H, Smeeth L, Douglas IJ.: ‘Validation of 
asthma recording in electronic health records: protocol for a systematic review’. BMJ 
Open. 2017 May 29;7(5), https://www.ncbi.nlm.nih.gov/pubmed/28554919 
The systematic review was published in Clinical epidemiology, and is available on: 
Nissen F, Quint JK, Wilkinson S, Mullerova H, Smeeth L, Douglas IJ. ‘Validation of 
asthma recording in electronic health records: a systematic review’. Clin Epidemiol. 
2017 Dec 1;9:643-656. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716672/ 
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3.2 Research paper 1: Protocol for a systematic review 
Validation of asthma recording in electronic health records: protocol for a 
systematic review 
Authors: Francis Nissen,1 Jennifer K Quint,2  Samantha Wilkinson,1 Hana Mullerova,3 
Liam Smeeth,1 Ian J Douglas1 
1Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical 
Medicine, London, UK 
2National Heart and Lung Institute, Imperial College, London, UK 
3RWD & Epidemiology, GSK R&D, Uxbridge, UK 
 
ABSTRACT 
Background: Asthma is a common, heterogeneous disease with significant morbidity 
and mortality worldwide. It can be difficult to define in epidemiological studies using 
electronic health records, as the diagnosis is based on non-specific respiratory 
symptoms and spirometry, neither of which are routinely registered. Electronic health 
records can nonetheless be valuable to study the epidemiology, management, health-
care utilization and control of asthma. For health databases to be useful sources of 
information, asthma diagnoses should ideally be validated. The primary objectives 
are to provide an overview of the methods used to validate asthma diagnoses in 
electronic health records and summarise the results of the validation studies.  
Methods: EMBASE and MEDLINE will be systematically searched for appropriate 
search terms. The searches will cover all studies in these databases up to October 2016 
with no start date and will yield studies that have validated algorithms or codes for 
the diagnosis of asthma in electronic health records. At least one test validation 
measure (sensitivity, specificity, positive predictive value, negative predictive value 
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or other) is necessary for inclusion. In addition, we require the validated algorithms 
to be compared with an external golden standard, such as a manual review, a 
questionnaire or an independent second database. We will summarise key data 
including author, year of publication, country, time period, date, data source, 
population, case characteristics, clinical events, algorithms, gold standard and 
validation statistics in a uniform table. 
Ethics and dissemination: This study is a synthesis of previously published studies 
and, therefore, no ethical approval is required. The results will be submitted to a peer-
reviewed journal for publication. Results from this systematic review can be used to 
study outcome research on asthma and can be used to identify case definitions for 
asthma. 
Trial registration number 
The protocol has been registered in the PROSPERO database with registration number 
CRD42016041798. 
Keywords 
Asthma, Validation, Electronic Health Records, Sensitivity, Specificity, Positive 
Predictive Value, Negative Predictive Value 
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Strengths and limitations of this study 
To our knowledge, this is the first systematic review to identify and evaluate methods 
used to validate a recording of asthma diagnosis in electronic health records.  
The review of validation of asthma diagnosis in electronic health records could inform 
selection of asthma identification algorithms used by future health outcome studies 
and identify any gaps in quality and scope of validation studies. It will also provide 
an overview of the algorithms with their PPV, NPV, sensitivity or specificity. 
Different databases may validate different algorithms to identify asthma, which might 
limit the generalisability of these algorithms as they are context-specific. 
This review is focused on the methodology of asthma recording validation, and not 
on all outcome results of studies (except the validation results). Because of this, 
publication bias might be an issue (methods that do not find positive results may be 
less likely to have been published).  
BACKGROUND 
Asthma is a common chronic inflammatory disease of the airways. This condition is 
characterised by a variable expiratory airflow limitation which is generally reversible.  
The core symptoms are cough, wheeze, breathlessness and chest tightness.(2) Asthma 
episodes can range from mild attacks, which interrupt daily life and work 
productivity, to severe and life-threatening attacks.(3) Asthma is inherently variable, 
and individuals will experience fluctuating symptoms. Most commonly, asthma 
emerges in childhood, but it can also arise in adulthood. Therefore, adult asthma 
consists of both persistent or relapsed childhood disease and true incident adult 
disease. There is no cure, but with the right treatment, symptoms can usually be 
managed and asthma patients can lead their lives without disruption.(260) 
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The widespread adoption of electronic health records (EHR) means that large 
population-based primary and secondary care databases are available, proving a great 
opportunity for research on asthma and other diseases. The availability of routinely 
generated longitudinal records for research has dramatically increased over the last 
decades.(260) However, the primary function of EHR is to support healthcare clinical 
decision making, not research purposes. The integrity of the research generated from 
EHR may be questionable, unless data are thoroughly validated for this purpose. 
(209,261–263) 
EHR are a digital reflection of the paper medical chart, while the main purpose of 
administrative claims data is administration of reimbursements to healthcare 
providers for their services. This systematic review will only consider data from EHR, 
as the quality measures between the two types of data can be markedly 
different.(264,265) 
EHR store information about diagnoses as clinical codes. A single code, or an 
algorithm consisting of multiple codes, can be used to retrieve records from EHR, and 
additional restrictions can be applied such as age or exclusion of other diseases. 
(263,266)Alternatively, several authors have recently used natural language 
processing and machine learning techniques to automate algorithm generation for the 
identification of asthma diagnoses from large databases.(255,267,268) The most 
common method to assess the validity of  algorithms is to compare them with a gold 
standard such as another linkable dataset or request a verification from the treating 
physician or the patient via a questionnaire.(266) Another approach is active case 
detection where the databases are constantly screened to identify cases that 
emerge.(269) 
Several limitations apply to the validation of diagnosis recording in EHR. First,  
individual databases often only cover a single care setting (primary or secondary 
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care), as such case ascertainment only relies on a partial description of the healthcare 
pathway [15].(270) Another issue is that the validity of different diseases will not 
necessarily be the same in a given dataset. For example, mental health disorders such 
as anxiety or depression might be coded using less specific symptoms, whereas the 
validity of diagnoses with a very high specificity such as breast cancer is likely to be 
superior. There have been multiple studies which have measured the validity of 
specific databases for asthma.(271,272) Sharifi et al. have conducted a systematic 
review on validated methods to capture acute bronchospasm using administrative or 
claims data,(253) which yielded two validation studies of bronchospasm 
codes.(254,255) 
This systematic literature review aims to provide an overview of methods used to 
validate asthma diagnoses, specifically in EHR. Such a study has not yet been 
published in the medical literature, to the best of our knowledge. 
Research question 
The primary objectives of this systematic review are to provide an overview of both 
the methods with which asthma diagnosis recording has been validated in EHR and 
the estimates of the validation test measures. 
The questions of interest for this systematic review are: 
• Which EHR that are not only based on claims data have been used to obtain 
information on the diagnosis of asthma? 
• Which algorithms have been used to define an asthma diagnosis (including 
diagnostic codes, possible spirometry tests and clinical descriptions)? 
• How were the diagnostic criteria applied to the data sources and which other 
approaches have been used to validate a case definition? 
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• What are the estimates for the PPV, NPV, specificity and sensitivity for a 
diagnosis of asthma in EHR that are not solely claims-based? 
METHODS 
MEDLINE and EMBASE will be searched for the terms “asthma”, “validation”, 
“electronic databases” and synonyms for each of these terms. In addition, reference 
lists of review articles and retrieved articles will be reviewed. The PRISMA flow 
diagram of this protocol, from Moher et al.,(273) can be found in figure 1 and the 
search strategy can be found in the supplementary file. 
Inclusion criteria 
Any type of observational study design that used EHR to validate the recording of an 
asthma diagnosis will be considered. Articles will only be considered if published in 
English and before October 2016 without any specific start date.  Within the databases, 
we will consider asthma diagnoses based on both structured data (such as laboratory 
results and prescriptions) and free text data (such as spirometry results). We require 
the validated algorithms to be compared with an external gold standard, such as a 
manual review, questionnaires (completed by the patient or their physician) or an 
independent second database. We will include algorithms formed of single codes, 
those requiring multiple case characteristics and algorithms generated by natural 
language processing or machine-learning. 
Exclusion criteria 
Studies which involve pharmacovigilance databases (signal detection or spontaneous 
reporting), studies without validation process of asthma recording and conference 
abstracts will be excluded. Algorithms used in databases originating from only claims 
data will also be excluded, as a systematic review on the validated methods to capture 
acute bronchospasm using claims data has been published recently.(253) 
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Two independent authors will scan the abstracts and titles against the research 
questions and exclusion criteria and select articles for full-text review. After this full-
text article review, eligibility for inclusion in the report will be decided by consensus 
or arbitration by a third reviewer. A uniform table with information of each included 
study will be populated after data extraction, which will include information on the 
author, date of publication, journal, database, algorithms, population, gold standard 
and test measure(s). 
Data synthesis 
Studies and study data will be managed using EndNote and Microsoft Excel, 
respectively. The methods for asthma recording validation will be summarised in a 
narrative synthesis and tables describing all identified verification processes, and their 
results. These results will consist of the recorded PPV, NPV, sensitivity and specificity 
of the included studies. Where possible, these tests will be calculated if they are not 
reported within the study. 
Dissemination and ethics 
This study is a synthesis of previously published studies, so no ethical approval is 
required. The protocol has been registered in the PROSPERO database with 
registration number CRD42016041798. The results will be submitted for publication 
and will be disseminated through research conferences and peer reviewed journals.  
Funding statement 
This work was supported by GlaxoSmithKline (GSK), through a PhD scholarship for 
FN with grant number EPNCZF5310. The publishing of this study was supported by 
the Wellcome Trust: grant number 098504/Z/12/Z. 
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3.3 Research paper 2: Systematic review 
Validation of asthma recording in electronic health records: a systematic review 
Authors: Francis Nissen,1 Jennifer K Quint,2  Samantha Wilkinson,1 Hana Mullerova,3 
Liam Smeeth,1 Ian J Douglas1 
1Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical 
Medicine, London, UK 
2National Heart and Lung Institute, Imperial College, London, UK 
3RWD & Epidemiology, GSK R&D, Uxbridge, UK 
 
ABSTRACT 
Objective: To describe the methods used to validate asthma diagnoses in electronic 
health records and summarise the results of the validation studies.  
Background:  Electronic health records are increasingly being used for research on 
asthma to inform health services and health policy. Validation of the recording of 
asthma diagnoses in electronic health records is essential to use these databases for 
credible epidemiological asthma research. 
Methods: We searched EMBASE and MEDLINE databases for studies that validated 
asthma diagnoses detected in electronic health records up to October 2016. Two 
reviewers independently assessed the full text against the predetermined inclusion 
criteria. Key data including author, year, data source, case definitions, reference 
standard and validation statistics (including sensitivity, specificity, PPV and NPV) 
were summarised in a uniform table. 
Results: Thirteen studies met the inclusion criteria. Most studies demonstrated a high 
validity using at least one case definition (PPV>80%). Ten studies used a manual 
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validation as the reference standard; each had at least one case definition with a PPV 
of at least 63%, up to 100%. We also found 2 studies using a second independent 
database to validate asthma diagnoses. The PPV’s of the best performing case 
definitions ranged from 46% to 58%. We found one study which used a questionnaire 
as the reference standard to validate a database case definition; the PPV of the case 
definition algorithm in this study was 89%.  
Conclusions:  
Attaining high PPV’s (>80%) is possible using each of the discussed validation 
methods. Identifying asthma cases in electronic health records is possible with high 
sensitivity, specificity or positive predictive value, by combining multiple data 
sources, or by focussing on specific test measures. Studies testing a range of case 
definition show wide variation in the validity of each definition, suggesting this may 
be important for obtaining asthma definitions with optimal validity.  
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Strengths and limitations of this study 
The review of validation of asthma diagnosis codes in electronic health records 
informs selection of asthma definitions used by future studies and identify any gaps 
in quality and scope of validation studies. It also provides an overview of the case 
definitions and algorithms with their PPV, NPV, sensitivity or specificity. 
Validated case definition algorithms are often very specific to the database they were 
developed in, limiting their generalizability. 
Publication bias might be an issue as methods that do not find favorable results may 
be less likely to have been published.  
BACKGROUND 
Asthma is one of the most common chronic diseases, and its core symptoms are cough, 
wheeze, breathlessness and chest tightness.(2) There is no cure, but with the right 
treatment, symptoms ranging from mild attacks to severe and life-threatening 
exacerbation2 can be managed.(3) Despite this, a sizeable percentage of asthma 
patients are poorly controlled.(274,275)  
 Electronic health records (EHR) have been widely adopted, which allows for the 
construction of large population-based patient databases. The availability of these 
routinely generated longitudinal records for research has greatly increased over the 
last decades.(260)   However, the accuracy of diagnoses recorded in these large 
databases may be low, which would introduce bias into studies using the data. Unless 
the data are validated for research, the quality of studies generated from EHR’s may 
be debatable.(209,261–263) Furthermore, the validity of different disease definitions is 
not always the same in a given dataset. Some diseases (such as asthma) might be coded 
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using less specific symptoms, whereas the validity of diagnoses with very specific 
symptoms (such as tension pneumothorax) is likely to be better.  
EHRs predominantly store information about diagnoses as clinical codes. A single 
code, or a case definition consisting of multiple codes (with or without additional 
information such as tests or prescribing) can be used to retrieve records from EHRs, 
and additional restrictions can be applied such as age or exclusion of other 
diseases.(263,266) Validity of coding is generally assessed by comparing a code (or 
algorithm) with i) the diagnosis as verified by the treating physician either by manual 
review of the chart notes or in clinic, ii) a reference standard such as another linked 
dataset or iii)  a patient questionnaire.(266) A previous systematic review by Sharifi et 
al reviewed validation methods to capture acute bronchospasm in administrative or 
claims data;(253) this review identified two validation studies of bronchospasm 
codes.(254,255) However, the study was limited to administrative and claims 
databases, from the United States and Canada. Al Sallakh et al explored approaches 
to defining asthma or assessing asthma outcomes using electronic health record-
derived data in the recent literature (calendar years 2014 and 2015) and examined the 
clarity of reporting.(256) This systematic review focuses on how asthma was defined 
and does not include an overview of test measures or validation statistics.  
There is currently no consensus on approaches to defining asthma or assessing asthma 
outcomes using electronic health record-derived data. We explored these approaches 
in the recent literature and examined the clarity of reporting. 
Research objective 
The primary objectives of this systematic review are to provide an overview of the 
methods used in the literature for validating asthma diagnosis in EHR, and the 
corresponding estimates of the validation test measures. 
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METHODS 
The methods are described in detail in the study protocol.(276) We searched Medline 
and Embase up to October 2016 for relevant articles. Our search strategy was 
composed of the following sets of terms: [1] electronic health records or databases 
AND [2] [validity or validation or case definition or algorithm or sensitivity or 
specificity or positive predictive value or negative predictive value] AND [3] the 
medical subject heading terms for asthma. Reference lists of articles of interest were 
reviewed to add potential additional studies in which a validation of asthma diagnosis 
was done. The PRISMA flow diagram can be found in figure 1 and the search strategy 
can be found in the appendix. We considered any type of observational study design 
that used EHR to validate the recording of a diagnosis of asthma. In addition, we 
required a clear case definition to define asthma from EHR, including a description of 
the validation of said case definition through at least one test measure (sensitivity, 
specificity, Positive Predictive Value (PPV) or Negative Predictive Value (NPV)). Two 
investigators (FN and SW) separately assessed the abstracts and full text of each 
potential study against our inclusion criteria; disagreements were resolved through a 
third investigator or by discussion to reach consensus.  The first author independently 
extracted all relevant data regarding methodologic elements of included studies;  
author, year of publication, country, time period, date, data source, population, case 
characteristics, clinical events, algorithms, reference standard and validation statistics. 
Bias was assesses using QUADAS-2 tailored to this specific review.(277)  
The questions of interest for this systematic review are: 
• Which EHR databases were used to obtain information on the diagnosis of 
asthma? 
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• Which case definitions, algorithms or codes were used to define an asthma 
diagnosis? 
• How were the diagnostic criteria applied to the data sources and which other 
approaches have been used to validate a case definition algorithm? 
• What are the estimates for the PPV, NPV, specificity and sensitivity for a 
diagnosis of asthma in an EHR? 
 
Inclusion criteria 
Any type of observational study design which validated the recording of an asthma 
diagnosis in EHR was considered. Articles were only considered if published in 
English and published before October 2016 without any specific start date.  Within the 
databases, we considered asthma diagnoses based on both structured data (such as 
laboratory results and prescriptions) and unstructured data (such as spirometry 
results). We required the validation case definitions to be compared with an external 
reference standard, such as a manual review, questionnaires (completed by the patient 
or their physician) or an independent second database. We included case definitions 
formed of single codes, those requiring multiple case characteristics and case 
definitions generated by natural language processing and/or machine-learning. 
Exclusion criteria 
EHR are a digital reflection of the key facts a healthcare provider needs to record in 
order to facilitate ongoing and potentially complex clinical care. By contrast, the main 
purpose of administrative claims data is administration of reimbursements to 
healthcare providers for their services. This systematic review included only studies 
from EHR, as the quality measures between the two types of data can be markedly 
different; studies using administrative claims data were excluded. Studies involving 
pharmacovigilance databases (signal detection or spontaneous reporting), studies 
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without validation of asthma recording, and conference abstracts were 
excluded.(264,265)  
Data synthesis 
Studies and study data were managed using EndNote and Microsoft Excel, 
respectively.  
The methods for validation of asthma recording in the included studies were outlined 
in a narrative synthesis.  In addition, table 1 summarises the methods and table 2 
describes the results, consisting of the recorded PPV, NPV, sensitivity and specificity 
of the included studies. 
RESULTS 
In total, 1,346 titles were found in the EMBASE and MEDLINE databases, of which 
946 were non-duplicates. Of those, 54 articles were reviewed in full text, we found 13 
articles that contained a validation process of asthma diagnosis that met all eligibility 
criteria. Characteristics of the 13 included studies ordered by year of publication are 
summarised in table 1, and the study results are displayed in table 2. The asthma 
prevalence necessary for the interpretation of PPVs and NPVs is presented in table 1, 
where available. 
 The reference standard used to validate the asthma diagnosis in the EHR differed 
between the studies: ten studies used manual validation by a clinician, while two other 
studies compared the studied records with independent linked databases and one 
study used patient questionnaires. The test measures also differ between the different 
papers, encompassing sensitivity, specificity, PPV and NPV. We focus on 13 studies 
in this review, ordered by reference standard used and by date of publication. Bias 
assessment results using QUADAS-2 are presented in table 3. 
92  
  
 
Figure 1: PRISMA diagram 
  
93  
  
Author, year, 
country 
Data source, 
population 
Sample/case 
characteristics 
Clinical 
event 
Algorithm Validation 
Manual validation 
Xi et 
al,(271) 2015 
Canada 
2 large 
academic 
primary care 
clinics 
Primary care 
398 randomly 
selected patients 
16 years and 
older 
Asthma 
code 
COPD 
code 
Other 
respiratory 
condition 
code 
Other 
condition 
code 
Search algorithms: 
1. Asthma in disease registry 
2. Billing code 
3. Asthma in CPP 
4. Asthma medications 
5. Asthma in chart notes 
6. Asthma in CPP OR billing 
code 493 
7. Asthma in CPP OR billing 
code 493 (exclusion codes 
491,492, and 496) 
8. (Asthma in chart notes OR 
asthma medications) AND billing 
code 493 
9. (Billing code 493 OR 
medications) AND asthma in 
chart notes 
10. Billing diagnostic code 493 
AND asthma in chart notes 
Manual review 
Engelkes et 
al,(278) 2014 
the Netherlands 
ICPI: Dutch 
GP EHR 
Primary care 
63,518 potential 
cases identified 
22,699 cases 
after automated 
text validation 
Children aged 5–
18 
Definite, 
probable, 
and 
doubtful 
cases of 
asthma 
Combination of ICPI 
communication codes, clinician 
codes, drug names and free text 
generated by a machine-learning 
algorithm (RIPPER) 
22,699 cases manually 
validated, 14,303 
asthma cases found 
Afzal et 
al,(267) 2013 
the Netherlands 
January 2000–
January 2012 
ICPI: Dutch 
GP EHR 
Primary care 
63,618 potential 
asthma cases 
identified, 
children aged 5–
18 
Definite, 
probable, 
and 
doubtful 
cases of 
asthma 
Combination of ICPI 
communication codes, clinician 
codes, drug names and free text 
generated by a machine-learning 
algorithm (RIPPER) 
5,032 patients manually 
validated by clinician 
Dexheimer et 
al,(279) 2013 
United States 
1 pediatric 
A&E 
department 
15,163 assessed, 
1,100 asthma 
patients all 
asthma patients 
(2–18 years) in a 
3-month time 
window 
Asthma 
code 
Bayesian network system 
previously used on claims data 
(Sanders) 
Paediatric 
asthma/respiratory 
distress protocol filled 
in for identified patients 
Wu et 
al,(280) 2013, 
2014 
United States 
Children 
enrolled in 
the Mayo 
Clinic sick-
child daycare 
program, 
Secondary 
care 
112 children 
younger than 4 
ICD-9 
codes 
Natural 
language 
Natural language processing 
(logic) 
Natural language processing 
(machine learning) 
Manual review by a 
clinician 
94  
  
Author, year, 
country 
Data source, 
population 
Sample/case 
characteristics 
Clinical 
event 
Algorithm Validation 
Kozyrskyj et 
al,(281) 2009 
Canada 
SAGE: birth 
cohort of 
16,320 
children born 
in 1995 in 
Manitoba, 
Canada 
Questionnaire 
in 2002 had 
3,598 
responses 
Manitoba’s 
health care 
registry 
records 
723 children 
from the group 
with completed 
questionnaires 
246 cases, 477 
controls 
Asthma Database definitions in health 
care records 
Paediatric allergist 
diagnosis of asthma 
Pacheco et 
al,(282) 2009 
United States 
NUgene 
Project 
Genome-
wide 
association 
study 
7,970 people 
with DNA 
samples, of 
which 521 had an 
asthma diagnosis 
Asthma 
diagnosis 
Initial asthma cases algorithm: 
Asthma diagnosis and asthma 
medication prescription on ≥1 
visit AND no other chronic lung 
disease diagnosis on ≥2 visits 
AND no reported smoking 
history ≥10 years 
Final asthma cases algorithm: 
Asthma diagnosis on ≥1 visit 
AND asthma diagnosis or 
medication prescription on ≥1 
other visit AND no other chronic 
lung disease diagnosis on ≥2 
visits AND no reported smoking 
history ≥10 years 
Initial asthma controls 
algorithm: 
No diagnosis for any respiratory 
disease or cancer AND no 
prescription of any 
astha/COPD/iimmunodepressant 
medication AND no reported 
smoking history ≥10 years 
Final asthma controls 
algorithm: 
≥2 visits with any asthma 
diagnosis or prescriptions AND 
no diagnosis for any respiratory 
disease or listed cancer AND no 
prescription of any 
asthma/COPD/immunodepressant 
medication AND no reported 
smoking history ≥10 years 
Manual review of 100 
cases for both 
algorithms 
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Author, year, 
country 
Data source, 
population 
Sample/case 
characteristics 
Clinical 
event 
Algorithm Validation 
Vollmer et 
al,(283) 2004 
United States 
July 1998 to 
January 1999 
KPNW, Epic, 
OSCAR, 
TOPS ED, 
secondary 
care 
235,000 patients 
with continuous 
health plan 
eligibility aged 
15–55 in January 
1999 
9,723 asthma 
patients 
identified 
ICD-9 
codes 
Health care utilization profiles 
used for validation study 
1. Four “high-probable” 
categories: 
→ Two or more non-urgent care 
outpatient contacts for asthma 
→ A single non-urgent contact 
and one or more ED or inpatient 
contact for asthma 
→ Any Industrial Medicine visit 
for asthma 
→ Any asthma visit and either of 
the two medication dispensing 
criteria 
2. Single non-urgent outpatient 
visit only 
3. Four or more β-agonists, with 
or without a nebulizer treatment 
order, but no asthma visits of any 
kind and no ICS dispensing 
4. ED or urgent care visit for 
asthma and nebulizer treatment 
order, but no other medication 
criteria met and no other types of 
asthma visits 
5. Hospitalization for asthma, but 
neither asthma medication 
criterion met and no outpatient 
asthma visits of any kind 
6. ED or urgent care visit for 
asthma, but no other types of 
asthma visits and no asthma 
medication criteria met 
7. Nebulizer treatment but no 
asthma visits of any kind and no 
other medication criteria met 
8. All other cases 
Criteria used in 
medical records 
review Probable 
asthma 
• Two or more asthma 
health care visits 
• A single visit for 
asthma with a chart 
notation indicating a 
prior history of asthma 
• A single health care 
visit for active 
symptoms of asthma 
(wheeze, cough, 
shortness of breath) 
• A single visit for an 
asthma exacerbation 
that responds to 
therapy, even if no prior 
history 
Possible asthma 
• Patient-reported 
history of asthma noted 
in chart, but no 
evidence of active 
asthma or treatment for 
asthma 
• An uncorroborated 
ED diagnosis of asthma 
• Diagnosis of “rule out 
asthma” with no clear 
resolution 
Donahue et 
al,(284) 1997 
United States 
Harvard 
Pilgrim 
Health Care 
(HPHC); 
Primary, 
secondary 
and 
emergency 
care 
Random sample 
of 100 patients 
Asthma 
code 
Asthma diagnosis and asthma 
drug dispensing 
Manual review by 
clinicians 
Premaratne et 
al,(285) 1997 
Accident and 
emergency 
departmentss 
All asthma 
patients January–
March 1994 
String 
containing 
“asth*” 
String containing “asth*” in the 
free text records 
Affirmation of asthma 
diagnosis: 
Final diagnosis of 
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Author, year, 
country 
Data source, 
population 
Sample/case 
characteristics 
Clinical 
event 
Algorithm Validation 
United Kingdom 
1994 
of two 
hospitals 
1,185 records, of 
which 209 did 
not have enough 
data 
asthma by clinical 
officer OR symptoms 
of asthma and (history 
of asthma or 
bronchodilators given, 
with improvement) 
OR known asthmatic 
presented with 
symptoms or for 
medication 
Rejection of asthma 
diagnosis: 
Clear alternative 
diagnosis Sufficient 
other information to 
reject asthma diagnosis 
Comparison with an in dependent database 
Engeland et 
al,(286) 2009 
Norway 
MBRN: 
population-
based birth 
registry, all 
births in 
Norway since 
1967 (more 
than 2.3 
million) 
NorPD: all 
dispensed 
prescriptions 
from January 
2004 in 
Norway 
108,489 
pregnancies, of 
which 4,549 
mothers were 
recorded as 
having asthma in 
MBRN 
Asthma Asthma diagnosis in MBRN NorPD: asthma 
medication 
Coulter et 
al,(287) 1989 
United Kingdom 
7 general 
practices in 
the Oxford 
community 
health project 
2,199 
patients on 
medication 
Primary care 
2,443 on digital 
register 
Bronchodilators, 
inhaled CS, 
prophylactic 
drugs 
Asthma 
diagnosis 
Asthma diagnosis on register Manual review against 
the list of patients on 
long-term medication 
Comparison with a questionnaire 
Ward et 
al,(288) 2004 
United Kingdom 
1995–2004 
GP Practice 
with 14,830 
patients 
83 1 controls, 
587 
833 asthma 
patients, 659 
responses 
16–55 years on 1 
October 1997 
Asthma in 
GP 
database 
One of the following criteria: 
1. Read coded “asthma” 
diagnosis, H33 
2. Attendances recorded on the 
asthma care screen 
3. An intervention for asthma 
Questionnaire to 
determine bronchial 
hyperreactivity 
Cases: asthma in 
database Asthma 
diagnosis and bronchial 
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Author, year, 
country 
Data source, 
population 
Sample/case 
characteristics 
Clinical 
event 
Algorithm Validation 
responses 
Primary care 
recorded 
4. A textual entry “asthma” or 
“wheez” in the medical history 
5. Inhaled steroids in the repeat 
prescriptions 
6. Inhaled bronchodilators in the 
repeat prescriptions 
7. Cromolyns in the repeat 
prescriptions 
hyperreactivity: 
considered positive 
Asthma diagnosis 
without bronchial 
hyperreactivity: further 
investigated in GP 
record 
Controls: bronchial 
hyperreactivity but no 
asthma diagnosis 
Table 1: Characteristics of studies with validated asthma algorithms 
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Table 2: Characteristics of studies with validated asthma algorithms 
Author, 
year, 
country 
Algorithm Sensitivity, 
95% CI 
Specificity, 
95% CI 
PPV, 
95% CI 
NPV, 
95% 
CI 
Prev-
alence 
Manual validation 
Xi et 
al,(271) 2015 
Canada 
1. Asthma in disease registry 7%  
(5–10) 
99%  
(97–100) 
67% 
(38–87) 
73% 
 (72–
74) 
8.1% 
2. Billing code 77%  
(75–83) 
89%  
(86–92) 
74% 
(67–80) 
91% 
(88–94) 
 
3. Asthma in CPP 63%  
(59–68) 
92%  
(90–95) 
76% 
(68–83) 
87%  
(83–89) 
 
 4. Asthma medications 79%  
(75–83) 
64%  
(59–68) 
46% 
(41–50) 
88% 
(84–92) 
 
 5. Asthma in chart notes 85%  
(81–88) 
76%  
(72–80) 
58% 
(52–63) 
93% 
(89–95) 
 
 6. Asthma in CPP OR billing code 493 90%  
(87–93) 
84%  
(80–88) 
69% 
(63–74) 
96% 
(93–97) 
 
 7. Asthma in CPP OR billing code 493 
(exclusion codes 491, 492, and 496) 
87%  
(83–90) 
85%  
(82–89) 
70% 
(63–76) 
94%  
(91–96) 
 
 8. (Asthma in chart notes OR asthma 
medications) AND billing code 493 
78%  
(74–82) 
92%  
(89–95) 
79% 
(72–85) 
91%  
(88–94) 
 
 9. (Billing code 493 OR medications) 
AND asthma in chart note 
84%  
(80–88) 
84%  
(80–88) 
67% 
(61–73) 
93%  
(90–95) 
 
 10. Billing diagnostic code 493 AND 
asthma in chart notes 
74%  
(70–78) 
93%  
(91–96) 
81% 
(73–87) 
90%  
(87–93) 
 
Engelkes et 
al,(278) 2014 
Netherlands 
Definite, probable and doubtful cases   63%   
Afzal et 
al,(267) 2013 
Netherlands 
Definite asthma 98% 95% 66%  6% 
Definite + probable 96% 90% 82%  29% 
Definite, probable and doubtful cases 95% 67% 57%  32% 
Dexheimer et 
al,(279) 2013 
United States 
Algorithm constructed using a 
Bayesian network system 
  64%  7–10% 
Wu et 
al,(280) 2013/ 
ICD-9 codes 31 93 57 82 4–17% 
Natural language processing: logic 81 95 84 94  
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Author, 
year, 
country 
Algorithm Sensitivity, 
95% CI 
Specificity, 
95% CI 
PPV, 
95% CI 
NPV, 
95% 
CI 
Prev-
alence 
2014 
United States 
Natural language processing: machine 
learning 
85 97 88 95  
Kozyrskyj et 
al,(281) 2009 
Canada 
At least one asthma hospitalization, or 
two physician visits, or four 
prescription medications 
47%  
(35–60) 
92%  
(78–98) 
91% 
(76–98) 
 11% 
At least one asthma hospitalization, or 
two physician visits, or two 
prescription medications 
67%  
(54–78) 
92%  
(78–98) 
94% 
(82–99) 
  
At least one asthma hospitalization, or 
one physician visit, or two prescription 
medications 
77%  
(65–87) 
92%  
(78–98) 
94% 
(85–99) 
  
 At least one asthma hospitalization, or 
one physician visit, or two 
bronchodilators, or one controller 
medication 
80%  
(69–89) 
89%  
(74–97) 
93% 
(83–98) 
  
 At least one asthma hospitalization, or 
one physician visit, or two 
bronchodilators, or one bronchodilator 
and ketotifen or an oral steroid, or one 
controller medication 
80%  
(69–89) 
89%  
(74–97) 
93% 
(83–98) 
  
 At least one asthma hospitalization, or 
one physician visit, or one 
bronchodilator, or one controller 
medication 
82%  
(70–90) 
83%  
(67–94) 
90% 
(79–96) 
  
Pacheco et al, 
(282) 2009 
United States 
Initial algorithm 70%  
(60–78) 
100% 100% 
(90–
100) 
77%  
(65–86) 
7.2% 
 Final algorithm 95%  
(84–99) 
96%  
(87–99) 
95%  
(84–99) 
96%  
(87–99) 
 
Vollmer et 
al,(283) 2004 
United States 
Algorithm 1: population of 4460   95%  4.1% 
Algorithm 2: population of 2334   90%   
Algorithm 3: population of 545   70%   
 Algorithm 4: population of 25   100%   
 Algorithm 5: population of 11   50%   
 Algorithm 6: population of 721   80%   
 Algorithm 7: population of 99   27%   
 Algorithm 8: population of 1528   80%   
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Author, 
year, 
country 
Algorithm Sensitivity, 
95% CI 
Specificity, 
95% CI 
PPV, 
95% CI 
NPV, 
95% 
CI 
Prev-
alence 
Donahue et 
al,(284) 1997 
United States 
Asthma code and drug dispensing   86%  3% 
Premaratne et 
al,(285) 1997 
United 
Kingdom 
String containing asth* in free text 
records 
80%  
(75–86) 
96%  
(96–99) 
91% 
(87–94) 
94%  
(93–95) 
20.6% 
Comparison with an in dependent database  
Engeland et 
al,(286) 2009 
Norway 
Asthma in MBRN and NorPD 51%  
(49–52) 
98%  
(98–98) 
46% 
(45–48) 
 4.20% 
Coulter et 
al,(287) 1989 
United 
Kingdom 
Percentage of people on long term 
medication and recorded on the 
register 
  58%   
Comparison with a questionnaire 
Ward et 
al,(288) 2004 
United 
Kingdom 
 
Total of all reviewed patients 
Cases without bronchial 
hyperreactivity 
Controls with bronchial 
hyperreactivity 
  89% 
73% 
78% 
 5.60% 
Table 2: Test measures of studies with validated asthma algorithms 
Manual validation 
We found ten studies that used a manual validation as the reference standard. All 
studies had at least one case definition algorithm with a PPV of at least 63%. Where 
other measurements could be calculated, the studies had at least one case definition 
with a sensitivity of at least 85%, specificity of at least 92% and NPV of at least 94%. 
Within this group, four studies used case definition algorithms generated by machine 
learning. Five studies included only children, while two studies included only persons 
older than 16 years. 
Xi and colleagues tested a variety of EHR search algorithms based on two large 
academic primary care clinics in Hamilton, Canada.(271) The reference standard 
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consisted of a physician chart review–based diagnosis. The eight case definitions are 
presented in table 1, and their PPVs in table 2.  The algorithm searching for patients 
who had asthma in their patient profile or had an asthma billing code was the most 
accurate with a sensitivity of 90% (95% CI (87% to 93%)) and a specificity of 84% (95% 
CI (80% to 88%)). 
Engelkes and colleagues undertook a study to determine the validity of case 
definitions generated by machine learning to define asthma cases, based on a previous 
study be Afzal et al.(267,278) Originating from a large Dutch general practitioner 
database, the authors manually reviewed 22,699 potential asthma cases. Among those, 
14,303 asthma cases were found, which resulted in a PPV of 63%. 
The study by Afzal et al uses the same dataset and machine-learning algorithm for 
definite and potential asthma cases as the study by Engelkes.(267,278) Clinicians 
manually validated 5,032 potential asthma cases identified by a broad search 
algorithm out of 63,618 patients. This training set was used for the machine-learning 
algorithm. The test measures are measuring the validity of the machine learning 
algorithm within the smaller population, not of the broad search algorithm.  The PPV, 
sensitivity and specificity for three case definition algorithms (definite cases; definite 
and probable cases; definite, probable and doubtful cases) were calculated. The PPV’s 
range from 57% for all definite, probable and doubtful asthma cases to 82% for only 
the definite asthma cases.  
Dexheimer and colleagues evaluated a computerized asthma detection system in an 
urban, tertiary care paediatric emergency department in a 3-month prospective, 
randomized controlled trial in 2009.(279) A Bayesian network system screened all 
emergency department patients for acute asthma. The system identified 1,100 patients 
with asthma exacerbations, of which 704 were confirmed by a paediatric emergency 
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care physician within 3 days of the visit. The PPV for the Bayesian network system 
was 65%.  
Wu et al evaluated the accuracy of a computational approach to asthma 
ascertainment. The authors developed a natural language processing (NLP) system 
for extracting predetermined asthma from free text in EHR.(280) Manual chart review 
by a clinician was the reference standard. The patient group consisted of 112 children 
younger than 4 years. The NLP-generated case definition algorithms had a sensitivity 
of 85%, specificity of 97%, PPV of 88%, a NPV of 95%. For comparison, the test 
measures of the ICD-9 asthma codes were calculated (sensitivity 31%, specificity 93%, 
PPV 57%, NPV 82%).  
Kozyrskyj and colleagues described the Study of Asthma, Genes and the Environment 
(SAGE). The study captures the longitudinal healthcare records of 16,320 children 
born in 1995 in Manitoba (Canada) and contains detailed information on early-life 
exposures in relationship to the development of asthma.(281) Within the birth cohort, 
a nested case-control study with 723 children was partly created to confirm asthma 
status in children and these data were used to validate healthcare database measures 
of asthma. These 723 children were chosen by random sampling from the birth cohort; 
the parents of 288 children with and 435 without a parental report of asthma in the 
last 12 months agreed to participate. The reference standard for the validation 
consisted of paediatric allergist-diagnosed asthma, methacholine challenge tests and 
skin tests. The PPV of asthma definitions varied from 90% to 94%, the sensitivity from 
47% to 82% and the specificity from 83% to 92%. 
Pacheco and colleagues constructed case definitions to identify asthmatic patients as 
cases, and healthy patients as controls using data from electronic medical records in 
the United States. This was done to identify asthma patients for future Genome-Wide 
Association Studies (GWAS). The case definitions consisted of a combination of 
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diagnoses, medications, and smoking history.(282) By applying stringent criteria, the 
study results show a PPV of 95% and a NPV of 96% for identification of asthma cases 
and controls, using clinician review as the reference standard. Genome-wide 
association studies require a high specificity, PPV and NPV. A high specificity was 
achieved but at the loss of 24% of the potential asthma cases. 
Vollmer et al used the electronic databases of a large health maintenance organisation 
to develop a case definition for defining prevalent asthma and to validate it against 
chart review.(283) The data systems of this organisation, the Kaiser Permanente 
Northwest Division (KPNW) consist of both EHR (inpatient data, emergency 
department data, EpicCare) and administrative data: “Outside claims database” 
(OSCAR) and “The outpatient pharmacy system” (TOPS). Table 2 presents the PPV of 
the eight different case definition algorithms to define asthma. The fourth case 
definition based on a combination of an urgent care visit and the order of nebuliser 
treatment (N=25) had the highest PPV (100%), while the first case definition, based on 
non-urgent care visits, (N=4460) had a high PPV of 95%. 
Donahue and colleagues sought to determine the reliability of identifying asthmatics 
through automated medical and pharmacy records. All adult members of the Harvard 
Pilgrim Health Care (HPHC) program who received an asthma diagnosis and at least 
one asthma drug between April 1988 and 1991 were identified.(284) The authors 
manually reviewed records of a random sample of 100 patients to validate the asthma 
diagnosis. The PPV of a coded asthma diagnosis was 86%. 
Premaratne and colleagues measured the validity of the string ‘asth’ in the accident 
and emergency department (A&E) attendance diagnosis field for identifying patients 
with asthma-related conditions attending the A&E departments of two hospitals in 
the UK in 1995.(285) A reception clerk entered the diagnosis field in a database at 
arrival in the A&E department. The reference standard was a confirmation of the 
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asthma diagnosis by a clinical officer, or symptoms of asthma plus a history of asthma 
or bronchodilators given with improvement, or a previously diagnosed asthmatic 
with symptoms or prescribed asthma medication. An ‘attendance diagnosis’ of 
asthma was excluded if there was a clear alternative diagnosis or sufficient other 
evidence to exclude asthma. The string ‘asth’ in the attendance diagnosis field had a 
sensitivity of 80% (75-86%) and a specificity of 97% (96-98%) for a confirmation of 
asthma.  
Linked databases  
Our search found 2 studies which used a second independent database to validate 
asthma diagnoses in the first database. The PPV’s ranged from 46% to 58%. 
Coulter et al (287) compared repeat prescriptions for asthma, epilepsy and thyroid 
disease with chronic disease registers stored on general practice computers in the early 
days of EHR (1989). PPV of an asthma diagnosis on the register was 58% for asthma 
when using medication prescriptions as the reference standard. 
Engeland et al evaluated the reliability of maternal disease registration (diabetes, 
asthma and epilepsy) in the Medical Birth Registry of Norway (MBRN).(286) The data 
they examined consisted of the EHR of 108,489 pregnancies between April 2004 and 
January 2007. The reference standard was the prescriptions in the Norwegian 
Prescription Database (NorPD). The overall sensitivity of an asthma diagnosis in 
MBRN was 51% (49-52), but increasing when considering with a higher asthma 
treatment step in NorPD. The sensitivity was 40% when considering records which 
only used inhaled selective beta-2-adrenoreceptor agonists (step1), while the 
sensitivity of asthma diagnosis in records with systemic drugs other than adrenergics 
for obstructive airway diseases was 73%. 
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Questionnaires 
There was only one study which used a questionnaire as the reference standard for 
database validation.  
Ward and colleagues aimed to determine the degree of under- or over reporting of the 
diagnosis of asthma for patients aged 16–55 years in one large general practice in the 
UK.(288) The case definition described in table 1, (based on either codes, text strings 
or prescriptions) yielded 833 potential asthma cases and 831 age- and sex-matched 
controls from the GP database. A questionnaire validated for the detection of 
bronchial hyper-reactivity was sent to all asthma patients and their matched controls. 
Patients with a diagnosis of asthma and bronchial hyper-reactivity in the 
questionnaire were considered to have asthma. Evidence of asthma was sought for 
two groups: patients with asthma and without symptoms of bronchial hyper-
reactivity, and controls with symptoms of bronchial hyper-reactivity. The results 
show an overall PPV of the case definition of 89%. 
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Table 3: Quality assessment using QUADAS-2 
 Patient 
selection 
Index test Reference 
standard 
Flow and 
timings 
Xi et al, 2015 😊 ? 😊 ? 
Engelkes et al, 2014 😊 😊 😩 😊 
Afzal et al, 2013 😩 😊 😊 😊 
Dexheimer et al, 2013 😊 😊 😊 😊 
Wu et al, 2013,2014 😩 😊 ? 😊 
Kozyrskyj et al, 2009 😩 😩 😊 😊 
Pacheco et al, 2009 😩 😊 😊 😊 
Vollmer et al, 2004 😩 😊 😊 😊 
Donahue et al, 1997 😊 😩 😩 😊 
Premaratne et al, 1997 😊 😩 😊 😊 
Engeland et al, 2009 😩 😩 😩 😩 
Coulter et al, 1989 😩 😩 😩 ? 
Ward et al, 2004 😩 😩 😊 😩 
Table 3: Quality assessment using QUADAS-2 
Note: Happy face: low risk; sad face: high risk; question mark: unclear risk. 
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DISCUSSION 
The main finding of this review is that case definitions and methods of asthma 
diagnosis validation vary widely across different EHR databases. This is evident in 
the diversity of databases used by the studies, such as primary care databases, 
combined EHR and administrative databases, or data from nested case-control studies 
within larger cohorts. Some databases originate from a single or a few health centres, 
while others span millions of patients. The source of the EHR databases (primary care, 
secondary care and urgent care) influences the case definition of asthma and the way 
the validation is conducted. Patients seeking care for asthma symptoms will present 
differently in each setting, and the test measures might reflect this. 
Case definitions are designed with different purposes in mind, and each of the studied 
test measures (sensitivity, specificity, PPV and NPV) have different uses. A high 
sensitivity is needed to identify all asthma patients from a database, but if the aim is 
to exclude all records which do not have asthma, a high specificity is more important.32 
The PPV reflects the percentage of the records identified with a case definition actually 
have asthma, while the NPV shows the percentage of records who do not fit the case 
definition do not have asthma. PPVs and NPVs are directly related to the prevalence 
of asthma in the population. The PPV will increase with rising prevalence; the NPV 
will decrease with rising prevalence assuming all other factors remain constant. 
Studies whose main aim was not database validation were able to demonstrate a high-
test measure to suit their specific needs (PPV, NPV, sensitivity or specificity greater 
than 80%). If this was not the case, their main study results (not including validation) 
would not be reliable, and thus potential studies with low validity of asthma diagnosis 
might not have been conducted or published. In contrast, studies whose main aim was 
the validation of asthma in databases have a wider range of test measures depending 
on the case definition. The PPV in these studies range from 46% (286) to 96%.(280)  
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Manual validation was the most common reference standard in the validation studies 
included in this systematic review. The computer-generated case definitions studied 
recently by Engelkes, Afzal, Dexheimer and Wu et al provide ways to create 
algorithms with high sensitivities and specificities. The PPV’s of these methods 
(whether a person identified as having an asthma diagnosis actually has asthma) 
might not be sufficient for all purposes (63%-82%). Preselected case definitions were 
used in five out of ten studies which manually validated the databases. The studies by 
Xi, Kozyrskyj, Pacheco, Vollmer, Donahue and Premaratne used this approach and all 
report at least one case definition algorithm with a PPV above 85%. The best results 
arise when combining diagnostic data and prescription data.  
Other studies by Engeland and Coulter used an external data source as reference 
standard. This approach needs two databases with near complete data, so their test 
measures are reliable on the quality and completeness of the two databases. It also 
requires that the validity of the reference standard is already known. However, they 
are much cheaper to carry out overall. Manual validation requires a considerable 
amount of time to complete, and questionnaires to hundreds of patients or clinicians 
can be expensive or unreliable. Coulter et al measured database completeness and 
integrity by studying different diseases including asthma. Their focus was not on 
asthma validation, but rather to check whether a digital database can be a valid 
alternative for analogue registration.  
Typical problems of validation studies are the lack of availability of a reliable reference 
standard and the interdependence of different data sources used for validation. There 
were four studies, not included in this review, which used face validity to compare 
the prevalence of asthma using a case definition to the general asthma prevalence. 
This method was not considered sufficiently exact for inclusion (289–292) and by 
definition was unable to verify the validity of individual records. 
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 The diagnosis of asthma can represent different conditions in different regions of the 
world. Thus, several authors used an inclusive strategy and many diagnosis codes in 
order to maximize sensitivity. Researchers must weigh the benefits of a case-finding 
algorithm with high sensitivity against the likely lower specificity and PPV, according 
to the purpose of their research. In future studies using predetermined case 
definitions, it may be of interest to evaluate the predictive value of a specific set of 
codes validated by chest physicians or general practitioners working in the health 
system the database originates from. This group may be more accurate when 
assigning the diagnosis, and the codes applied may yield a much higher predictive 
value than when evaluating the same group of codes assigned by all providers. The 
PPV, NPV, sensitivity and specificity can differ greatly within a single study, as shown 
in the studies by Xi, Afzal, Kozyrskyj and Vollmer et al. For this reason, the testing of 
multiple case definitions to obtain the algorithm with the highest test measure needed 
would be beneficial for future studies. 
Conclusion 
Asthma validation studies using EHRs are very varied in their approach to the 
validation. This seems driven by the nature of the data and the reference standards 
used. The method of sampling records using machine learning in algorithm 
development allow for measuring all elements of validity. Different case definitions 
within a single data source have different validity highlighting the importance of 
testing a range of case definitions.  
Dissemination and ethics 
This study is a synthesis of previously published studies, so no ethical approval is 
required. We have registered the protocol in the PROSPERO database with 
registration number CRD42016041798, and the protocol has been published.(276) 
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Results from this systematic review can be used to study outcome research on asthma 
and can be used to identify case definitions for asthma. 
Appendices 
Search algorithms in the Embase and Medline databases 
QUADAS-2 
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3.4 Appendix 
Algorithms used for literature review 
MEDLINE 
1 (validat* or verif*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
2 (positive predictive value or negative predictive value or likelihood ratio or receiver 
operating characteristic or kappa).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier]  
3 Validation Studies/ or validation.mp. or Validation Studies as Topic/  
4 (electronic* or digital* or computeri?ed or programmed or automated or database or 
data base).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier]  
5 asthma.mp. or Asthma/ or Asthma, Occupational/ or Asthma, Exercise-Induced/  
6 Database Management Systems/  
7 1 or 2 or 3  
8 4 or 6  
9 5 and 7 and 8 
 
EMBASE 
1 (validat* or verif*).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword]  
2 validation.mp. or validation study/ or validation process/  
3 (sensitivity or specificity or "Sensitivity and Specificity").mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword]  
4 (positive predictive value or negative predictive value or likelihood ratio or receiver 
operating characteristic or kappa).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword]  
5 (electronic* or digital* or computeri?ed or programmed or automated or database or 
data base).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword]  
6 mild persistent asthma/ or nocturnal asthma/ or experimental asthma/ or moderate 
persistent asthma/ or severe persistent asthma/ or Asthma.mp. or exercise induced asthma/ 
or occupational asthma/ or intrinsic asthma/ or asthma/ or allergic asthma/ or extrinsic 
asthma/ or mild intermittent asthma/  
7 1 or 2 or 3 or 4  
8 5 and 6 and 7 
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QUADAS-2 
QUADAS-2 tool designed to allow for more transparent rating of bias and 
applicability of primary diagnostic accuracy studies and can be found on the 
QUADAS website (www.quadas.org). 
This tool composes 4 domains: patient selection, index test, reference standard, and 
flow and timing and is available Each of those four domains are assessed on the risk 
of bias, and the first three domains are assessed on applicability. Each domain of the 
QUADAS-2 is applied in four phases. 
DOMAIN PATIENT 
SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
FLOW AND 
TIMING 
Description     
Signalling 
questions(yes/no/unclear) 
    
Risk of bias: 
High/low/unclear 
    
Concerns regarding 
applicability: 
High/low/unclear 
    
Table 4: Appendix QUADAS-2, adapted from www.quadas.org 
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Research paper cover sheet 
 
  
114  
  
Chapter 4: Validation of asthma recording in 
the Clinical Practice Research Datalink (CPRD)  
  
Summary 
• We have estimated the PPV of several different algorithms based on clinical 
codes for asthma, reversibility testing and asthma medication prescriptions in 
the CPRD GOLD based on GP questionnaires.  
• Diagnoses were confirmed in a high proportion of patients with specific asthma 
codes, suggesting that epidemiological asthma research conducted using 
CPRD GOLD data can be conducted with reasonably high validity. 
• The PPVs for the algorithms based on specific asthma Read codes and non-
specific asthma Read codes in combination with additional evidence were all 
greater than 0.84.  
• A specific asthma code algorithm alone appears to be the most practical 
approach to identify patients with asthma in CPRD GOLD (PPV=0.86; 95% CI 
0.77-0.95).  
• The algorithm using non-specific asthma codes, information on reversibility 
testing, and respiratory medication use scored highest (PPV=90.7%, 95% CI 
82.8% to 98.7%), but had a much lower total identifiable population. 
• The inclusion of reversibility testing or asthma medications in the algorithm 
did not clearly improve accuracy. 
• In conclusion, people with asthma can be accurately identified from UK 
primary care records using specific Read codes. 
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4.1 Preface   
The research paper presented in this chapter is a validation study of algorithms to 
identify people with asthma in the CPRD GOLD. The aim of this study was to test the 
accuracy of different approaches to identifying asthma in the CPRD GOLD using the 
positive predictive value (PPV), by comparing the database records with a gold 
standard constructed from a review by two study physicians based on information 
provided by asthma patients’ general practitioners.  
The algorithms consisted of a combination of clinical codes for probable or definite 
asthma, codes indicating reversibility testing had taken place and codes for asthma 
medication prescriptions. The validity of these algorithms was tested by randomly 
selecting patients who qualified for an algorithm and sending extensive 
questionnaires to the General Practitioners of those patients. These questionnaires 
were then examined by one chest physician and one study GP to assess how many 
patients truly had asthma in order to assess the validity of the pre-specified algorithms 
against a reference standard. Validity of each algorithm was expressed using PPVs. 
One reason asthma is difficult to assess in health-care database epidemiological 
studies is because the diagnostic criteria are based on non-specific respiratory 
symptoms and variable expiratory airflow limitation. These symptoms and airflow 
limitation measures are often not recorded in electronic medical records. The other 
reasons are the overlap with other diseases and the absence of a universal case 
definition. As the clinical examination necessary for the diagnosis of asthma is time 
and resource demanding, it can be useful for epidemiological studies to rely on EHR 
data to obtain accurate records of asthma diagnosis to determine asthma status. As 
epidemiological research is extremely reliant on data accuracy and misclassification 
of study variables compromises the validity of study results, validation of algorithms 
is imperative for valid inference.(293) When using EHR, the usual epidemiological 
116  
  
challenges related to validity of study findings remain in place and may even be 
amplified.(294,295) Results from validation studies allows researchers to estimate the 
extent of misclassification and can help coding clinicians to remain motivated to use 
systematic coding schemes.(296) Validity for algorithms to identify patients with other 
conditions including COPD were proven high in the CPRD GOLD.(229,297) 
There was no validated definition of asthma diagnosis in the CPRD GOLD before the 
publication of this study. In terms of this thesis, the primary motivation for validating 
the recording of asthma was to provide a definition to be used in the next studies. The 
results of this validation study were used to inform patient selection for the studies 
included in chapter 5 and 6 of this thesis. 
The questionnaire described in Chapter 2 of this thesis was used to construct a 
reference standard for asthma validation. This questionnaire is included in the 
appendix of this chapter. 
This article was originally published in the BMJ Open, and is available here:   
Nissen F, Morales DR, Mullerova H, Smeeth L, Douglas IJ, Quint JK. Validation of asthma 
recording in the Clinical Practice Research Datalink (CPRD). BMJ Open. 017;7(8). 
https://www.ncbi.nlm.nih.gov/pubmed/28801439 
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4.2 Research paper  
Validation of asthma recording in the Clinical Practice Research Datalink (CPRD) 
 
Authors: Francis Nissen,1 Daniel R. Morales,2 Hana Mullerova,3 Liam Smeeth,1 Ian J 
Douglas,1 Jennifer K Quint4   
1. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and 
Tropical Medicine, London, UK 
2. Division of Population Health Sciences, University of Dundee, Dundee, UK 
3. RWE & Epidemiology, GSK R&D, Uxbridge, UK 
4. National Heart and Lung Institute, Imperial College, London, UK 
 
ABSTRACT 
Objectives: The optimal method of identifying people with asthma from electronic 
health records in primary care is not known. The aim of this study is to determine the 
Positive Predictive Value (PPV) of different algorithms using clinical codes and 
prescription data to identify people with asthma in the United Kingdom Clinical 
Practice Research Datalink (CPRD).  
Methods: 684 participants registered with a GP practice contributing to CPRD 
between 1st of December 2013 and 30th of November 2015 were selected according to 1 
of 8 pre-defined potential asthma identification algorithms. A questionnaire was sent 
to the general practitioners to confirm asthma status and provide additional 
information to support an asthma diagnosis. Two study physicians independently 
reviewed and adjudicated the questionnaires and additional information to form a 
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gold standard for asthma diagnosis. The Positive Predictive Value was calculated for 
each algorithm. 
Results: 684 questionnaires were sent, of which 494 (72%) were returned and 475 
(69%) were complete and analysed. All 5 algorithms including a specific Read code 
indicating asthma or non-specific Read code accompanied by additional conditions 
performed well. The PPV for asthma diagnosis using only a specific asthma code was 
86.4% (95% CI 77.4% to 95.4%). Extra information on asthma medication prescription 
(PPV 83.3%), evidence of reversibility testing (PPV 86.0%) or a combination of all three 
selection criteria (PPV 86.4%) did not result in a higher PPV. The algorithm using non-
specific asthma codes, information on reversibility testing, and respiratory medication 
use scored highest (PPV 90.7%, 95% CI [82.8% to 98.7%]), but had a much lower 
identifiable population. Algorithms based on asthma symptom codes had low PPVs 
(43.1% to 57.8%). 
Conclusions: People with asthma can be accurately identified from UK primary care 
records using specific Read codes. The inclusion of spirometry or asthma medications 
in the algorithm did not clearly improve accuracy.  
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Article summary 
Strengths: 
This study describes algorithms to identify people with asthma from CPRD, a large 
electronic health records database, and measures the positive predictive value of those 
algorithms. 
Supporting information, including outpatient referral letters, other emergency 
department discharge letters, airflow measurements and radiography records were 
used to identify asthma patients and calculate the test measures. 
Limitations: 
The gold standard to calculate a PPV (GP questionnaire and review by study 
physicians) is not absolute, even though information from secondary care was used. 
GPs of patients with complicated medical histories could be less likely to return the 
questionnaire, but remuneration makes this less likely. 
BACKGROUND 
Asthma is one of the most common chronic diseases, with an estimated prevalence of 
241 million people worldwide with asthma.(298) The United Kingdom has one of the 
highest asthma prevalence and mortality rates in Europe.(165,299) The disease is a 
significant burden to the National Health Service, with 5.4 million people receiving 
treatment and approximately 65,000 hospital admissions yearly.(300) Cough, wheeze, 
breathlessness and chest tightness are its core symptoms (301) but it has a wide variety 
of different presentations.(101) 
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Electronic health records (EHR) have been adopted worldwide, facilitating the 
construction of large population-based patient databases that have become available 
over the last decades for epidemiological research.(260) Validation of diagnoses or 
outcomes based upon codes recorded in EHRs is required because their accuracy is 
uncertain, and this may affect the reliability and validity of subsequent observational 
studies. The quality of studies generated from EHRs may be debatable unless their 
data are validated for specific research purposes.(261,295,302,303) 
The diagnosis of asthma relies on clinical judgement based on a combination of patient 
history, physical examination and confirmation of the variability or reversibility of 
airflow obstruction using airflow measurements. This can make it difficult to assess 
the accuracy of asthma diagnoses in EHR-based epidemiological studies as some 
symptoms and airflow measurements may not be recorded. In addition, individuals 
affected by asthma can vary greatly in their presentation and symptoms are 
sometimes similar to other respiratory diseases such as COPD (Chronic Obstructive 
Pulmonary Disease).(304,305) 
The aim of this study was to test the accuracy of different approaches to identifying 
asthma in the United Kingdom Clinical Practice Research Datalink (CPRD) using the 
positive predictive value (PPV), by comparing the database records with a gold 
standard constructed from a review by 2 study physicians based on information 
provided by asthma patients’ GPs.  
METHODS 
Dataset 
The Clinical Practice Research Datalink (CPRD) is a large UK primary care database 
containing anonymised data on the people registered with primary care practices 
from across the UK. CPRD is representative of the UK population with regard to age 
and sex.(208,306) Within CPRD, diagnostic accuracy has been demonstrated to be high 
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for many conditions and diseases, including COPD.(229,297,307,308) CPRD contains 
detailed clinical information on diagnoses, prescriptions, laboratory tests, symptoms 
and hospital referrals, in addition to basic sociodemographic information recorded by 
the general practitioners. These general practitioners (GPs) act as primary care 
providers and gatekeepers for other National Health Service services, and information 
from other healthcare providers is also transmitted back to the GP. Clinical events and 
diagnoses are coded as Read codes, a dictionary of clinical terms widely used in the 
UK National Health Services by both primary and secondary healthcare providers. 
Validation studies aid to ensure credibility and quality of epidemiological studies 
done in CPRD.(309) 
The random sample of individuals included in the study was constructed from all 
participants registered in CPRD on or after first of April 2004 who met the inclusion 
criteria (see below). For the main analysis, a patient was able to contribute to one 
algorithm only if an asthma medcode was recorded within the 24-month window 
prior to the end of data collection. It was possible an individual was eligible for more 
than one algorithm depending on the Read codes used in their medical record. The 
individuals were randomly selected from the algorithm with the fewest participants 
first and then removed from the cohort so that they could not be selected for another 
algorithm. We have chosen this strategy (as opposed to an individual being eligible 
for a single algorithm only) because we wanted to test strategies to identify asthma 
patients from a single cohort rather than to test validity of the diagnosis. Further 
studies could then use a single strategy or their combination to extract an asthma 
cohort. There was no special measures to ensure less frequent Read codes are used, 
because we assumed the validity of asthma diagnosis strategy would be not be 
different between common and less frequent Read codes and the quality of recording 
would also be comparable. In addition, less frequent Read codes are unlikely to be 
used in isolation; our experience with validation of COPD recordings had shown that 
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these infrequent Read codes usually accompanied more commonly used Read codes 
for the same condition. 
Inclusion criteria 
The study population consisted of people who had a record for a Read code indicating 
possible asthma in the two years before the index date (1st of December 2015) and who 
were registered in a GP practice meeting CPRD quality criteria. The Read code list is 
included in appendix. The data collection was planned before the index test and 
reference standard were performed. This timespan was chosen for several reasons: to 
overcome potential changes in quality of asthma diagnosis and recording over time; 
to reduce the chance that the database records were out of date; and to ensure the 
medical records were still available to GPs.  People were identified at random based 
on one of eight pre-defined algorithms exclusively, which means that we populated 
the algorithm resulting in the smallest population first and subsequently removed 
these people from the cohort, to prevent them from also being selected for another 
algorithm. We randomly selected 800 possible asthma cases for validation. Of these, 
116 asthma cases were excluded because their GP no longer participated with CPRD 
at the time questionnaires were sent to the clinicians for validation, as shown in figure 
1. Due to changes in CPRD data governance after the start of the study it was not 
possible to select replacement patients.  
• Acceptable user status registered in CPRD. 
• Practice was “up to standard” at study start 1/4/2004. From this date onwards, 
the Quality and Outcomes Framework (QOF) came in effect. 
• The patient fulfilled one of the asthma algorithms within the last 24 months 
• Patients were still alive and practice was currently active in the CPRD.  
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Figure 1: Study population. 
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GP questionnaire 
CPRD mailed a two-page questionnaire to the GPs of the people selected for inclusion 
as described above, requesting confirmation of current asthma diagnosis and 
additional information to support this diagnosis. This questionnaire can be found in 
the appendix. The questionnaire was designed to ascertain the diagnosis of asthma 
and verify the date of diagnosis. The questions included evidence of reversible airway 
obstruction, current symptoms, smoking history, respiratory comorbidities and 
Quality Outcome Framework (QOF) indicators. QOF is a national financial incentive 
scheme for GPs in the UK encouraging regular disease indicator measurement and 
recording. Asthma is one of the included diseases, and its indicators including airflow 
measurements and interference with work and night’s rest.(310) 
Specific information available from the medical record including spirometry printouts 
and hospital respiratory outpatient letters were also requested. Data were encrypted 
twice to ensure anonymity, between practices and CPRD and also from CPRD to 
researchers. A questionnaire was considered invalid if it was returned blank or every 
question was answered “unknown”. 
Code lists and algorithms 
Lists of medical codes (Read codes) deemed as specific and non-specific for asthma 
based on study physicians’ opinion were created prior to the start of the study. Read 
codes are a hierarchical clinical coding system that are used in general practice in the 
UK and are entered by the GP into a computer programme called Vision. Each Read 
code is linked to a specific string of text, which refers to a single diagnosis or symptom. 
These data are then uploaded by CPRD after they have been processed and quality 
checked. The list of codes used for specific or definite asthma codes and nonspecific 
or probable asthma codes can be found in the appendix. 
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Combinations of Read code lists, evidence of reversibility testing and respiratory 
medication use were used to make up the eight algorithms. A number of different 
algorithms were constructed with degrees of certainty of asthma using separate 
indicators. For example, the most stringent algorithm included an asthma code, 
asthma medication and demonstrated reversibility after trial of treatment.  The first 
four algorithms required a specific asthma diagnosis code, with the first three 
requiring additional documentation consisting of either respiratory medication use 
and/or evidence of reversibility testing. The fifth algorithm required a non-specific 
asthma code and additional documentation of both respiratory medications and 
reversibility testing; the last three algorithms required respiratory symptom codes 
indicating asthma symptoms with additional information. The presence of spirometry 
for inclusion in an algorithm was based on the existence of a specific spirometry Read 
code in the records rather than an examination of said spirometry, although where 
spirometry traces were provided as part of the additional information, they were 
examined. Evidence of reversibility testing only refers to whether airflow 
measurements or trial of treatment were done and does not reflect the results of these 
tests. Respiratory medication use was defined as at least two prescriptions of asthma 
medication for inhaled asthma therapy (Short Acting Beta-Agonists, Long Acting 
Beta-Agonists and Inhaled Corticosteroids) within 365 days of each other, within the 
two years before the index date. From the expected most specific to most sensitive, the 
eight algorithms were constructed as follows: 
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1. Specific asthma Read code + evidence of reversibility testing (spirometry, 
variable Peak Expiratory Flow Rate or trial of treatment) + respiratory 
medications  
2. Specific asthma code + evidence of reversibility testing 
3. Specific asthma code + respiratory medications  
4. Specific asthma code only 
5. Non-specific asthma code + evidence of reversibility testing + respiratory 
medications 
6. Asthma Symptoms (wheeze, breathlessness, chest tightness, cough) + evidence 
of reversibility testing + respiratory medications 
7. Asthma Symptoms + evidence of reversibility testing  
8. Asthma Symptoms + respiratory medications  
 
Sample size calculations 
The reasoning behind the sample size of the validation study was as follows: 
Assuming an estimated PPV of 0.85 for each algorithm and an accuracy of the PPV 
(95% CI ± 0.08), a sample size of 77 individuals for each algorithm was needed. A 
similar study conducted for COPD had a 77.6% response rate and 73.2% of the sent 
questionnaires were fit to be included in the final analysis.(311) Considering a random 
sample of fully completed responses of 77 asthma patients for 8 algorithms is needed 
with 20% extra to account for a potential lower response rate, 800 questionnaires in 
total were sent. We also assumed that the probability of data being missing was 
independent of accuracy of the asthma diagnosis. However, we anticipated little 
missing relevant data in this study based on past research. In addition, the covariates 
were needed for stratification analysis only, rather than for adjustment.  
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Missing data 
The plan for addressing missing data for the validation study was as follows: We 
planned to do a complete case analysis, assuming that the probability of data being 
missing is independent of accuracy of the asthma diagnosis, conditional on covariates. 
If the amount of missing data was small, any violation of the assumption is unlikely 
to importantly affect the results.  
 
128  
  
 
Table 1: Characteristics of the 475 patients included in the final study analysis*As stated by patient’s GP on the study questionnaire. 
Algorithm 
1. Specific 
asthma code 
+ 
reversibility 
testing + 
medication 
2. Specific 
asthma code 
+ 
reversibility 
testing 
3. Specific 
asthma 
code + 
medication 
4. Specific 
asthma 
code 
5. Non-
specific 
asthma 
code + 
reversibility 
testing + 
medication 
6. Symptoms 
+ 
reversibility 
testing + 
medication 
7. Symptoms 
+ 
reversibility 
testing 
8. 
Symptoms 
+ 
medication Total 
Individuals, n (%) 68 (100) 57 (100) 60 (100) 59 (100) 54 (100) 55 (100) 58 (100) 64 (100) 475 
Asthma diagnosis by own 
GP 56 (82.4) 49 (86) 48 (80) 51 (86.4) 48 (88.9) 29 (52.7) 23 (39.7) 38 (59.4) 342 
Confirmation by respiratory 
physician before study start 55 (80.9) 29 (50.9) 38 (63.3) 45 (76.3) 34 (63) 23 (41.8) 25 (43.1) 36 (56.3) 285 
Evidence of reversible 
airway obstruction 47 (69.1) 37 (64.9) 32 (53.3) 32 (54.2) 31 (57.4) 26 (47.3) 19 (32.8) 26 (40.6) 250 
Mean age 52.3 51.4 47 41.9 45 60.9 61.3 52.1  
 Mean age (95% CI) (47.4-57.2) (46.2-56.7) (41.4-52.6) (36.1-47.6) (38.7-51.3) (55.3-66.4) (57.1-65.5) (45.4-58.7)  
 <18 years old (%) 7.35 7.02 15.25 18.64 16.67 7.27 1.72 20.31 11.81 
Sex: male 31 (45.6) 17 (29.8) 16 (26.7) 23 (39) 26 (48.1) 28 (50.9) 24 (41.4) 31 (48.4) 196 
Current smoker* 11 (16.2) 10 (17.5) 10 (16.7) 5 (8.5) 4 (7.4) 5 (9.1) 8 (13.8) 4 (6.3) 57 
Ex-smoker* 16 (23.5) 14 (24.6) 17 (28.3) 16 (27.1) 15 (27.8) 11 (20) 10 (17.2) 12 (18.8) 111 
Never smoker* 35 (51.5) 26 (45.6) 25 (41.7) 36 (61.0) 32 (59.3) 18 (32.7) 11 (19.0) 27 (42.2) 210 
Individuals with supporting 
info 23 (33.8) 21 (36.8) 22 (36.7) 14 (23.7) 14 (25.9) 17 (30.9) 14 (24.1) 22 (34.4) 147 
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Primary outcome 
The primary outcome was confirmation of a diagnosis of asthma in each of the eight 
predefined algorithms. The gold standard for the diagnosis of asthma was the 
adjudicated asthma status agreed by the two study physicians, a respiratory physician 
and a GP who reviewed all questionnaires and evidence from the patient’s GP 
independently. The reviewers were blinded to the code lists/algorithm. Where 
opinion differed, the cases were discussed, and agreement was reached by consensus. 
The reviewing physicians did not know with which algorithm a person was selected. 
Statistical analysis 
The Positive Predictive Value (PPV) was calculated using the proportion of cases 
identified by each algorithm that were confirmed as actual cases by the study 
physicians through a review of the questionnaire and supporting evidence. All 
analyses were conducted using Stata 14.0. The gold standard consisted of the opinion 
of 2 medical experts independently reviewing the questionnaires and any additional 
supporting medical information provided. If there was a disagreement of diagnosis, 
the case would be discussed by the two experts. If an agreement was not found, a third 
opinion was sought. 
A patient could contribute only to a single algorithm for the main analysis. In the post 
hoc analysis, individuals could be placed into multiple algorithms where possible to 
reduce the confidence intervals.  The PPV in this analysis was calculated for all 
individuals who had a specific asthma code compared with those with a specific 
asthma code and additional information. We also performed a sensitivity analysis to 
check whether the age and sex for patients whose questionnaire was returned was 
similar to the age and sex of those patients whose questionnaire was not sent out or 
were there was no response.  
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Sample size calculation 
As there were 116 patients that could not be evaluated, precision was expected to be 
slightly lower than in the original sample size calculations. However, a percentage 
difference in PPV of 0.13 is demonstrable with a sample size of 60 per algorithm 
(assuming PPV=0.85, alpha=0.05 and power=0.8). 
RESULTS 
A total of 800 potential asthma cases were selected for validation, of which 116 cases 
had migrated out of the database at the time the questionnaires were sent.  Of the 
remaining 684 cases, there were 494 returned questionnaires. Nineteen of the returned 
questionnaires were considered invalid. Thus, 475 valid questionnaires were received, 
which yielded a response rate of 69.4% (475/684) using the practices that could have 
answered as denominator, as shown in figure 1. The time interval between the mailing 
of questionnaires and the review by the study physicians varied, but none of these 
time intervals was greater than 8 months. 
The baseline characteristics of the 475 patients with valid returned questionnaires are 
shown in table 1. The study populations were mostly middle aged, never smokers and 
female. There were 97 individuals whose smoking status was not filled in on the 
questionnaire. Differences in the majority of characteristics were seen among most 
algorithms. 
The positive predictive values of the eight algorithms are displayed in table 2. The 
PPVs of algorithms containing specific or non-specific asthma codes in algorithms 1-
5 (ranging from 83.3% to 90.7%) are markedly higher than the PPVs of the algorithms 
based on asthma symptoms (ranging from 43.1% to 57.8%). The combination of a 
specific code and asthma medication prescription and/or evidence of reversibility 
testing (PPV varies from 83.3% to 86.8%) did not considerably increase the PPV 
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compared with a specific asthma code alone (PPV 86.4%). The highest PPV was found 
in the fifth algorithm combining a non-specific asthma code with evidence of 
reversibility testing and asthma medication use. However, the total number of 
patients identifiable with this algorithm (n=33,280) was less than one fifth of those 
identifiable by the fourth algorithm consisting of a specific asthma code alone 
(n=188,133) in the chosen time period. We have not examined the validity of a non-
specific asthma code alone. 
A post hoc analysis was performed where individuals were placed in every algorithm 
they qualified for. In this analysis, we found that the use of additional information on 
evidence of reversibility testing or medication in an algorithm with a specific asthma 
code again did not meaningfully increase the PPV. The PPV for all individuals who 
had a specific asthma code and information on reversibility testing or medication was 
86.7% (95% CI 83.3% to 90.1%), and the PPV for individuals with only a specific 
asthma code was 86.4% (95% CI 83.0% to 89.7%). 
When validating the record of possible asthma with a gold standard based on the 
study physicians’ view of extra evidence provided by the GP, the PPV slightly 
improved across all algorithms. Figure 2 demonstrates the PPV of the different 
algorithms as diagnosed by the patient’s own GP and the study physicians (overall 
κ=0.81).  
There was no considerable difference in age or sex between patients whose 
questionnaire was returned and patients whose questionnaire was not sent out (age: 
p=0.74, sex: p=0.73) or were there was no response (age p=0.50, sex p=0.13) using χ² 
tests. 
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Table 2: The positive predictive value (PPV) and proportion of patients diagnosed with 
chronic obstructive pulmonary disease within each algorithm 
Algorithm 
Eligible 
population 
Questionnaires 
sent out 
Valid returned 
questionnaires 
(n, %) 
Confirmed 
asthma cases PPV (95% CI) 
Specific asthma 
code + reversibility 
testing + 
medication 
36 516 92 68 (60) 61 86.8  
(78.5 to 95.0) 
Specific asthma 
code + reversibility 
testing 
38 796 90 57 (63.3) 51 86.0  
(76.7 to 95.3) 
Specific asthma 
code + medication 
169 574 89 60 (67.4) 51 83.3  
(73.6 to 93.0) 
Specific asthma 
code 
188 133 84 59 (70.2) 51 86.4  
(77.4 to 95.4) 
Non-specific 
asthma code + 
reversibility testing 
+ medication 
33 280 78 54 (69.2) 49 90.7  
(82.8 to 98.7) 
Symptoms + 
reversibility testing 
+ medication 
53 117 87 55 (63.2) 32 56.4  
(42.8 to 69.9) 
Symptoms + 
reversibility testing 
66 477 88 58 (65.9) 26 43.1  
(30.0 to 56.2) 
Symptoms + 
medication 
190 753 78 64 (82.1) 38 57.8  
(45.4 to 70.2) 
Table 2: The positive predictive value (PPV) and proportion of patients diagnosed with asthma within each algorithm 
Medication use was defined as two prescriptions within 365 days. Evidence of reversibility 
testing does not hold information on the outcome of these tests. 
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Figure 2: PPV as diagnosed by the patient’s own GP, and agreement between the study 
physicians. GP, general practitioner; PPV, positive predictive value 
 
Figure 2: PPV as diagnosed by the patient’s own GP, and agreement between the study physicians. GP, general practitioner; PPV, positive predictive 
value 
DISCUSSION 
We tested the accuracy of eight algorithms to identify asthma within CPRD using a 
gold standard constructed using a consensus of the two study physicians. The 
algorithm with the highest PPV consisted of a combination for nonspecific asthma 
codes, evidence of reversibility testing and multiple asthma prescriptions within one 
year (PPV 90.7, 95% CI 82.8 to 0.98.7) followed by a combination for specific asthma 
codes, evidence of reversibility testing and multiple asthma prescriptions within one 
year. The confidence interval of this PPV overlaps with the confidence intervals of 
each of the PPVs of the first four algorithms based on specific asthma codes, so the 
difference might be due to chance alone. The algorithm with the lowest PPV consisted 
of asthma symptoms and evidence of reversibility testing (PPV 0.43, 95% CI 0.30-0.55). 
The results of this validation study suggest that the clinical code-based algorithms that 
use asthma codes to identify asthma cases have high PPVs (between 0.84 and 0.91). In 
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this dataset, a specific asthma code algorithm alone appears sufficient to identify 
current asthma patients from CPRD. As the additional requirements of medication 
use and evidence of reversibility testing do not appear to significantly increase the 
PPV, the total number of individuals who can potentially be included in a study 
increases from 33,280 to 188,133 in the chosen time period (1st of December 2013 to 30th 
of November 2015). The total identifiable population of people living with asthma is 
thus much larger when only using a specific asthma code for identification. 
Comparison with previous studies 
Validity of asthma codes in electronic health records can be assessed by comparison 
with three different sets of gold standard: comparison with an external database, 
questionnaire and manual review by a clinician. This validation study uses 
questionnaires and manual review. Our gold standard consisted of the agreement of 
the study respiratory physician and study GP, both of whom were experienced with 
CPRD. 
Previous studies which validated asthma in other EHR databases used manual review 
by clinicians to validate asthma in EHR and all reported at least one algorithm with a 
PPV above 85%.(271,281–285) In contrast with this study, the best results in previous 
studies arose when combining diagnostic data and prescription data.  
The CPRD has provided anonymised primary care records for public health research 
since 1987; research was always a focus of interest when it was established. GPs 
contributing to the CPRD have been trained on how to record data for research use. 
As a consequence, data quality may be higher than in many other databases, in which 
research is only a secondary product.  
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Strengths of this study 
This study has several strengths. First, we were able to investigate the accuracy of 
eight pre-defined different algorithms and how they perform in identification of 
people with asthma in CPRD, as well as the accuracy of the actual GP diagnosis of 
asthma using additional information provided. Second, we included supporting 
information such as outpatient referral letters, other emergency department discharge 
letters, airflow measurements and radiography records. Finally, we validated asthma 
diagnoses found in CPRD, which is a primary care database that is extensively used 
for studying different health outcomes in epidemiological research. This primary care 
database provides health and medication history of millions of patients. A validated 
definition in CPRD of asthma allows for informed health-care service planning by 
increasing the reliability of evidence generated from observational studies. 
Limitations of this study 
This study has limitations to consider. The gold standard consisting of a GP 
questionnaire and review by study physicians is not absolute, even if we mitigated 
this with additional information from secondary care. A GP can look in the electronic 
health record to see if a specific diagnosis has been recorded for a specific patient when 
asked. This may lead to an overestimation of the PPV, but there is no suitable practical 
alternative. Ideally, airflow measurements and reversibility testing on each potential 
patient would form the optimal gold standard, but this would not be feasible in this 
setting due to cost. The overall number of questionnaires sent out (n=684) was less 
than requested (n=800) as some patients and practices were no longer part of CPRD 
and could not be contacted. However, the precision of PPV estimates was not 
substantially reduced. 
Although practices contributing to CPRD are a sample of all practices in the UK, they 
are considered representative of the UK population with few patients opting out of 
contributing data, and is therefore unlikely to bias the results.(208) 
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GPs of patients with complicated medical histories could be less likely to return the 
questionnaire. The GPs were remunerated for their participation however, which is 
likely to have reduced the chance of this happening. Within the returned 
questionnaires, the amount of missing data was low, which suggests reasonable data 
quality. In addition, only living patients were assessed, as GPs no longer have access 
to the patient records after death. This excludes the records of the deceased patients 
and could result in survival bias. Patients had to be alive to be included, but it is 
unlikely that coding would differ between living and deceased individuals. If 
deceased people had died of asthma, the PPV in this study would be underestimated. 
Our findings are likely to be generalizable to other UK primary care databases using 
Read coding, but these would ideally still require validation. Databases using other 
coding systems may need to validate different algorithms to identify asthma, which 
might limit the generalisability of our findings. Another limitation is that we were not 
able to assess the Negative Predictive Value (NPV) of asthma diagnoses in CPRD 
because we evaluated only patients belonging to one of the eight algorithms.  We 
could not calculate the specificity or sensitivity as we had preselected our population 
of possible asthma cases. We also assumed the validity of asthma diagnoses would 
not be different between common and less frequent Read codes and the quality of 
recording would also be comparable for pragmatic reasons. However, the less 
commonly used codes will by definition identify a smaller proportion of all asthma 
patients, so the validity we report will apply to the majority of patients. In future 
practice when identifying patients with asthma, the less commonly used codes will 
continue to identify a smaller proportion of all asthma patients and so the validity we 
measure will apply to the majority of patients. Using a GP questionnaire as the source 
of patient information in order to obtain a gold standard to validate the asthma 
diagnosis has its limitations as the GP can consult the electronic health record to see if 
there was an asthma diagnosis. This could lead to an overestimation of the PPV. 
Incomplete diagnostic information could lead to missing data which we were 
unaware of which could lead to some inaccuracy in PPV or classification of asthma 
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probability. Response rate for the questionnaire might have been lower than expected, 
and the sample size of the completed questionnaires could have been too small. Not 
all GP practices contribute to CPRD GOLD, and patients might refuse to participate 
in the CPRD programme. This could have resulted in selection bias. 
CONCLUSION 
We have successfully estimated the PPV of several different algorithms to identify 
people with asthma in CPRD. The PPVs for specific asthma Read codes alone and non-
specific ones in a combination with additional evidence were all greater than 0.84. A 
specific asthma code algorithm alone appears to be the most practical approach to 
identify patients with asthma in CPRD (PPV 0.86; 95% CI 0.77-0.95). Diagnoses were 
confirmed in a high proportion of patients with specific asthma codes, suggesting that 
epidemiological asthma research conducted using CPRD data can be conducted with 
reasonably high validity. 
Dissemination and ethics 
The protocol for this research was approved by the Independent Scientific Advisory 
Committee (ISAC) for MHRA Database Research (protocol number15_257) and the 
approved protocol was made available to the journal and reviewers during peer 
review.   Generic ethical approval for observational research using the CPRD with 
approval from ISAC has been granted by a Health Research Authority (HRA) 
Research Ethics Committee (East Midlands – Derby, REC reference number 
05/MRE04/87). 
The results will be submitted for publication and will be disseminated through 
research conferences and peer reviewed journals. 
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Figure legend 
Figure 1: Study population 
Figure 2: PPV as diagnosed by the patient's own GP, and agreement between the study 
physicians 
Appendices 
Appendix 1: General Practitioner questionnaire  
139  
  
4.3 Appendix 
 
Questionnaire for asthma validation study 
Study into asthma: questionnaire for £55, further information for £55 
The London School of Hygiene and Tropical Medicine is conducting a study to investigate the 
best way to identify asthma within the Clinical Practice Research Datalink (CPRD). We have 
developed several methods for identifying asthma in the database, and we would like to 
obtain some information on the current asthma status of the patient from GPs so that we can 
decide which method is the most suitable. 
We would be very grateful if you could supply us with the following information. 
 
A. Do you agree this patient has a current diagnosis of asthma? 
   Yes: Proceed to question B 
   No: Proceed to question C 
   Uncertain: Proceed to question B 
 
If you answered yes or uncertain to question A: 
B1. Has the diagnosis been made or confirmed by a respiratory physician? 
  Yes 
  No 
 
B2. Does this patient have evidence of reversible airway obstruction?  
  Yes 
  No 
 
 If yes: Was this based on; 
   Spirometry reversibility with a bronchodilator 
   Trial of treatment with oral or inhaled corticosteroids and diurnal  
         variation on a peak flow diary 
 
B3. In what year was the asthma first diagnosed?  
  
B4. Were any other factors taken into consideration in making the diagnosis? 
 Yes No 
a. History of atopic disorder   
b. Family history of asthma and/or atopic 
disorder   
c. Widespread wheeze heard on auscultation of 
the chest   
d. Otherwise unexplained low FEV (Forced 
Expiratory Volume) or PEF (Peak Expiratory Flow) on 
spirometry   
e. Otherwise unexplained variability in PEFR 
(Peak Expiratory Flow Rate) on spirometry   
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f. Otherwise unexplained peripheral blood 
eosinophilia   
g. FeNO (Fractional exhaled Nitric 
Oxide) measurement   
h. Other (please name)   
 
B5. Based on the QOF (Quality and Outcomes Framework) indicators: 
 Yes No 
a. Does the patient have any difficulty sleeping 
because of asthma symptoms, including cough   
b. Does the patient have the usual asthma symptoms 
during the day (cough, wheeze, chest tightness of 
breathlessness)?   
c. Does the asthma interfere with the patient's usual 
activities (housework, work, school, etc.)?   
 
B6. What is the patient's smoking status?  
  Current smoker 
  Ex-smoker 
  Never-smoker 
 
B7. Does the patient have any other respiratory diseases? (Multiple responses possible) 
  Chronic Obstructive Pulmonary Disease (COPD) 
  Bronchiectasis 
  Interstitial Lung Disease 
  Other, please list: 
  No 
 
If you answered no to question A: 
C. Do you think this patient has a history of asthma? 
  Yes 
  No 
  Uncertain 
 
 
Please provide anonymised copies of any additional relevant information allowing 
corroborating asthma diagnosis e.g. medical notes, discharge letters, test values. Payment 
for further information is £55 per patient. 
  
 
Please return responses to CPRD in the freepost envelope provided or to our freepost 
address: 
Freepost RSKH-TTAU-UKKX, CPRD, MHRA, 
151 Buckingham Palace Rd, London, SW1W 9SZ 
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Chapter 5: Quantifying concomitant diagnosis 
of asthma and COPD in UK primary care 
Summary 
• This study aims to quantify how commonly patients with COPD have a 
concomitant diagnosis of asthma, and how commonly patients with asthma 
have a concomitant diagnosis of COPD in UK primary care. 
• 400 COPD patients and 351 asthma patients were identified from the Clinical 
Practice Research Datalink (CPRD) GOLD in separate validation studies and 
the diseases were confirmed by the review of GP questionnaires by two study 
physicians.  
• We examined the prevalence of concurrent asthma and COPD based on CPRD 
GOLD coding, GP questionnaires and requested additional information. We 
also aimed to determine the extent of possible misdiagnosis and missed 
opportunities for diagnosis. 
• A concurrent asthma and COPD diagnosis appears to affect a relative minority 
of patients with COPD (14.5%, 95% CI 11.2-18.3) or asthma (14.8%, 95% CI 11.3-
19.0).  
• More than half of the validated COPD patients had ever received an asthma 
diagnosis Read code, suggesting over diagnosis of asthma in COPD patients 
commonly occurs, particularly early in the diagnostic process.  
• Over diagnosis of COPD in asthma patients and under diagnosis of asthma or 
COPD in patients with the other disease are less likely. 
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5.1 Preface   
The study included in this chapter quantifies and discusses concomitant diagnosis of 
asthma and COPD in the CPRD GOLD. In brief, we aimed to quantify the point 
prevalence of concomitant asthma and COPD in the diagnosed populations of both 
asthma and COPD patients in the UK using the CPRD GOLD. Validated definitions 
exist for the identification of both diseases in the CPRD GOLD. In addition, we also 
examined possible misdiagnosis and missed diagnosis in patients with obstructive 
lung diseases. 
The distinction between the two diseases in electronic health records is not trivial, as 
they share many symptoms and characteristics. In addition, there was a gap in the 
current literature on the prevalence of concomitant disease in primary care. 
The concomitant diagnosis of asthma and COPD has been grounds for controversy 
within respiratory medicine research. The existence of both diseases in the same 
patient has been accepted, but the mechanism of the underlying pathology has been 
cause for discussion. The Dutch hypothesis suggests that both diseases are 
manifestations of the same disease process, with asthma preceding COPD. The 
overlap syndrome is then called “Asthma COPD Overlap Syndrome” (ACOS). The 
other school of thought, sometimes called the British hypothesis, proposes asthma and 
COPD are distinct disease entities with different causal mechanisms. Asthma and 
COPD can coexist independently in the same patient according to this 
hypothesis.(111) 
The group of individuals with a concomitant diagnosis merits attention, as patients 
with both asthma and COPD have more frequent exacerbations, increased morbidity 
and mortality, faster lung function decline and a poorer quality of life than patients 
with only asthma or only COPD.(312,313) 
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Epidemiological studies on concomitant asthma and COPD have been scarce, as the 
differential diagnosis of both diseases is difficult (single spirometry measurements 
cannot clearly distinguish between asthma and COPD).(314,315) In addition, many 
studies have insisted on a separation of both diseases, excluding asthma patients from 
COPD studies and vice versa to avoid misclassification and these studies are also 
based on narrow inclusion criteria.(316,317) . The symptoms of asthma and COPD 
overlap, and the differential diagnosis is not always trivial to make. Information on 
reversibility testing, the QOF indicators, smoking status, concurrent respiratory 
diseases and other sources including consultant and hospital discharge letters, lung 
function tests and radiography results was requested in the questionnaire.  
A review of this information by a respiratory consultant and study GP aimed to 
identify the actual cases of COPD in confirmed asthma patients. This review was used 
as the gold standard to calculate the PPV, NPV, sensitivity and specificity of recorded 
GP diagnoses of COPD in the primary care records of asthma patients. 
The availability of the data of two validation studies provided the opportunity to look 
at the prevalence of COPD in validated asthma patients in the CPRD GOLD, and the 
prevalence of asthma in validated COPD patients in the CPRD GOLD. The data on 
the validated asthma patients came from the study included in the previous chapter, 
and the data on the validated COPD patients came from an earlier validation study of 
COPD recording in the CPRD by Quint JK et al, in which I did not participate. 
The validation studies are available here: 
• Nissen F, Morales DR, Mullerova H, Smeeth L, Douglas IJ, Quint JK. Validation of 
asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open. 
017;7(8). https://www.ncbi.nlm.nih.gov/pubmed/28801439 
• Quint JK, Mullerova H, DiSantostefano RL, Forbes H, Eaton S, Hurst JR, et al. 
Validation of chronic obstructive pulmonary disease recording in the Clinical Practice 
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Research Datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. 
https://www.ncbi.nlm.nih.gov/pubmed/25056980 
 
This paper was accepted for publication in the British Journal of General Practice. 
• Francis Nissen, Daniel R.Morales, Hana Mullerova, Liam Smeeth, Ian J Douglas, 
Jennifer K Quint ‘Quantifying concomitant diagnosis of asthma and COPD in UK 
primary care.’ BJGP 2018 
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5.2 Research paper  
Quantifying concomitant diagnosis of asthma and COPD in UK primary care 
Authors: Francis Nissen,1 Daniel R. Morales,2 Hana Mullerova,3 Liam Smeeth,1 Ian J 
Douglas,1 Jennifer K Quint4   
1. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and 
Tropical Medicine, London, UK 
2. Division of Population Health Sciences, University of Dundee, Dundee, UK 
3. RWE & Epidemiology, GSK R&D, Uxbridge, UK 
4. National Heart and Lung Institute, Imperial College, London, UK 
 
ABSTRACT 
Background: Asthma and COPD share many characteristics and symptoms, and the 
differential diagnosis between the two diseases can be difficult in primary care. This 
study explores potential overlap between both diseases in a primary care 
environment. 
Aim: This study aims to quantify how commonly patients with COPD have a 
concomitant diagnosis of asthma, and how commonly patients with asthma have a 
concomitant diagnosis of COPD in UK primary care.  
Design and Setting: 400 COPD patients and 351 asthma patients were identified from 
the Clinical Practice Research Datalink (CPRD) in separate validation studies and the 
diseases were confirmed by review of GP questionnaires.  
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Method: The prevalence of concurrent asthma and COPD in validated cases of either 
disease was examined based on CPRD coding, GP questionnaires and requested 
additional information. We also aimed to determine the extent of possible 
misdiagnosis and missed opportunities for diagnosis. 
Results: More than half (52.5%) of validated COPD patients had ever received a 
diagnostic asthma Read code. However, when considering additional evidence to 
support a diagnosis of asthma, concurrent asthma was only likely in 14.5% (95% CI: 
11.2%; 18.3%) of validated COPD patients. Of the validated asthma patients, 15.1% 
have ever received a diagnostic COPD Read code, although COPD was only likely in 
14.8% (95% CI:  11.3%; 19.0%) of validated asthma patients.  
Conclusion: A concurrent asthma and COPD diagnosis appears to affect a relative 
minority of patients with COPD (14.5%) or asthma (14.8%). Asthma diagnosis may be 
over recorded in people with COPD.  
How this fits in 
The prevalence of concomitant asthma and COPD is likely to be overestimated in 
studies using only electronic health records as their symptoms are similar. This study 
reports on this issue by including only validated asthma and COPD patients from two 
previous validation studies. A concurrent asthma and COPD diagnosis affects a 
relative minority of patients in primary care with either asthma (14.8%) or COPD 
(14.5%). Asthma may be over recorded in people with COPD in electronic health 
records. 
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INTRODUCTION 
Worldwide, 358 million people are estimated to be affected by asthma (299) and 174 
million by COPD (Chronic Obstructive Pulmonary Disease).(41) Both diseases can 
vary greatly in their presentation and imprecision of diagnosis in both diseases 
remains a problem. (304,305) 
Accurate diagnosis of asthma and COPD is essential, as correct treatment of asthma 
and COPD can reduce the frequency and severity of exacerbations and improve 
overall quality of life.(41) In addition, information on chronic respiratory disease can 
help patients to quit smoking.  
The differential diagnosis of COPD and asthma rests on differences in clinical 
presentation, triggering factors, and on demonstration of reversibility of airflow 
obstruction. This airflow obstruction is not fully reversible in COPD, whereas it is in 
asthma. However, the differential diagnosis remains difficult and the existence of an 
overlap syndrome called ACOS (Asthma-COPD Overlap Syndrome) remains 
controversial,(318,319) as consensus regarding the clinical definition has not yet been 
reached. Some guidelines classify asthma cases with a persistent airway obstruction 
as COPD, and the two diseases are often mutually exclusive in studies to obtain 
unblended populations of asthma and COPD patients. In addition, the prevalence of 
a concomitant diagnosis of asthma and COPD varies greatly in different studies.  
This study aims to quantify the point prevalence of concomitant asthma and COPD in 
the diagnosed populations of both asthma and COPD patients in the UK using 
electronic health record databases where validated definitions exist for the 
identification of both diseases. In addition, we also examine possible misdiagnosis and 
missed diagnosis in patients with obstructive lung diseases. 
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METHODS 
Study population and validation studies 
The study populations consist of people who were included in earlier validation 
studies.(297,320)  and are summarised in figure 1 and 2.  Questionnaires were sent out 
to the GPs of possible asthma and COPD patients with the intent to validate the 
recording of asthma and COPD in the CPRD.  The full selection criteria of both 
validation studies can be found in their respective articles.(297,320) Patient data for 
the asthma recording validation study were collected from 1 December 2013 to 30 
November 2015, and patient data for the COPD recording validation study was 
between 1 January 2004 and 31 December 2012. In the asthma validation study, full 
data was only available for the patients for whom the GP stated a current asthma 
diagnosis and only current asthma diagnoses were considered. In the COPD 
validation study, the population was preselected as current or ex-smokers.  The two 
patients populations included in this study have been thoroughly validated in their 
respective validation studies using these detailed GP questionnaires and requested 
supporting information including outpatient referral letters, other emergency 
department discharge letters, airflow measurements and radiography records.  In the 
validation studies, the Positive Predictive Value was 86.5% (77.5-92.3%) for COPD 
(297) and 86.4% (77.4%-95.4%) for asthma (320) when only using a single diagnostic 
code for the respective disease. 
In the asthma questionnaire, details were requested on evidence of airway 
obstruction, current symptoms, smoking history, respiratory comorbidities and 
Quality Outcome Framework (QOF) indicators (QOF is a national financial incentive 
scheme for GPs in the UK encouraging regular disease indicator measurement and 
recording). The COPD questionnaire requested information on COPD diagnosis, 
smoking history, symptoms, spirometry, confirmation by a respiratory physician and 
respiratory comorbidities. Additional information available from the medical record 
including spirometry printouts and letters from respiratory physician or hospitals 
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were also requested. Data were encrypted twice to ensure anonymity. If a 
questionnaire was returned blank or every question was answered “unknown”, it was 
considered invalid. 
Database 
The Clinical Practice Research Datalink (CPRD) GOLD is a large anonymised UK 
primary care database which is representative of the UK population with regard to 
age and sex.(306) Diagnostic accuracy has been demonstrated to be high in CPRD 
GOLD for many conditions,(229) including asthma and COPD. This database contains 
detailed clinical information on diagnoses, prescriptions, laboratory tests, symptoms 
and hospital referrals of included individuals, in addition to basic sociodemographic 
information recorded by the general practitioners. In the original validation studies, 
lists of medical codes (Read codes) deemed as specific for asthma or COPD were used 
to select algorithms to identify asthma and COPD patients; these codes have a high 
validity in their respective validation studies. Read codes are a hierarchical clinical 
coding system that is used in general practices in the UK; each Read code is linked to 
a specific string of text, which refers to a single diagnosis or symptom. 
Primary outcome and measurements 
The primary outcome for this study was the proportion of patients with either asthma 
or COPD who had the other disease in the validated asthma and COPD populations. 
The presence of a diagnostic asthma Read code and positive reversibility tests 
supported an asthma diagnosis in the COPD population. The presence of a diagnostic 
COPD Read code, smoking history and fixed airflow obstruction supported a current 
COPD diagnosis in the population with validated asthma. Spirometry measurements 
with at least one airflow measurement with fev1/fvc ≤ 70% were considered as 
evidence for an obstructive airflow limitation. The quality of the spirometry procedure 
undertaken in UK primary care to diagnose COPD is high as determined in a previous 
validation study.(321)  
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Possible misdiagnosis and/or lacking diagnosis of asthma in validated COPD patients, 
and vice versa, were examined using spirometry measurements, results of 
reversibility tests and smoking history. To study the temporality of recorded 
diagnostic Read codes in patients with concomitantly recorded asthma and COPD, we 
reported the proportion of patients where the time lapse between the date of 
validation of one disease and the last known diagnosis of the other disease was greater 
than two years. This was done as we had learned from the validation studies that a 
COPD patient would sometimes receive their first asthma diagnosis in the 2 years 
leading up to the first COPD diagnosis. An asthma code shortly before a first diagnosis 
of COPD is likely to be a misdiagnosis of asthma. If the asthma code was given 
multiple years before the COPD diagnosis, asthma before COPD onset is more 
probable.  
Conversely, if the last COPD code was given more than 2 years before the validation 
of an asthma diagnosis (and we assume the validated asthma diagnosis is true), the 
COPD might be misdiagnosed as the code was not repeated afterwards. 
Asthma and COPD diagnoses are based on symptoms, signs and spirometry, but there 
is no clear reference test. A panel consisting of two physicians determined whether 
asthma or COPD were present in the validated patients using all available 
information, and according to national and international guidelines. Both physicians 
were blinded to the patient selection algorithm and adjudicated the asthma and COPD 
statuses independently. Where opinion differed, the cases were discussed, and 
agreement was reached by consensus.   
Statistical analysis 
We calculated the proportion of asthma patients with COPD and vice versa with 95% 
confidence intervals using exact binomial Clopper-Pearson intervals. Cells with less 
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than 5 entries were merged for presentation. All analyses were conducted using Stata 
14.0 in 2017.  
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Table 1:  Baseline characteristics
Data Source  Asthma validation Total COPD validation Total 
  COPD Read code No COPD Read code   Asthma Read code No Asthma Read code   
Individuals (%) 52 (15%) 299 (85%) 351 210 (52%) 190 (48%) 400 
Mean age: (95% CI) 67 (64-70) 45 (42- 47) 48 (46-50) 73 (71-74) 73 (72-75) 73 (72-74) 
Sex: male (%) 22 (42%) 114 (38%) 136 (39%) 99 (47%) 104 (55%) 203 (51%) 
(Ex-) smoker (%) 43 (82%) 112 (37%) 200 (57%) * * * 
    *The COPD population was preselected to only include (ex-) smokers 
Table 1: Baseline characteristics of the validated asthma and validated COPD patients 
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RESULTS 
Background characteristics 
The baseline characteristics of the 751 patients with confirmed asthma and COPD 
diagnoses are shown in table 1. Amongst patients with validated asthma, those with 
a COPD diagnosis were older than those without (67 and 45 years, respectively). There 
was no noticeable difference in mean age between validated COPD patients with or 
without an asthma Read code (73 years in both groups). The validated asthma study 
population was mostly female (61.2%), while the validated COPD population was 
more evenly split regarding sex (50.7% male). The table is further split into two age 
categories. In the validated asthma patients, a concomitant COPD diagnosis is more 
likely when the patient is over 50 years of age. Only a small percentage of validated 
COPD patients is under 50 years of age. 
Validated asthma patients 
We studied 351 patients with a validated asthma diagnosis of which 52 (15%) had a 
recorded COPD Read code. The details are summarised in figure 1. For 6 of the 52 
asthma patients with COPD codes, the COPD codes were more than 2 years prior to 
asthma validation. For the remaining 46, COPD codes were within 2 years of the 
asthma validation date. Of the 46 with validated asthma and recent COPD codes, 38 
were smokers or ex-smokers and 8 were recorded as never-smokers. Out of 299 
asthma patients without COPD codes, 112 were (ex-) smokers, while 187 were 
recorded as never-smokers. 
We assumed concomitant asthma and COPD in validated asthma patients in the 
following cases: if the validated asthma patients had a recent diagnosis of COPD and 
were (ex-) smokers; or if they showed obstruction on their spirometry and were (ex-) 
smokers but lacked a COPD code. As such, concomitant asthma and COPD was likely 
in 52 patients (14.8%, 95% CI: 11.3%-19.0%): 38 of those 52 patients had a recent COPD 
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diagnosis (within 2 years of their asthma Read code) and were smokers or ex-smokers; 
the remaining 14 patients had no COPD Read code but showed obstruction on their 
spirometry and were smokers or ex-smokers. 
We assumed solitary asthma (without COPD) in validated asthma patients in three 
scenarios: either if they did not have a COPD code nor showed obstruction on lung 
function tests; or if they had a past COPD code more than two years ago (as the coding 
should have been repeated); or if they had a recent COPD code but no smoking 
history. As such, a solitary diagnosis of asthma was likely in 299 patients (85.2%; 95% 
CI 81.0-88.7): 187 never smokers without a COPD Read code, 98 (ex) smokers without 
obstruction or a COPD Read code, 8 patients with a recent COPD code but no smoking 
history, and 6 patients whose COPD Read code was more than 2 years since their last 
asthma code. 
Validated COPD patients 
We studied 400 patients with a validated COPD diagnosis, of which 210 (52%) had a 
recorded asthma Read code. The details are summarised in figure 2. For 82 of the 210 
COPD patients with asthma codes, the asthma codes were more than 2 years prior to 
COPD validation. For the remaining 128, asthma codes were within 2 years of the 
COPD validation date. Of the 128 with validated COPD and recent asthma codes, 42 
had a recording of positive reversibility testing and 86 did not have a recording of 
positive reversibility testing. Out of 190 COPD patients without asthma codes, 16 had 
a recording of positive reversibility testing, while 174 did not have lung function tests 
indicating reversibility of their airflow obstruction. 
We assumed concomitant asthma and COPD in validated COPD patients in two 
scenarios: validated COPD patients with a recently recorded asthma code and a 
recording of positive reversibility testing; and validated COPD patients without a 
recent asthma code but with positive reversibility testing recorded. As such, 
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concomitant asthma and COPD was likely in 58 patients (14.5% (95% CI 11.2%-
18.3%)): 42 patients who had a recently recorded asthma diagnosis and positive 
reversibility testing recorded, in addition to 16 patients without asthma Read codes 
who had positive reversibility testing recorded. 
We assumed solitary COPD (without asthma) in validated COPD patients based on 
the following criteria: validated COPD patients with no asthma codes nor recording 
of positive reversibility testing; validated COPD patients where the last asthma code 
was more than two years before asthma validation (indicating asthma prior to COPD); 
and validated COPD patients with recent asthma codes but without positive 
reversibility testing. As such, COPD without clear evidence of current asthma was 
likely in the remaining 342 patients (85.5% (95% CI: 81.7%-88.8%)): 174 patients with 
neither asthma Read codes nor positive reversibility testing, 82 patients where the last 
asthma Read code was more than 2 years before the COPD validation and 86 with 
recent asthma Read codes (less than 2 years before validation), but without positive 
reversibility testing. 
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Figure 1: Validated asthma patients 
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Figure 2: Validated COPD patients 
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DISCUSSION 
Summary 
We were able to investigate the prevalence of COPD in validated asthma patients and 
vice versa using CPRD GOLD data on smoking, spirometry and reversibility testing; 
in addition to detailed GP questionnaires and supporting information including 
outpatient referral letters, other emergency department discharge letters, airflow 
measurements and radiography records. The main finding of this study is that the 
14.8% of validated asthma patients had a concurrent COPD diagnosis, while 14.5% of 
validated COPD patients had a concurrent asthma diagnosis. Asthma may also be 
over recorded in CPRD GOLD in COPD patients. 
Comparison with existing literature 
In primary care, most consultations on respiratory diseases start with a provisional 
diagnosis made on clinical grounds from the patients' symptoms, in addition to 
previous specialists' correspondence if available.(322–325) Spirometry is needed to 
accurately differentiate the diagnosis of asthma and COPD, but is not always used in 
a primary care setting.(326–329) 
The prevalence of asthma in COPD populations is lower compared with many 
previously published studies, especially those based on electronic health records. 
However, the prevalence of COPD in asthma populations is similar to a previous 
cross-sectional study measuring the prevalence for comorbidities in asthma which 
reported 13.4% of patients with asthma had a COPD diagnosis compared with 3.4% 
of the remaining general population. A previous systematic review stated a pooled 
prevalence of asthma in COPD patients of 27%, with considerable heterogeneity.(330) 
The definition of asthma and COPD diagnosis tends to differ between studies, which 
might explain this observation. A study using Norwegian GP data confirmed COPD 
diagnosis using spirometry in 17.1% of patients with only a previous asthma 
diagnosis.(331) Among subjects with a spirometry-based study diagnosis of COPD in 
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GP practices in Scotland and the United States, 51.5% reported a prior diagnosis of 
asthma without a concurrent chronic bronchitis or emphysema diagnosis.(332) A 
systematic review on the asthma-COPD overlap syndrome in 2015 found a pooled 
prevalence of 27% in population-based studies of COPD patients and 28% in hospital-
based studies of COPD patients.(330) A recent multicentre study on COPD patients in 
Japan found an asthma prevalence of 9.2% or 4.2%, depending on the FEV1 cut-
off.(333) Other studies report a very wide range of prevalence of concomitant asthma 
and COPD, as the diagnosis criteria are heterogeneous and a consensus on diagnostic 
criteria is needed.(305,318) 
Strengths 
This study has a few strengths. Firstly, we were able to quantify the burden of 
concomitant diagnosis of asthma and COPD in a large cohort of primary care patients 
(CPRD GOLD), which is representative in terms of age and sex to the general UK 
population. Secondly, we used information included in both the CPRD GOLD and in 
the questionnaires sent out for the original validation studies in order to differentiate 
between asthma and COPD. Finally, this study adds to the relatively small body of 
literature on the epidemiology of concomitant asthma and COPD in primary care. 
 
Limitations 
This study has potential limitations which need consideration.  
First, the results of this study are only applicable to the records in the Clinical Practice 
Research Datalink, although this database is considered representative of the general 
UK population.(306) 
161  
  
Second, only asthma and COPD patients for whom their GP responded to verify their 
diagnosis in the original questionnaire were included in this study. GPs of more 
complicated cases might be less likely to respond where diagnostic uncertainty may 
exist. However, this issue is mitigated to an extent as GPs were paid for providing the 
information for validation, and the baseline characteristics of the individuals for 
whom a questionnaire was returned were similar to the characteristics for which no 
questionnaire was returned.(297,320) Data on eligible patients who were not included 
as there was no returned questionnaire were available from CPRD GOLD but did not 
contain all the information of a completed questionnaire. 
Third, the validation process was mostly based on the GP questionnaires, which are 
available in the original studies. (297,320) Additional information (discharge letters, 
spirometry measurements and radiography) were available for 31.5% of asthma 
patients. This means the strength of evidence for confirmation or rejection of recorded 
diagnosis in CPRD varied among the participants, and a panel diagnosis for chronic 
respiratory diseases can be considered as subjective. In the original validation studies, 
PPV’s were calculated separately for people for whom additional information was and 
was not provided, with similar results in these sensitivity analyses. 
Fourth, we are assuming the samples are representative of the asthma and COPD 
populations, while both sampling methods were based on possible identification 
strategies. The identification strategies or algorithms used for sampling are described 
in detail in their respective validation studies. (297,320) Fifth, this study clarifies the 
burden of concomitant asthma and COPD diagnosis in primary care, but additional 
information on how these patients are treated is needed in further studies. 
Fifth, the COPD population was selected to include only current or ex-smokers. This 
implies that our findings in the COPD populations are only valid for (ex-) smokers.  
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Finally, GPs could have more information on the clinical status which was not shared 
in the questionnaire. This risk is present but diminished as the provision of additional 
information was remunerated.  
Implications for research and/or practice 
This study suggests that over diagnosis of asthma in COPD patients is more likely 
than over diagnosis of COPD in asthma patients. COPD is possibly more 
conservatively diagnosed as it is considered a more severe disease, while asthma can 
be more liberally diagnosed. In addition, a COPD patient can be diagnosed with 
asthma in the years before first COPD diagnosis, after which no further recording of 
asthma is made. This suggests the asthma diagnosis was likely to be false. In patients 
with presumed concomitant diagnosis of asthma and COPD, reversibility testing can 
be used to verify the asthma diagnosis.  
The findings from our study have implications on further research into concomitant 
asthma and COPD. Identifying potential concomitant asthma and COPD using 
electronic health records should be done cautiously. If only a single code for both 
diseases is required for the identification algorithm, the prevalence of concomitant 
diagnosis of asthma and COPD is likely to be overestimated.  
In addition, this study also has implications for the management of COPD patients 
with a past asthma diagnosis, as the previous asthma diagnosis might be either 
outdated or misdiagnosed. Incorrect management can expose them to adverse effects 
and incur additional costs for the patient and health system, for example though 
unnecessary medication regimens such as the usage of montelukast in COPD patients. 
This study did not go into detail on the current treatment of either validated asthma 
or validated COPD patients.  
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CONCLUSION 
Concomitant asthma and COPD was likely in 14.8% (95% CI: 11.3%-19.0%) of 
validated asthma patients, and in 14.5% (95% CI 11.2%-18.3%) of validated COPD 
patients. However, more than half of the validated COPD patients had ever received 
an asthma diagnosis Read code, suggesting over diagnosis of asthma in COPD 
patients commonly occurs, particularly early in the diagnostic process. Over diagnosis 
of COPD in asthma patients is less likely. 
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Chapter 6: Clinical profile of pre-defined 
asthma phenotypes in a large cohort of UK 
primary care patients (CPRD)  
Summary 
• Established asthma phenotypes can be identified in a general asthma 
population, although many patients did not fit into the specific phenotypes 
which we studied. 
• 3.9% of asthma patients were categorised as benign asthma, 28.6% as atopic 
asthma, and 4.8% as obese non-eosinophilic asthma.  
• 62.7% of patients were included in the asthma NOS (Not Otherwise Specified) 
group, including asthma NOS without treatment (10.4 %), only on SABA (6.1%) 
and on maintenance treatment (46.2%).  
• Exacerbation rates per 1000 person-years were lowest for benign asthma (106.8 
[95% CI:101.2-112.3]), and highest for obese non-eosinophilic asthma (469.0 
[451.7-486.2]).  
• Asthma incidence rate ratios for all phenotype groups compared with the 
benign asthma group decreased when stratified by treatment step but 
remained raised. 
• Phenotyping along with knowledge of asthma treatment step helps anticipate 
future treatment needs and could further aid clinical management. 
• However, this is only possible in a minority of primary care patients based on 
current phenotypes and EHR records so either more complete records or EHR 
specific phenotypes would be helpful. 
• The treatable traits strategy might represent a better conceptual framework 
towards precision medicine for asthma than phenotyping using primary care 
EHR at this stage. 
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6.1 Preface   
The research paper presented in this chapter aims to answer the final aim of this thesis 
by investigating the prevalence, exacerbation risk and patient profile of different 
asthma phenotypes in a general population. This study builds upon the foundations 
of the studies included in earlier chapters and on one other study conducted by Chloe 
Bloom using a similar patient cohort in the CPRD GOLD on which I am second author. 
(1)  
The findings of the research papers included in the previous chapters of this thesis 
have provided relevant information for the rationale and design of this study. The 
systematic review indicated possible ways to identify asthma patients from EHR. The 
validation study identified the optimal algorithm to determine which patients had 
asthma from the CPRD GOLD, and the study on concomitant asthma and COPD 
assessed the prevalence and possible misdiagnosis of COPD in asthma patients in the 
CPRD. 
The study by Bloom et al. examined the general asthma population in the UK and their 
exacerbation risk and patient characteristics by age cohort, as most of the earlier 
literature has focused on more severe patients or severe exacerbations. The study 
design was a population-based cohort study using CPRD GOLD and HES, from 2007 
to 2015. The population was divided into four age cohorts, under 5, 5-17, 18-54 and 
older than 55. Poisson regression was used for the regression analysis. The risk factors 
included gender, socioeconomic status, smoking, body mass index, atopy, rhinitis, 
gastro-oesophageal reflux, anxiety, depression, COPD and asthma severity defined by 
asthma treatment according to the British Thoracic Society (BTS) stepwise approach. 
This study found a total population of 424 326 patients, of whom 60% had mild 
asthma. The results indicated most UK patients with asthma (60%) had mild asthma 
(corresponding to BTS steps 1 and 2) and did not have an exacerbation during the 
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follow-up. Older patients (aged older than 55 years) were more likely to have a higher 
treatment step and had a higher exacerbation rate. Patients aged between 5 and 18 
years were less likely to have a high treatment step and had the lowest exacerbation 
rates. This study used the asthma algorithm validated in the fourth Chapter of this 
thesis and similar definition of covariates as the study presented in this chapter. 
For the cohort study presented in this chapter, we applied the phenotype 
categorization identified in primary care by Haldar et al.: benign asthma, early-onset 
atopic asthma and obese non-eosinophilic asthma.(2) The method section was kept 
brief to fit the article in a 3000-word limit for publication. The following paragraph 
expands upon the methods section in the submitted article under section 6.2. 
Baseline characteristics were tabulated for each phenotype. Asthma exacerbation 
incidence rates were calculated for each phenotype using negative binomial 
regression with lexis expansion for age. We used negative binomial regression over 
Poisson regression with overdispersion as it provides a better fit to the distribution of 
data in exacerbation studies.(3,4) A random effects model was used to account for 
consecutive asthma exacerbations in the same study participant. The minimally 
adjusted model was adjusted only for age and sex. The fully adjusted model 
additionally adjusted for confounding by lifestyle factors and comorbidities: smoking, 
body mass index, socio-economic status through the index of multiple deprivation 
(IMD), gastro-oesophageal reflux disease (GORD), anxiety, depression and COPD. In 
addition, we stratified the final treatment step by asthma severity, defined by the 
received treatment. Sensitivity analyses were performed by including those patients 
without information on their smoking status and body mass index. We looked for 
evidence of interaction between phenotypes and age and between phenotypes and sex 
in the final model using likelihood ratio tests between models with and without 
interaction terms. Results were displayed using Forest plots and Cumulative Hazard 
ratios. 
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This study used negative binomial regression over Poisson regression (a common 
model in exacerbation studies). The rationale for this was that Poisson regression 
would not specifically account for interpatient variability, and the distribution of 
exacerbations would be more dispersed than would be predicted in a Poisson 
distribution. An overdispersion correction (deviance correction or Pearson 
correction)(27) could partially resolve these problems, but this would remain only a 
generic correction and the exacerbation variability in patients would not be an 
explicit component of the Poisson regression model.(334,335) The data had the 
potential to be overdispersed (when the conditional variance exceeds the conditional 
mean. The negative binomial regression model is similar to a Poisson regression 
model as is has the same mean structure, but it has an extra parameter to model 
overdispersion. Negative binomial regression could provide a better model for 
exacerbation data than Poisson regression.(336,337) The assumption of this model is 
that each individual has their own underlying rate of exacerbations. While the 
exacerbation count of each individual follows a Poisson distribution, the expected 
number of exacerbations varies across individuals following a gamma 
distribution.(334) The confidence intervals using the negative binomial regression 
would be narrower compared to a Poisson regression model if there is 
overdispersion of the conditional distribution of the outcome variable. The data was 
not overly dispersed in retrospect, but nothing was lost by using this negative 
binomial regression over Poisson regression.(334) 
 
Furthermore, Poisson regression would not account for survivor bias, e.g. if patients 
who are more likely to exacerbate would also be more likely to be lost to follow-
up.(338) Patients who exacerbate often tend to withdraw earlier from follow-up.(338) 
The survivor bias referenced in the thesis did not refer to the competing risk of 
death, but rather the time when an exacerbation could not be measured, similar to 
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immortal time bias.(339,340) In a Poisson model, each unit of time is weighted 
equally (a patient who is followed up for 12 months is weighted 4 times more than a 
patient who is followed for 3 months). A negative binomial model includes the 
modelling of variability between patients in the estimation of rates. If the 
exacerbation number follows the distribution above, it can account for increased 
exacerbation rates in patients who withdraw early.(335) 
The negative binomial regression analysis presented a model that assumed each 
participant has their own underlying exacerbation rate.(336,337) Within each 
participant, the exacerbation number followed a Poisson distribution but the 
predicted number of exacerbations varied across participants according to a gamma 
distribution (a variant on the normal distribution).(334) The advantages of negative 
binomial regression over Poisson regression included the less simplistic assumption 
about participant variability, and that the negative binomial regression model 
accounted better for participants with frequent exacerbations withdrawing 
early.(335,341) 
The research paper presented in this chapter has been submitted for peer review to 
the “Journal of Asthma and Allergy”. 
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6.2 Research paper  
Clinical profile of pre-defined asthma phenotypes in a large cohort of UK primary 
care patients (CPRD). 
Short Title: Pre-defined asthma phenotypes in CPRD 
Authors: Francis Nissen,1 Ian J Douglas,1 Hana Mullerova,2 Neil Pearce,1 Chloe Bloom,3 
Liam Smeeth,1 Jennifer K Quint3 
1. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and 
Tropical Medicine, London, UK 
2. RWE & Epidemiology, GSK R&D, Uxbridge, UK 
3. National Heart and Lung Institute, Imperial College, London, UK 
  
ABSTRACT 
Background:  
Distinct asthma phenotypes have previously been suggested, including benign 
asthma, atopic asthma and obese non-eosinophilic asthma. This study aims to 
establish if these phenotypes can be identified using data recorded in primary care 
clinical records and reports on patient characteristics and exacerbation frequency. 
Methods: A population-based cohort study identified 193,999 asthma patients in UK 
primary care from 2007 to 2017. We used linked primary and secondary care data from 
the Clinical Practice Research Datalink, Hospital Episode Statistics and Office of 
National Statistics. Patients were classified into predefined phenotypes or included in 
an asthma “not otherwise specified” (NOS) group. We used negative binomial 
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regression to calculate the exacerbation rates and adjusted rate ratios. Rate ratios were 
further stratified by asthma treatment step. 
Results:  
In our cohort, 3.9% of patients were categorized as benign asthma, 28.6% atopic 
asthma, and 4.8% obese non-eosinophilic asthma. 62.7% of patients were asthma NOS, 
including asthma NOS without treatment (10.4 %), only on SABA (6.1%) and on 
maintenance treatment (46.2%). Crude severe exacerbation rates per 1000 person-
years were lowest for benign asthma (106.8 [95% CI:101.2-112.3]), and highest for 
obese non-eosinophilic asthma (469.0[451.7-486.2]). Incidence rate ratios for all 
phenotype groups decreased when stratified by treatment step but remained raised 
compared with benign asthma. 
Conclusion:  
Established phenotypes can be identified in a general asthma population, although 
many patients did not fit into the specific phenotypes which we studied. Phenotyping 
patients and knowledge of asthma treatment step could help anticipate clinical course 
and therefore could aid clinical management but is only possible in a minority of 
primary care patients based on current phenotypes and EHR records. 
INTRODUCTION 
Asthma is a heterogeneous disease with recognisable clusters called asthma 
phenotypes.(62,113,342,343) These phenotypes are defined as the set of observable 
characteristics of an individual resulting from the interaction of its genotype with the 
environment.(93) Classifying asthma into phenotypes allows to deconstruct the 
disease into separate identifiable and treatable traits (8) and better understand disease 
172  
  
progression and response to treatment, further enabling practice of precision 
medicine.(113) 
There have been multiple studies describing asthma phenotypes, (101–110,344) 
involving populations with asthma alone or as part of an entity called “obstructive 
airways disease” together with COPD.(111,112) Criteria to distinguish asthma 
phenotypes include inflammatory profiling based on leucocyte counts (eosinophils, 
neutrophils and paucigranulocytic), symptom expression, age-of-asthma onset, and 
airflow measurements.(94–100) Classification by eosinophil counts has been found to 
be particularly important due to treatment response.(114–116) 
One of the most impactful studies on clinical asthma phenotypes was conducted by 
Haldar et al using cluster analysis of multiple clinical variables.(101) Among 184 
patients managed in primary care, three clusters were found: one group with benign 
asthma, one group with obese non-eosinophilic asthma and one group with early-
onset atopic asthma (figure 1). Cluster analysis of two further mostly refractory 
asthma populations managed in secondary care (N=255 total) added an early 
symptom predominant cluster and an inflammation predominant cluster. Other 
phenotyping studies using comparable clinical variables found similar 
phenotypes.(103,106,194–196) 
In this study, we examined if it is possible to identify asthma patients with one of three 
phenotypes identified in primary care by Haldar et al from electronic health records 
and report their characteristics and medication use. To accurately classify patients into 
a phenotype, strict criteria were applied. The exact criteria are described in the 
methods section. Blood eosinophil tests were used as they are well recorded in CPRD, 
unlike sputum eosinophils.(345)  
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We used the CPRD (Clinical Practice Research Datalink) GOLD database to identify 
asthma patients. To define asthma exacerbations, we also linked to the Hospital 
Episodes Statistics (HES) and Office of National Statistics data. 
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Figure 1: Asthma Phenotypes, based on cluster analysis (quote from Haldar et al., reproduced 
with permission. Reprinted with permission of the American Thoracic Society. Copyright © 
2018 American Thoracic Society. Haldar P et al. Cluster analysis and clinical asthma 
phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–24.  The American Journal of 
Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.) 
Aim and Objectives:  
To evaluate the extent to which three previously suggested asthma phenotypes 
(benign asthma, atopic asthma, obese non-eosinophilic asthma) could be identified 
using data included in routinely collected electronic health records, and to assess the 
exacerbation frequency, clinical profile and medication use by phenotype. 
METHODS 
Data sources 
We used the July 2017 dataset of the Clinical Practice Research Datalink (CPRD), a 
large UK primary care database containing anonymized data of people registered 
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with primary care practices from across the UK. CPRD is representative of the UK 
population with regard to age and sex.(208,306) Diagnostic accuracy is high in CPRD, 
including for asthma and COPD,(229,297,308,320) and CPRD can be used to identify 
individuals at risk of recurrent asthma attacks.(346,347) Only patients with linkage to 
Hospital Episodes Statistics (HES) and Office for National Statistics (ONS) were 
considered for inclusion. Linked data are available for patients registered at 
consenting English practices. This study used only data on patients who were linked 
to Hospital Episodes Statistics (HES) for all hospital inpatient admissions and 
emergency visits and Office for National Statistics for deaths and socio-economic 
status through the index of multiple deprivation (IMD). 
Study population and follow-up 
Adult patients in CPRD (18 years of age or older) with linkage to HES and ONS and 
a validated asthma Read code between April 2007 and July 2017 in addition to a valid 
blood eosinophil count, BMI and determinable smoking status were eligible for 
inclusion.(320) Patients entered the cohort at the latest date of: 1 year of follow-up  
from the practice up-to-standard date (contributing research quality data to CPRD); 
reaching 18 years of age; available linkage and from April 2007 at earliest. Once all 
these criteria were fulfilled, participants were included in one of the phenotypes 
below after one year of continuous follow-up in which their SABA and inhaler use is 
measured and remained in their respective phenotype(s) during further follow up. 
The index date was the time point after the one year of follow-up, when the 
participants are included in a phenotype. The follow-up ended when the patient was 
transferred out, death or end of study period. During this year, their reliever 
medication (short-acting beta agonist, SABA) and maintenance treatment 
prescriptions (see covariate section) were measured. The time point after one year 
when patients were assigned to a phenotype and after which exacerbations were 
measured was designated as the index date (figure 2). We used SABA prescription 
count as proxy for symptom expression,(348,349) as asthma symptoms are non-
176  
  
specific and often not recorded in CPRD. Blood eosinophil counts, routinely recorded 
in primary care, were used as proxy for sputum eosinophil counts.(345,347,350) 
Patients were assigned their phenotype group on index date, after which severe 
asthma exacerbations were ascertained and counted. Patients remained in their 
respective phenotype group and followed-up until the earliest date of transfer-out of 
CPRD practice, last collection date, death or end of study period (01/07/2017). 
 
 
Figure 2: Cohort timeline 
 
Definition of the phenotypes 
Each patient was assigned to a single phenotype group on index date based on 
previously recorded information. Stringent inclusion criteria were used to keep the 
phenotype groups specific. All code lists for covariates and comorbidities are included 
in attachment and on Data compass. Patients were only allowed to be classified into a 
single phenotype. Obese non-eosinophilic asthma held priority over atopic asthma as 
the former phenotype was deemed more specific. Phenotype groups were defined as 
follows: 
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1) Benign asthma: low eosinophil counts on the latest blood test from April 2007 
onward (< 300 cells/µL and <4% of leucocytes), absence of SABA prescriptions and of 
severe exacerbations of asthma in the year before index date, and aged 40-60 at study 
entry. 
2) Atopic asthma: occasional SABA prescriptions (2-4 in year before index date, 
excluding 23% of patients without SABA prescriptions and 26% with 5+ prescriptions) 
and ≥1 atopy or ≥2 antihistamine codes ever recorded. 
3) Obese non-eosinophilic asthma: low eosinophil counts on the last blood count (ie 
blood eosinophil levels less than 300 cells/µL (36) and less than 4% of blood 
leucocytes), female, frequent SABA prescriptions (≥3 prescriptions in year before 
index date, which corresponds to 42% of patients) and at least one record for BMI >30 
in last five years before index date. 
4) Asthma NOS (Not Otherwise Specified): patients who did not fit in previous 
phenotypes were split into three sub-groups: (1) patients without any asthma 
medication prescriptions, (2) patients only on SABA and (3) patients with at least one 
maintenance treatment prescription during the one year before index date. We 
described these groups to determine whether they fit other phenotypes described in 
the literature. 
Definition of severe asthma exacerbations 
An exacerbation was defined as any of the following:  prescription of ≤300mg oral 
corticosteroids (OCS) outside an annual asthma review (4) or an A&E visit, acute 
hospital visit of <1 day duration, overnight hospitalisation or death due to asthma. 
This corticosteroid dose cut-off was chosen to eliminate chronic oral corticosteroid use 
for other conditions than asthma. Exacerbations within fourteen days of a previous 
exacerbation were excluded. 
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Definition of covariates 
Age was defined in 10-year age bands, socio-economic status was assigned at patient 
level using the ONS Index of Multiple Deprivation. Smoking status was categorized 
as either current smoker, ex-smoker or never-smoker. Co-morbid conditions were 
determined by Read codes: COPD, atopic dermatitis, GORD (Gastro-oesophageal 
Reflux Disease), atopy (eczema or rhinitis), anxiety and depression. Influenza and 
pneumococcal vaccinations during last 10 years were included as covariates. The final 
model was stratified by disease severity based on the stepwise approach in the 2016 
British Thoracic Society Asthma Management Guidelines (BTS/SIGN) which includes 
inhaled ICS thresholds.(4) Step 1 was defined by absence of maintenance asthma 
treatment. Step 2 by regular prescription of low-dose ICS. Step 3 added long acting 
beta agonists (LABA). Step 4 by medium-dose ICS with or without additional 
therapies (LABA, theophyllines, leukotriene receptor antagonists or long-acting 
antimuscarinics). Step 5 was defined by high-dose ICS and step 6 by 
continuous/frequent use of oral corticosteroids. 
Data analysis 
Baseline characteristics were tabulated for each phenotype.  Asthma exacerbation 
incidence rates and rate ratios were calculated using negative binomial regression 
with a random effects model and lexis expansion for age. We used negative binomial 
regression over Poisson regression with overdispersion as it provides a better fit to the 
distribution of the data.(334,335) The minimally adjusted model included age and sex 
only. The fully adjusted model additionally controlled for smoking status, body mass 
index, socio-economic status, GORD, pneumococcal and influenza vaccinations, 
anxiety, depression and COPD. In addition, we stratified incidence rate ratios (IRRs) 
by severity, defined by prescribed treatment. Stata 15.0 was used for data analysis. 
Results were displayed using Forrest plots and a Kaplan-Meier survival plot to 
display time to first exacerbation. 
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Sample size calculations 
The reasoning behind the sample size of the cohort study was as follows: We would 
need 3786 asthma patients in each of the different phenotypes to detect an 
exacerbation rate ratio of 0.9 (alpha 0.05 and power 0.9) considering an equal amount 
of asthma patients in 2 phenotypes. A 95% confidence interval for baseline 
characteristics and rate ratios quantified the random error associated with our 
estimate. 
Missing data 
The plan for addressing missing data for the cohort study was as follows:Two 
phenotypes require an absence of high eosinophilia counts, but tests for eosinophils 
have not been recorded for all asthma patients. Feasibility counts on the number of 
patients with asthma from 2004-2015 show that 71% of records have a valid eosinophil 
count. We anticipated a small degree of missingness for the BMI and smoking 
covariates based on previous studies. Decisions regarding how to deal with missing 
values were based on the proportion of missing data, and assumptions regarding 
whether data was missing at random (MAR) or not. Where appropriate we would 
undertake a complete case analysis.  
If data was thought to be MAR we would consider using multiple imputation, 
however this MAR assumption did not seem likely. MAR means that there might be 
systematic differences between the missing and observed variables, but these can be 
entirely explained by other observed variables. We would not be able to predict 
variables such as eosinophil values based on other observed variables. Where data 
was not missing at random, for example with BMI or smoking data, but where we 
expect the data to be ~80% complete (based on previous studies), we would use a 
complete case analysis but will discuss biases that may occur as a result of adopting 
that approach. BMI data is unlikely to be MAR as patients with overweight would be 
more likely to have their BMI recorded as it would be more clinically relevant. If 
multiple imputation was not appropriate and large quantities of data would be 
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missing, we would consider using those covariates only as part of a secondary analysis 
and discuss any biases and limitations that would occur as a result of that.  
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Benign 
Asthma 
Atopic 
Asthma  
Obese non-
eosinophilic 
NOS no 
med 
NOS with 
only SABA 
NOS with 
maintenance Total 
Total 7,495 55,455 9,372 20,204 11,926 89,547 193,999 (100.0%) 
 Percentage of total 3.9% 28.6% 4.8% 10.4% 6.1% 46.2% 100.0% 
 Follow-up median & IQR 4.28 (2.05;6.36) 4.34 (2.10;6.46) 4.54 (2.21;6.84) 3.46 (1.41;5.26) 4.11 (1.93;6.11) 4.35 (2.10;6.46) 4.24 (1.99;6.34) 
Gender               
 Female 4,727 (63.1%) 38,060 (68.6%) 9,372 (100.0%) 13,627 (67.4%) 7,142 (59.9%) 53,828 (60.1%) 126,756 (65.3%) 
Age category               
 18-30 y 0 10,693 (19.3%) 813 (8.7%) 6,536 (32.4%) 1,966 (16.5%) 9,600 (10.7%) 29,608 (15.3%) 
 31-50 y 4,201 (56.1%) 19,762 (35.6%) 3,127 (33.4%) 6,810 (33.7%) 4,736 (39.7%) 26,585 (29.7%) 65,221 (33.6%) 
 51-70 y 3,294 (43.9%) 17,005 (30.7%) 3,888 (41.5%) 4,365 (21.6%) 3,451 (28.9%) 32,381 (36.2%) 64,384 (33.2%) 
 ≥71 y 0 7,995 (14.4%) 1,544 (16.5%) 2,493 (12.3%) 1,773 (14.9%) 20,981 (23.4%) 34,786 (17.9%) 
Socio-economic status               
 1: least deprived 2,092 (27.9%) 13,647 (24.6%) 1,260 (13.4%) 4,696 (23.2%) 2,465 (20.7%) 17,971 (20.1%) 42,131 (21.7%) 
 2 1,724 (23.0%) 12,153 (21.9%) 1,644 (17.5%) 4,306 (21.3%) 2,405 (20.2%) 18,813 (21.0%) 41,045 (21.2%) 
 3 1,513 (20.2%) 11,090 (20.0%) 1,801 (19.2%) 4,154 (20.6%) 2,450 (20.5%) 18,352 (20.5%) 39,360 (20.3%) 
 4 1,219 (16.3%) 10,189 (18.4%) 2,149 (22.9%) 3,844 (19.0%) 2,423 (20.3%) 17,655 (19.7%) 37,479 (19.3%) 
 5: most deprived 943 (12.6%) 8,350 (15.1%) 2,513 (26.8%) 3,192 (15.8%) 2,180 (18.3%) 16,702 (18.7%) 33,880 (17.5%) 
Smoking status               
 Current smoker 1,473 (19.7%) 10,523 (19.0%) 2,485 (26.5%) 4,637 (23.0%) 3,541 (29.7%) 22,165 (24.8%) 44,824 (23.1%) 
 Ex-smoker 2,884 (38.5%) 22,930 (41.3%) 3,813 (40.7%) 6,679 (33.1%) 4,090 (34.3%) 38,000 (42.4%) 78,396 (40.4%) 
 Never smoker 3,138 (41.9%) 22,002 (39.7%) 3,074 (32.8%) 8,888 (44.0%) 4,295 (36.0%) 29,382 (32.8%) 70,779 (36.5%) 
BMI               
 <20 278 (3.7%) 3,257 (5.9%) 0 1,477 (7.3%) 756 (6.3%) 6,018 (6.7%) 11,786 (6.1%) 
 20-25 2,041 (27.2%) 16,819 (30.3%) 0 6,596 (32.6%) 3,488 (29.2%) 25,468 (28.4%) 54,412 (28.0%) 
 25-30 2,703 (36.1%) 18,814 (33.9%) 0 6,267 (31.0%) 4,080 (34.2%) 31,068 (34.7%) 62,935 (32.4%) 
 >30 2,473 (33.0%) 16,565 (29.9%) 9,369 (100.0%) 5,864 (29.0%) 3,602 (30.2%) 26,993 (30.1%) 64,866 (33.4%) 
    
Table 1: Baseline characteristics of the study population by phenotype     
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Benign 
Asthma 
Atopic 
Asthma  
Obese non-
eos 
NOS no 
med 
NOS with 
only SABA 
NOS with 
maintenance Total 
BTS step        
 BTS1 4,401 (58.7%) 11,612 (20.9%) 754 (8.0%) 20,204 (100.0%) 11,926 (100.0%) 0 48,897 (25.2%) 
 BTS2 1,186 (15.8%) 18,898 (34.1%) 2,526 (27.0%) 0 0 29,809 (33.3%) 52,419 (27.0%) 
 BTS3 520 (6.9%) 6,220 (11.2%) 1,164 (12.4%) 0 0 12,309 (13.7%) 20,213 (10.4%) 
 BTS4 978 (13.0%) 11,710 (21.1%) 2,625 (28.0%) 0 0 26,173 (29.2%) 41,486 (21.4%) 
 BTS5 263 (3.5%) 5,346 (9.6%) 1,831 (19.5%) 0 0 15,825 (17.7%) 23,265 (12.0%) 
 BTS6 3 (.0%) 243 (.4%) 129 (1.4%) 0 0 1,457 (1.6%) 1,832 (.9%) 
 Non BTS 144 (1.9%) 1,426 (2.6%) 343 (3.7%) 0 0 3,974 (4.4%) 5,887 (3.0%) 
Comorbid conditions               
 Atopy 3,069 (40.9%) 45,632 (82.3%) 3,965 (42.3%) 9,283 (45.9%) 1,388 (11.6%) 26,577 (29.7%) 89,914 (46.3%) 
 GORD 1,291 (17.2%) 11,331 (20.4%) 2,374 (25.3%) 2,965 (14.7%) 1,859 (15.6%) 18,242 (20.4%) 38,062 (19.6%) 
 Anxiety  2,161 (28.8%) 17,841 (32.2%) 3,584 (38.2%) 5,835 (28.9%) 3,397 (28.5%) 26,182 (29.2%) 59,000 (30.4%) 
 Depression 2,874 (38.3%) 21,826 (39.4%) 5,125 (54.7%) 7,240 (35.8%) 4,394 (36.8%) 34,056 (38.0%) 75,515 (38.9%) 
 COPD 351 (4.7%) 5,676 (10.2%) 1,836 (19.6%) 1,005 (5.0%) 1,313 (11.0%) 20,512 (22.9%) 30,693 (15.8%) 
Eosinophils               
 Eosinophils <300/µL & <4% 7,495 (100.0%) 24,967 (45.0%) 9,372 (100.0%) 9,800 (48.5%) 6,439 (54.0%) 38,539 (43.0%) 96,612 (49.8%) 
 Eosinophils >300/µL / >4% 0 30,488 (55.0%) 0 10,404 (51.5%) 5,487 (46.0%) 51,008 (57.0%) 97,387 (50.2%) 
SABA               
 0 prescriptions 7,495 (100.0%) 0 0 20,204 (100.0%) 0 16,306 (18.2%) 44,005 (22.7%) 
 1-2 prescriptions 0 0  (.0%) 0 7,430 (62.3%) 21,671 (24.2%) 68,381 (35.2%) 
 3-9 prescriptions 0 16,175 (29.2%) 7,519 (80.2%) 0 3,585 (30.1%) 36,703 (41.0%) 63,982 (33.0%) 
 10+ prescriptions 0 0 1,853 (19.8%) 0 911 (7.6%) 14,867 (16.6%) 17,631 (9.1%) 
Table 1: Baseline characteristics of the study population by phenotype
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RESULTS 
Background characteristics 
Of 323,862 asthma patients with complete linkages and eligible for inclusion, 193,999 
(59.9%) had at least one year of follow-up and an eosinophil count, BMI value and 
smoking variables and formed the analysis population (figure 3). Study participants 
were followed up for a median of 4.24 years (IQR:1.99-6.34); the median age at study 
entry was 51 years (IQR 37-66). 65.3% were female and 63.5% were smokers or ex-
smokers.  
 
Figure 3: Flowchart of study eligibility and participation 
In this primary care asthma population, 7,495 (3.9%) were classified into the benign 
asthma group, 55,455 (28.6%) as atopic asthma, and 9,372 (4.8%) as obese non-
eosinophilic asthma (Table 1). Of the remaining patients classified as asthma NOS, 
20,204 (10.4%) did not receive any asthma medication, 11,926 (6.1%) had only SABA 
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prescription codes and 89,547 patients (46.2%) had maintenance treatment in the year 
before index date. 
The patient characteristics and total follow-up duration varied between phenotypes. 
The asthma NOS group with maintenance treatment had the highest mean age on 
study entry (55 years, SD 18 years). Average BTS step was highest in the same group 
(mean 3.38), followed by obese non-eosinophilic and atopic asthma (Figure 4). GORD 
and anxiety were most common in the obese non-eosinophilic group (25.3% and 
38.2%, resp.), followed by atopic asthma and asthma NOS with maintenance 
treatment. Comorbid COPD was most common in the asthma NOS group with 
maintenance asthma treatment (22.9%). The last available eosinophil count was 
elevated in 50.2% of all patients and 65.8% were overweight or obese.  
 
Figure 4: BTS step by phenotype 
Severe Exacerbation Rates 
The study participants were followed for a total of 819,619 years and 258,388 
exacerbations were recorded (Table 2). Exacerbation rates (per 1000 person-years) 
were highest in the obese non-eosinophilic group and lowest in the benign asthma 
group. Minimally adjusted exacerbation rates per phenotype were as follows: 116.2 
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for benign asthma, 286.9 for atopic asthma, 454.9 for obese non-eosinophilic asthma, 
148.1 for asthma NOS without medication, 208.6 for asthma with only SABA 
prescriptions and 389.4 for asthma NOS with maintenance medication.  
Fully adjusted exacerbation rates controlling for lifestyle factors and comorbidities, 
show a similar relation between asthma phenotypes with event rates of: 143.2 for 
benign asthma, 322.1 for atopic asthma, 439.3 for obese non-eosinophilic asthma, 174.6 
for asthma NOS without medication, 240.0 for asthma NOS with only SABA 
prescriptions and 414.0 for asthma NOS with maintenance treatment.  
Table 2: Exacerbation rates with corresponding rate ratios by phenotype 
Phenotype 
No. of 
Events 
Time at Risk (1000 
person-y) 
Crude Rate/1,000 
Person-y (95% CI) 
Minimally 
Adjusted 
Adjusted rates 
Benign Asthma 3,431 30.867 106.8 (101.2-112.3) 116.2 (110.1-122.3) 143.2 (135.6-150.8) 
Atopic Asthma  68,143 239.664 283.2 (278.6-287.7) 286.9 (282.3-291.5) 322.1 (316.6-327.5) 
Obese non-eos 19,263 42.471 469.0 (451.7-486.2) 454.9 (438.0-471.7) 439.3 (422.5-456.2) 
NOS no med 10,495 70.978 143.8 (139.3-148.3) 148.1 (143.4-152.7) 174.6 (169.0-180.2) 
NOS with reliever Tx 9,529 48.238 200.7 (193.2-208.1) 208.6 (200.9-216.3) 240.0 (231.1-249.0) 
NOS with maint Tx 
147,527 387.403 388.2 (383.5-392.9) 389.4 (384.6-394.1) 414.0 (408.6-419.3) 
Minimally adjusted: adjusted for age and sex    
Adjusted rates: adjusted for age, sex, smoking, bmi, imd, anxiety, depression, COPD, GORD  
Note: Unless otherwise indicated, values are given as rates (95% CI).   
Table 2: Exacerbation rates with corresponding rate ratios by phenotype 
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Rate ratios 
Benign asthma had the lowest rate of exacerbations and was used as reference group 
for the calculation of incidence rate ratios (Figure 5). IRRs, (fully adjusted models) for 
asthma exacerbation were 2.28 (95% CI 2.16-2.41) for those with atopy; 3.11 (95% CI 
2.91-3.32) for obese non-eosinophilic asthma, 1.23 (95% CI 1.16-1.31) for asthma NOS 
without medication, 1.69 (95% CI 1.58-1.80) for asthma NOS with SABA and 2.92 (95% 
CI 2.77-3.08) for asthma NOS with maintenance treatment. When stratified by BTS 
treatment step, the IRRs of all phenotypes compared with benign asthma decreased 
across all steps, but difference in incidence rates between the groups and benign 
asthma was still notable. Time to first exacerbation analysis showed a pattern 
comparable with rates derived by negative binomial regression (Figure 6). Shortest 
median time to exacerbation was observed in the obese non-eosinophilic asthma 
group, and longest in the benign asthma group. No clinically important interaction 
between phenotype and age or phenotype and gender was observed. Sensitivity 
analyses including patients with missing BMI or smoking status found similar results 
to the main analysis. 
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Figure 5: Incidence rate ratios, stratified by treatment step. Adjustment for step 6 resulted in 
very wide confidence intervals due to low sample size. This made the Forrest plot unreadable, 
so this adjustment is not displayed. 
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Figure 6: Time to first exacerbation analysis in years, by phenotype and 95% CI 
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DISCUSSION 
Summary 
In this study on asthma phenotypes in a large general asthma population, we were 
able to identify patients who fitted three previously suggested phenotypes: benign, 
early-onset atopic and obese non-eosinophilic asthma. Due to strict criteria used to 
define the three main phenotypes, most patients with asthma (62.7%) were not 
included in any of three predefined primary care phenotypes and were categorized as 
asthma NOS. Patients in the asthma NOS groups partly reflected some of the 
established phenotypes, for example inflammation predominant or early symptom 
predominant phenotypes. For example, in the asthma NOS with maintenance 
treatment group, 57.0% of patients had high eosinophil counts; possibly indicating 
some patients with an inflammation predominant phenotype were included in this 
group. However, these patients also had more SABA prescriptions (and presumably 
more symptoms) than the total cohort. This group may include undiagnosed COPD 
patients based on their higher average age and treatment step. There was a higher 
exacerbation burden in those with obese non-eosinophilic atopic asthma, and a lower 
exacerbation rate in those with benign asthma compared with the asthma NOS group 
(with and without medication) in the crude model. These rate differences persisted 
after adjustment for lifestyle factors and comorbidities. When stratifying the patients 
by treatment step, differences in incidence rates between phenotypes remained but 
were decreased.  Phenotyping a greater proportion of asthma patients based on their 
primary care health records could be possible by either constructing different 
phenotypes or by creating more complete records (for example more full blood 
counts). However, this might not be the most efficient way to offer precision medicine 
to asthma patients. The recently proposed treatable traits strategy (24,351) might 
represent a better conceptual framework towards precision medicine for asthma than 
phenotyping using primary care EHR at this stage.(352,353) This strategy focuses 
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asthma management on single traits that are identifiable and treatable, such as airway 
inflammation (measured using eosinophil counts) or airflow limitation.(24) 
There are multiple strengths to the current study. The study is population-based and 
representative of the population of England (30) which allows estimation of asthma 
phenotype prevalence, and the median length of follow-up is considerable (4.1 years). 
Further strengths include the detailed methods to define the dependent (exacerbation 
rate) and independent (phenotype) variable and the inclusion of exacerbations in 
primary, secondary and emergency care, in addition to asthma deaths. The asthma 
codes in the CPRD have been validated in a previous validation study using GP 
questionnaires.(40) 
Comparison with existing literature 
In the past, phenotype categorisation was mostly based on variables such as age of 
onset, severity, reaction to treatment or comorbidities. More recently, cluster analysis 
of clinical variables including airflow measurements has been used to describe 
phenotypes. These cluster analyses have all been limited in terms of sample 
size,(101,103,108,194,195) or were preselected such as severe asthma populations.(354) 
To the best of our knowledge, this is the first longitudinal study on a general 
population-wide asthma cohort. As such, it is difficult to draw direct comparisons 
between this population-based asthma study and previous phenotyping studies. 
In the categorisation by Haldar et al, the three phenotypes we focused on here were 
described in a primary care cohort of 184 patients. In this cohort, 96 (52%) patients had 
benign asthma, 61 (33%) had early-onset atopic asthma and 27 (15%) had obese non-
eosinophilic asthma. In addition, two more phenotypes were identified from two 
separate populations (including a secondary care and a longitudinal study of mostly 
refractory patients). The early onset symptom predominant phenotype has high 
symptom expression and a tendency towards overtreatment, while the inflammation-
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predominant asthma phenotype has a lower symptom expression, but active 
eosinophilic inflammation. Another well-known categorisation of asthma phenotypes 
was undertaken by Moore et al (103) using cluster analysis in the U.S. Severe Asthma 
Research Program based on respiratory function and age-of-onset. While this analysis 
was heavily based on the latter (unfortunately routinely collected electronic records 
often lack information on age-of-onset), the obese non-eosinophilic asthma and early-
onset atopic asthma were also identified. A recent cluster analysis on two populations 
of severe asthma patients (n= 238 total) defined and validated four severe asthma 
phenotypes mainly differentiated by lung function and level of eosinophilic 
inflammation.(14) The exacerbation frequency is similar to those of previous studies 
on asthma exacerbation rates in the UK.(346,347) Comparison of exacerbation rates 
between countries remains difficult without consensus on the definition of 
asthma.(3,24)  
Limitations 
The main limitation of this study is due to the nature of routinely collected data. For 
example, the CPRD does not hold information on the age of onset, which is one of the 
defining traits of the early-onset atopic asthma phenotype. Our inability to identify 
phenotype for a sizable proportion of the population highlights the need for 
developing phenotypes that can be more readily identified from routine care records, 
as well as the need for improving routine care records so that important phenotypes 
can be identified.  
Residual confounding remains possible, despite the adjustment for several potential 
confounders. Misclassification of asthma is possible, but Read codes for asthma have 
a high PPV (86%) in CPRD.(320) The exacerbation cut-off of ≤300mg oral 
corticosteroids might have misclassified some patients. The blood eosinophil cut-off 
at <300 cells//μL for “eosinophilic asthma” is not absolute, and multiple different 
eosinophil levels are used in the literature.(76,355–357) We included only people with 
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full linkage, however exclusions were at practice level so unlikely to bias estimates. 
Asthma phenotypes might change over follow-up, but this would remain true even in 
a cohort study identified in real time. Similarly, we assume eosinophil levels do not 
change greatly over time. This assumption may not always hold as eosinophil levels 
are fluid and depend on the level of steroid treatment and inflammation (such as hay 
fever or recent viral infections). CPRD contains information on only prescriptions of 
treatments, without information on adherence to those treatments. In the case of SABA 
prescriptions, not all reliever treatment that was prescribed is necessarily used. BTS 
guidelines evolve over the years, so the treatment step given might not correspond 
exactly to the step at time of prescription. Nonetheless, the BTS 2016 guidelines were 
used for consistency. SABA prescriptions are an imperfect measure for asthma 
symptoms, as some practices may prescribe SABA as part of a patient’s repeat 
prescription, and some symptomatic patients may only use maintenance inhalers. 
SABA or inhaler use is not a perfect measure for asthma symptoms, as it would only 
count patients who visit their GP, obtain a SABA/inhaler prescription and have their 
prescription recorded. Specific Read codes have been chosen by a respiratory 
physician to maximize the sensitivity of diagnosing asthma. Ultimately, however, we 
are limited by the acumen of the clinician recording the diagnosis.  
Exacerbations were captured using CPRD, HES and ONS based on OCS prescriptions 
and hospitalisations. An exacerbation was defined as ≤300mg oral corticosteroids 
(OCS) (not prescribed during an annual asthma review), or an A&E visit, or an acute 
hospital visit of <1 day duration, an overnight hospitalisation or an asthma-related 
death. Exacerbations starting 14 days after the index one will be considered as part of 
the same exacerbation. We anticipated that this was unlikely to bias estimates of the 
rate ratio however, assuming missed outcomes are equally likely in each phenotype. 
We did not have any information on the age of onset of asthma, as this information is 
not available in CPRD. However, this is one of the criteria by which the asthma 
phenotypes were defined in the cluster analysis (6). 
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Problems with dichotomising eosinophil countsThere have been multiple studies that 
used blood eosinophil measurements as a proxy for eosinophilic inflammation, with 
a plethora of different thresholds in blood eosinophil counts used. In patients with 
eosinophilic asthma, inhaled corticosteroids form the pillar of treatment but are often 
insufficient in patients with severe asthma. Biological treatments have been developed 
in recent years, (358) but the treatment responses are heterogeneous and eosinophil 
counts are used to identify patients with the highest expected benefits. However, the 
eosinophil thresholds vary considerably between studies. The choice of cut-off seems 
largely driven by the positioning of drug manufacturers. The thresholds used to 
define asthma have varied considerably, and there is no clear consensus as to which 
would be the most appropriate.(350) Blood eosinophil cut-offs that have been used 
before are 150/μl, (359) 260/μl, (359,360) 300/μl (76,83,87,361–364), 400/μl (77,347,365–
367) and 500/μl (368). 
Adjusting the eosinophil threshold in the cohort study in Chapter 6 to a different count 
(instead of <300 cells/µL and <4% of leucocytes) would change the amount of people 
that could be classified into one of the predefined phenotypes. Any alteration in 
diagnosis of eosinophilic asthma and practice could be associated with changes in 
clinical outcomes of patients, as blood eosinophilia is a risk factor for future asthma 
exacerbations.(369,370) The association between blood eosinophil counts and 
exacerbation risk is likely to be continuous rather than dichotomised in asthma, as it 
is in COPD.(371) 
Changing the diagnostic threshold of eosinophilia could also change the 
pharmacological management of patients if the eosinophil counts are used to inform 
treatment. These treatment changes could then further impact exacerbation rates. 
Lowering the thresholds of eosinophilia may qualify more patients for biologic 
treatment, in specific anti-IL5s (including mepolizumab, benralizumab and 
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reslizumab). ICS treatment is a crucial component of severe asthma management and 
not dependent on eosinophil counts according to the GINA 2018 guidelines.(1) 
Progressively lowering diagnostic thresholds may result in misdiagnosis, initiation of 
non-cost-effective treatments and overall poorer clinical outcomes for patients. 
Lowering the diagnostic thresholds would also potentially increase the number of 
patients referred to secondary care and increase the use of secondary prevention. 
Potential future clinical trials’ success would depend on the selection and 
determination of the population which define the normal reference range. We 
assumed eosinophil counts remains stable over time, but this assumption might not 
always hold although blood eosinophilia has been proven reasonably stable in the 
CPRD GOLD in COPD patients.(372) For any patient with an eosinophil count close 
to the threshold of the dichotomised count, a step-wise change does not exist between 
eosinophil counts with risk, as would be the case with a true dichotomised variable. 
Cut-offs used with biomarkers that behave as continuous variables remain arbitrary, 
but this does not necessarily undermine their utility though.(373) 
 
CONCLUSION 
Primary care asthma phenotypes can be identified from large electronic healthcare 
databases, although a large proportion could not be classified. Exacerbation 
frequencies are lowest in the benign phenotype and highest for the obese non-
eosinophilic phenotype. Phenotyping along with knowledge of asthma treatment step 
could help anticipate future treatment needs but is only possible in a minority of 
asthma patients based on current phenotypes and primary care records. 
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Ethical Approval 
The protocol for this research was approved by the Independent Scientific Advisory 
Committee (ISAC) for MHRA Database Research (ISAC protocol 17_152A), the 
approved protocol was made available during peer review. Generic ethical approval 
for observational research using the CPRD with approval from ISAC has been granted 
by a Health Research Authority Research Ethics Committee (East Midlands – Derby, 
REC reference number 05/MRE04/87). Ethical approval for this study was also 
obtained from the London School of Hygiene and Tropical Medicine research ethics 
committee. 
All code lists for covariates and comorbidities are included in the appendix and on 
Data compass. (http://datacompass.lshtm.ac.uk/)  
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6.3 Appendix 
Appendix 1: Treatment steps of the identifiable phenotypes 
 
Appendix 2: Interaction between age and phenotype 
 
Figure 7: Interaction between age and phenotype 
  
Benign 
Asthma 
Atopic 
Asthma 
Obese non-
eosinophilic NOS all Total 
BTS step      
  BTS1 4,401 (58.7%) 11,612 (20.9%) 754 (8.0%) 32,130 (26.4%) 48,897 (25.2%) 
  BTS2 1,186 (15.8%) 18,898 (34.1%) 2,526 (27.0%) 29,809 (24.5%) 52,419 (27.0%) 
  BTS3 520 (6.9%) 6,220 (11.2%) 1,164 (12.4%) 12,309 (10.1%) 20,213 (10.4%) 
  BTS4 978 (13.0%) 11,710 (21.1%) 2,625 (28.0%) 26,173 (21.5%) 41,486 (21.4%) 
  BTS5 263 (3.5%) 5,346 (9.6%) 1,831 (19.5%) 15,825 (13.0%) 23,265 (12.0%) 
  BTS6 3 (0.0%) 243 (0.4%) 129 (1.4%) 1,457 (1.2%) 1,832 (0.9%) 
  Non BTS 144 (1.9%) 1,426 (2.6%) 343 (3.7%) 3,974 (3.3%) 5,887 (3.0%) 
Total 7,495 (3.9%) 55,455 (28.6%) 9,372 (4.8%) 121,1677 (62.7%) 193,999 (100%) 
Table 3: Treatment steps of the identifiable phenotypes 
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FIGURE legends 
• Figure 1: Cluster analysis and clinical asthma phenotypes Reprinted with 
permission of the American Thoracic Society. Copyright © 2018 American 
Thoracic Society. Haldar P et al. Am J Respir Crit Care Med. 2008 Aug 
1;178(3):218-224. The American Journal of Respiratory and Critical Care 
Medicine is an official journal of the American Thoracic Society. 
• Figure 2: Cohort timeline 
• Figure 3: Flowchart of study eligibility and participation 
• Figure 4: BTS step by phenotype 
• Figure 5: Incidence rate ratios, stratified by treatment step. Adjustment for step 
6 resulted in very wide confidence intervals due to low sample size. This made 
the Forrest plot unreadable and is not displayed. 
• Figure 6: Time to first exacerbation analysis in years, by phenotype and 95% CI 
• Figure 7: Interaction between age and phenotype 
TABLE legends 
• Table 1: Baseline characteristics of the study population by phenotype 
• Table 2: Exacerbation rates by phenotype 
• Table 3: Treatment steps of the identifiable phenotypes 
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Chapter 7: Thesis summary and discussion 
Summary 
This chapter presents an overall synopsis of the results for each of the original 
objectives of the thesis determined at the time of the upgrading seminar. In addition, 
this chapter lists the major strengths and weaknesses of the thesis as a single research 
body. The specific strengths and limitations of each study have been discussed in their 
respective chapters. This chapter also provides recommendations for clinical practice 
and future research that follow from the results of the studies included in this thesis. 
The section on recommendations for future research includes an assessment on the 
usefulness of asthma phenotyping based on primary care electronic health records. 
This chapter closes with an overall conclusion to the thesis. 
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The focus of this PhD thesis is the validation of asthma in de-identified EHR and the 
study of the treatment, severity and outcomes of different asthma phenotypes in the 
UK. Information on asthma risk factors, treatment and outcomes were retrieved from 
the CPRD GOLD, Hospital Episodes Statistics and Office of National Statistics data.  I 
undertook this project as there is no universal consensus on what constitutes asthma 
and asthma overlaps with many other diseases, which makes the identification of 
asthma patients from electronic health records (EHR) in primary care difficult. 
Asthma continues to carry a high morbidity and notable mortality worldwide. 
Distinct asthma phenotypes have previously been established based on cluster 
analyses in small populations, but how asthma phenotypes are related to disease 
outcomes was not known. 
This thesis is based on a series of studies on asthma in electronic health records. The 
systematic review (Chapter 3) and validation study (Chapter 4) show reliable ways to 
identify asthma patients from EHR using positive predictive values. The systematic 
review examined previous studies which encompassed a validation process of asthma 
in different electronic healthcare databases worldwide, and the validation study 
developed and validated algorithms to identify asthma patients in the CPRD GOLD 
database. Furthermore, this thesis demonstrates the prevalence and characteristics of 
a concomitant diagnosis of asthma and COPD in the UK primary care population 
through a study based on validated asthma and COPD patients in the CPRD GOLD, 
as presented in Chapter 5. In Chapter 6, I examined the presence, treatment and 
outcomes of different asthma phenotypes in primary care using a large cohort study 
of asthma patients in the CPRD GOLD. This study also investigated patient 
characteristics, comorbidities and exacerbation rates of people with these phenotypes. 
This study adds to the relatively small body of research on the epidemiology of asthma 
phenotypes in the general population.  
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7.1 Synopsis of findings by research objective 
This subchapter discusses and summarises the findings of each of the original research 
objectives of this thesis. 
 In order, the original objectives of this PhD thesis were: 
1. Understand how past epidemiological studies have identified asthma patients 
in EHR through a systematic review. 
2. Validate the recording of the diagnosis of asthma in the CPRD GOLD. 
3. Quantify the concomitant occurrence of asthma in COPD patients and vice 
versa in the CPRD GOLD. 
4. Identify established asthma phenotypes in the CPRD GOLD by studying risk 
factors and explore the variation of asthma severity (defined by treatment 
steps) by phenotype. 
5. Examine the difference in asthma control by asthma phenotype, stratified by 
treatment step. 
 
Objective 1: Understand how past epidemiological studies have validated 
asthma in EHR through a systematic review  
The validity of asthma diagnoses in electronic health records presents a problem for 
asthma researchers. Most asthma symptoms are non-specific and there is no 
consensus on the exact clinical definition of asthma and its key outcomes, including 
disease severity, asthma control and exacerbations.(62,304,374,375) Both the 
overdiagnosis and underdiagnosis of asthma have been reported and have been cause 
for concern.(213,376,377) In addition, tests that suggest an asthma diagnosis such as 
airflow measurements or trial of treatment are often poorly recorded in electronic 
health records. The approaches to defining asthma in electronic health records and the 
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validity of these definitions are diverse and complicate the critical appraisal and 
comparison of results from EHR-based studies.  
To understand how asthma researchers have dealt with the issue of defining and 
validating asthma diagnoses in electronic health records in the past, I have conducted 
a systematic review on this topic. The systematic review which is presented in Chapter 
3, provided an overview of the methods used in the literature for validating asthma 
diagnosis in EHR and presented a summary of the corresponding estimates of the 
validation test measures. In addition, this systematic review informed potential 
algorithms for the validation study of asthma recording in the CPRD GOLD covered 
in Chapter 4. 
The exploration of methods used in the literature for validating asthma diagnosis in 
EHR found a wide variety of approaches to validation. The variety was mostly based 
on the nature of the data, on the potential requirements for further studies in terms of 
test measures and on the availability of potential reference standards. Four types of 
validation methods were seen, with three using different types of reference standard. 
Ten studies included in the review used a manual validation as the reference 
standard;(267,271,278–285) in this case a clinician or researcher manually verified the 
electronic records with the patients’ physical charts or discharge notes. Two studies 
used a second independent database to validate asthma diagnoses.(286,287) This 
reference standard depends heavily on the availability and reliability of the second 
database. A veritable independent database that includes data on asthma status would 
not be available for most primary care databases, which makes this reference standard 
unfeasible for validation studies in most databases. One study retrieved by the 
systematic review used a questionnaire as the reference standard(288) to validate a 
case definition of asthma. There was a fourth method of validation, face validity, 
which consists of checking the prevalence of asthma in the database against the known 
prevalence in the population. This method was not considered as exact enough, as it 
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would not be able to detect a difference if the net overdiagnosis and net 
underdiagnosis of asthma are comparable. Furthermore, this systematic review 
suggested that there are method of sampling records using  machine learning to 
develop algorithms that can measure all frequently used test measures: the PPV, NPV, 
sensitivity and specificity. 
The summary of corresponding estimates of validation test measures demonstrated 
that the results of the test measures are strongly dependent on the underlying study 
question, case definition and data source. This is apparent in the diversity of the 
databases of the retrieved studies. For example, the records could have included either 
primary care, secondary care or emergency care records; they also greatly varied in 
total size from data on a single health centre to data on millions of patients. All 
included studies were able to validate a case definition for asthma. In the ten studies 
using manual validation as the reference standard, each study included at least one 
case definition with a PPV of at least 63%, up to 100%. In the two studies using a 
second independent database as reference standard, the PPV’s of the best performing 
case definitions ranged from 46% to 58%. In the last study using a questionnaire as the 
reference standard, the PPV of the case definition algorithm was 89%. Differing case 
definitions for asthma within a single data source greatly impacted the validity of a 
specific algorithm. As such, testing a range of case definitions when studying the 
validity of an asthma recording would be essential. 
In the light of these results, we opted to combine the reference standard of GP 
questionnaires with manual validation of the questionnaires and patient data in the 
CPRD GOLD records to validate the recording of asthma in the CPRD GOLD. 
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Objective 2: Validate the recording of the diagnosis of asthma in the CPRD 
GOLD 
The aim of the study presented in Chapter 4 was to validate the recording of asthma 
in the CPRD GOLD database. To do this, eight algorithms to identify asthma patients 
in the CPRD GOLD were constructed. These algorithms consisted of a combination of 
specific and non-specific asthma Read codes, evidence of reversibility testing and 
recorded airflow measurements. Subsequently, we requested CPRD to send 
questionnaires to the GPs of 880 patients which qualified for one of the algorithms 
(110 for each algorithm). A total of 684 questionnaires were sent out (the GPs of the 
remaining 196 asthma patients could not be contacted as they had recently migrated 
to a different system); 494 questionnaires were subsequently returned, and 475 were 
valid and analysed. The reference standard consisted of the review of GP 
questionnaires and additional materials by a respiratory physician and a study GP to 
test the eight algorithms.  Out of the eight tested algorithms, five algorithms reported 
a PPV higher than 80%. The 95% confidence intervals for the PPVs overlapped, which 
means the difference in PPVs between these five algorithms was consistent with 
random chance. The algorithm with the highest PPV consisted of a combination of 
nonspecific asthma codes, evidence of reversibility testing and multiple asthma 
prescriptions within one year (PPV 90.7, 95% CI 82.8 to 98.7). The most practical 
algorithm, however, was the algorithm which consisted of only a specific asthma code 
(PPV 86.4, 95% CI 77.4 to 95.4). The additional requirements of medication 
prescription codes and evidence of reversibility testing did not appear to significantly 
increase the PPV of the algorithms. The total number of individuals who potentially 
could be included in a study on asthma increased almost six-fold when the algorithm 
did not include these requirements. As a result, the total identifiable population of 
people living with asthma is much larger when only using a specific asthma code for 
identification. In conclusion, a specific asthma Read code had a reasonably high PPV 
(86.1%) and was used to identify asthma patients from the CPRD GOLD in this thesis 
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and more widely, can be adopted by others carrying out asthma research in the CPRD 
GOLD. 
Objective 3: Quantify the concomitant occurrence of asthma in COPD patients 
and vice versa in CPRD GOLD 
The study included in Chapter 5 investigated the prevalence of COPD in validated 
asthma patients, as well as the prevalence of asthma in validated COPD patients using 
data from the GP questionnaires of two validation studies and patient data recorded 
in the CPRD GOLD. The data on the validated asthma patients were available from 
the validation study of asthma recording included in Chapter 4, and the data on the 
validated COPD patients were available from a similar validation of COPD recording 
in the CPRD GOLD.(297) The data included in the analysis encompassed smoking 
history, spirometry records and reversibility testing results, detailed GP 
questionnaires and supporting information including outpatient referral letters, 
emergency department discharge notes and radiography records. Based on this 
information, and assuming the validated status of each of the asthma and COPD 
patients identified by their validation studies held true, I was able to review whether 
these patients had a record of concomitant diagnosis of asthma and COPD in the 
CPRD GOLD and whether this was likely to be a legitimate diagnosis. 
The main finding of this study indicated that more than half (52.5%) of validated 
COPD patients had received a diagnostic asthma Read code. When additional 
evidence that could support the diagnosis of asthma in these COPD patients was 
considered, concurrent asthma was only likely in 14.5% (95% CI: 11.2%; 18.3%) of the 
validated COPD patients as many had either no indication of airflow reversibility or 
the last asthma code was more than two years before the COPD code. The same 
pattern was not observed in the validated asthma patients. Only 15.1% of validated 
asthma patients had ever received a diagnostic COPD Read code, and a COPD 
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diagnosis was likely in 14.8% (95% CI:  11.3%; 19.0%) of those validated asthma 
patients. In conclusion, a concurrent asthma and COPD diagnosis was only likely in a 
minority of patients with validated COPD (14.5%) or validated asthma (14.8%), and 
asthma diagnoses appear to be over-recorded in people with COPD.  
Objective 4: Identify established asthma phenotypes in CPRD GOLD by studying 
risk factors and explore the variation of asthma severity (defined by treatment 
steps) by phenotype 
The fourth and fifth objective of this PhD thesis were addressed in the final study 
included in this thesis, which is presented in Chapter 6. This study evaluated the 
extent to which three previously suggested asthma phenotypes could be identified 
using data included in routinely collected electronic health records. In addition, this 
study also reported on the severity of asthma (defined by medication use) by 
phenotype, among other considerations. 
The categorisation into phenotypes was based on research by Haldar et al., which used 
cluster analysis of multiple clinical variables to identify potential asthma 
phenotypes.(101) This study identified five clusters, of which three were identified in 
primary care. Only the three phenotypes identified in primary care (benign asthma, 
obese non-eosinophilic asthma and early-onset atopic asthma) were studied in 
Chapter 6, as primary care EHR data was the main data source for this thesis. 
In the primary care asthma population, 7,495 (3.9%) were classified into the benign 
asthma group, 55,455 (28.6%) as atopic asthma, and 9,372 (4.8%) as obese non-
eosinophilic asthma. The remaining 121,167 (62.7%) patients were included in the 
asthma Not Otherwise Specified (NOS) group. In the original article, the asthma NOS 
group was further split by presence of treatment: one group without any asthma 
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treatment, one group with SABA prescriptions, and one group with asthma 
maintenance treatment. 
The variation of asthma severity was examined using medication prescriptions, based 
on the treatment steps described in the BTS/SIGN 2016 guidelines.(4) The classification 
into treatment steps expanded on earlier collaborative work.(346) The first treatment 
step was defined by the absence of maintenance asthma treatment (maintenance 
treatment does not include SABA use). The second treatment step was defined by the 
regular prescription of low-dose ICS, and the third treatment step included long-
acting beta agonists prescriptions. The fourth treatment step was defined by a higher 
dose of ICS with or without additional therapies such as LABAs, theophyllines, 
leukotriene receptor antagonists or long-acting antimuscarinics. The fifth treatment 
step was defined by high-dose ICS, and the sixth treatment step by continuous or 
frequent use of oral corticosteroids. 
For easier comparison of treatment steps between the phenotype groups, the asthma 
NOS group has not been subdivided by treatment in the third table of Chapter 6 
(included in the appendix of Chapter 6), which presents a summary of the BTS 
treatment step of the patients with different phenotypes. The benign asthma 
phenotype had the lowest average BTS step, followed by atopic asthma and asthma 
NOS with the obese non-eosinophilic asthma group on the highest average BTS step, 
and presumably the most severe asthma. 
In conclusion, we were only able to classify a minority (37.3%) into one of the 
predefined asthma phenotypes using stringent inclusion criteria. The asthma severity 
defined by BTS treatment step varied markedly among the different asthma 
phenotypes. 
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Objective 5: Examine the difference in asthma control by asthma phenotype, 
stratified by treatment step 
The final objective, addressed in the study presented in Chapter 6, was to investigate 
asthma control by phenotype, and further stratify by treatment step. The study 
reported the following adjusted exacerbation rates per 1000 person-years: 143.2 for 
benign asthma, 322.1 for atopic asthma, 439.3 for obese non-eosinophilic asthma, 174.6 
for asthma NOS without medication, 240.0 for asthma NOS with only SABA 
prescriptions, and 414.0 for asthma NOS with maintenance treatment. The 
exacerbation rates were adjusted for age, sex, smoking, BMI, socio-economic status 
anxiety, depression, COPD and GORD. Benign asthma was used as the reference 
group for the calculation of incidence rate ratios, as it had the lowest exacerbation rate. 
Incidence rate ratios (IRRs) in the fully adjusted models for asthma exacerbation were 
2.28 (95% CI 2.16-2.41) for those with atopic asthma; 3.11 (95% CI 2.91-3.32) for obese 
non-eosinophilic asthma, 1.23 (95% CI 1.16-1.31) for asthma NOS without medication, 
1.69 (95% CI 1.58-1.80) for asthma NOS with SABA, and 2.92 (95% CI 2.77-3.08) for 
asthma NOS with maintenance treatment. When stratified by BTS treatment step, the 
IRRs of all phenotypes compared with benign asthma decreased across all steps 
although they remained elevated.  
This study expands upon the findings of previous studies on asthma exacerbations 
using the CPRD GOLD, including one study exploring the age variation of the general 
asthma population in the UK by Bloom et al., to which I contributed. (346,347,378) The 
findings of this study are briefly explained as the methodology of classifying asthma 
patients by asthma severity (defined by BTS treatment step) were shared between the 
two studies. This study by Bloom et al. examined the general asthma population in 
the UK and their exacerbation risk and characteristics by age cohort, as most of the 
earlier literature has focused on patients with either more severe asthma or more 
severe exacerbations. It was a population-based cohort study using CPRD GOLD, 
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ONS and HES, from 2007 to 2015 using a similar patient cohort as the study included 
in Chapter 6. The study population was divided into four age cohorts and their 
exacerbation rates were calculated using Poisson regression. The study found a total 
population of 424,326 patients, of whom 60% had mild asthma. Older patients over 55 
years were more likely to have more severe asthma and had a higher exacerbation rate 
compared with the general cohort. The patients aged between 5 and 18 years were less 
likely to have a high treatment step and had the lowest exacerbation rates of the whole 
study population.  
In conclusion, exacerbation frequencies were lowest in the benign phenotype and 
highest for the obese non-eosinophilic phenotype. Stratifying by treatment step 
decreased the exacerbation rate ratios of each phenotype compared with benign 
asthma, but remained raised. Phenotyping along with knowledge of asthma treatment 
step could help anticipate future treatment need but remains limited as only a 
minority of patients could be classified into one of the phenotypes. 
7.2 Overall strengths 
The specific strengths of the studies included in this thesis are discussed in their 
respective chapters. However, there are several strengths to the integral thesis.  
Firstly, the systematic literature review informed the design of the algorithms to 
identify asthma cases in the CPRD GOLD. Multiple methods to determine the asthma 
status of potential patients from the CPRD GOLD database were considered and 
evaluated.  
Secondly, the breadth of the data used for the conduct of this thesis is a strength of the 
research presented here. The CPRD GOLD includes not only information on disease 
diagnoses, medication prescriptions and clinical tests such as airflow measurements, 
but also on important life-style factors such as BMI and smoking. In particular, the 
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availability of information on the smoking status of potential asthma patients was 
vital for the conduct of the last two studies included in this thesis. In addition, multiple 
additional linked data sources were used throughout the thesis: the HES and ONS 
databases for the cohort study presented in Chapter 6, and GP questionnaires, 
discharge letters, radiography records and airflow measurements that were not 
recorded in the CPRD GOLD in the studies presented in Chapters 4 and 5. 
Thirdly, the categorisation of asthma treatment in steps based on the BTS/SIGN 
guidelines allowed me to stratify the analysis of the final cohort study by severity, 
defined by treatment step.(4) As there are many different drug classes that are used in 
the treatment of asthma, controlling or stratifying for each of them separately would 
be unfeasible. Furthermore, the exposures, covariates and outcomes of the studies 
included in this thesis were clearly defined using code lists. The validity of many of 
these covariates in CPRD GOLD have been found to be high, e.g. BMI and 
smoking.(234,379) The code lists of the covariates and medications are included in the 
appendix of this thesis. In addition, the cut-offs and standards for measured 
continuous variables such as Body Mass Indices, eosinophil levels and airflow 
measurements were clearly defined and stated in the studies where appropriate. 
Fourthly, as the CPRD GOLD is representative of the UK population with respect to 
age and sex, the findings of the cohort and validation study can be generalised to the 
general UK asthma population. The practices contributing to CPRD GOLD are a 
sample of all UK practices, but are considered representative of the UK population 
and there are only few patients opting out.(208,229) In addition, the relatively large 
sample size allows for enough power to precisely estimate asthma exacerbation rates 
of patients with different asthma phenotypes. The consequential power also allowed 
the stratified analysis by treatment step to be carried out. 
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Finally, the sample size of the CPRD GOLD allowed for the improvement of the 
precision of the estimates of the studies in this thesis. However, the accuracy of these 
estimates could still be affected by biases and systematic errors (which is a different 
issue altogether). 
7.3 Overall limitations 
The limitations which are specific to a single study were discussed in their respective 
chapters. Overall limitations are discussed below. 
Data sources 
(a) CPRD (Clinical Practice Research Datalink) GOLD  
The major limitations of the CPRD GOLD database are: firstly, the lack of standard 
definitions for specific diseases and conditions; secondly, the missing information 
from secondary care; thirdly the variability in completeness of the data; and, fourthly, 
the issue that some data is not accurately captured.(208) The validation study on 
asthma recording and a consistent asthma definition alleviated the issue of the lack of 
standard definition for asthma, but this remained a limitation for the covariates used 
in the last two studies. The linkages to HES, ONS and questionnaires mitigated the 
problem of missing information that originated in secondary care. The variability in 
completeness of the data remained an issue for the studies presented in Chapters 5 
and 6. There are some characteristics that can be used to phenotype asthma patients 
that were not adequately recorded in the CPRD GOLD, including allergen exposure 
in childhood, family history of asthma, early life infections, maternal smoking and 
TH2 cytokines. As a result, the phenotypes that required knowledge on one of these 
characteristics could not be studied. The age of asthma onset is not available in the 
CPRD GOLD. The study in Chapter 6 used atopic asthma as one of the established 
phenotypes, while the original cluster analysis identified the early onset atopic asthma 
phenotype. Multiple imputation was considered for smoking status and BMI values, 
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but was decided against as the patterns of missingness were likely to not meet the 
assumptions required. Furthermore, some data that might have been useful as 
covariates, such as over-the-counter medication prescriptions, could not be extracted 
from the CPRD GOLD as the datasets do not contain these variables. Finally, the 
CPRD GOLD contains information on whether a treatment was prescribed, rather 
than whether it was administered. The adherence to treatment is, therefore, difficult 
to measure. This is a general limitation of studying medication in EHR databases. 
(b) HES (Hospital Episode Statistics) 
While the linkage to HES was advantageous to obtain information from secondary 
care, it also brought a few limitations with it. The data quality of inpatient data (HES 
APC) was found to be excellent in a systematic review as 96% of primary diagnoses 
were correct, but the accuracy varied according to hospital.(246) In addition, HES APC 
data do not include specific diagnosis dates for asthma exacerbations. Furthermore, 
the data originating from the accidents and emergency care and outpatient 
departments were not used as they did not add much information.  
Information bias 
(a) Misclassification of asthma 
The identification of asthma patients from the CPRD GOLD was based on one of the 
algorithms tested by the validation study presented in Chapter 4. As a result, the 
limitations of this study are limitations that extend to the whole thesis. The limitations 
of this study are briefly summarised in this paragraph. First, the reference standard of 
the validation study (review of GP questionnaires and additional information) was 
not absolute and human error remained possible. Second, the contacted GPs might 
have consulted the same information available in the CPRD GOLD that led to the 
inclusion of a patient in one of the algorithms to fill in the questionnaires. Third, GPs 
connected to more complicated cases might be less likely to participate as the filling 
in of the questionnaires would require more effort, or the asthma diagnosis might be 
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inconclusive. Fourth, no questionnaires of deceased people were included, which may 
result in survivor bias. Finally, the methods of this study did not allow one to measure 
the sensitivity or specificity of a recording of an asthma diagnosis. An estimate of the 
sensitivity would allow to predict the total number of asthma patients in the CPRD 
GOLD and, by extension, the UK. The reliability of the study on concomitant asthma 
and COPD included in Chapter 5 depended on the results of the validation study of 
asthma recording presented in Chapter 4 and the results of a second validation study 
of COPD recording.(297) Both validation studies share the same limitations as the 
methods were similar. In addition, a PPV of 86.4% for the most practical algorithm to 
identify asthma patients is considerable, but also suggests misclassification of asthma 
status in the remaining 13.6% when the cohort of asthma patients was constructed for 
the cohort study presented in Chapter 6. 
(b) Misclassification of covariates 
When using the CPRD for observational research, the assumption must be made that 
people without a recording of a distinct diagnosis do not have this condition (for 
example, GORD), while this might not necessarily be true. Many diseases and 
covariates have a high PPV in the CPRD GOLD, but the sensitivity of those diagnoses 
is mostly unknown.(208,229) This can lead to underestimation of the adjusted risk or 
rate of the outcome. For example, in the cohort study presented in Chapter 6:, if a 
comorbidity is more likely to be recorded in patients with a phenotype and with 
frequent exacerbations, adjustment for this comorbidity would lead to an 
underestimation of the exacerbation rate. In addition, classifying measured factors 
such as eosinophil levels in a dichotomous variable can lead to misclassification as 
these factors can fluctuate in time.  
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Confounding 
Confounding by unmeasured factors, including those which are truly unknown and 
those which are not measured or recorded in the CPRD GOLD, remains possible in 
the cohort study included in Chapter 6. Furthermore, imperfect measures of variables 
lead to incomplete adjustment. 
Generalisability 
As the CPRD GOLD is representative of the population of the UK, the generalisability 
of the results included in this thesis to the UK general population is presumed to be 
sound.(228) There are some exclusions from the CPRD GOLD, however, including 
migrants and practices/individuals who have opted out of having their data available 
for research, that hamper the generalisability to a certain extent. In the paper included 
in Chapter 6, the exclusion of people without a valid eosinophil count limited the 
study population to those with at least one full blood count in the study period. 
Similarly, there was a small percentage of people who were excluded as their smoking 
status and BMI were not recorded or deducible. In addition, I restricted the study 
population to those registered at GP practices which agreed to HES linkage. There is 
a risk that the patient characteristics and prescribing habits of GPs differ between 
general practices that do allow linkage and those that do not allow linkages to HES. 
Sample size 
The relatively large size of the CPRD GOLD was listed earlier as a strength of this 
thesis, but the statistical power to detect difference in exacerbation rates after 
stratification by asthma severity may still be somewhat limited, as the overlapping 
95% confidence intervals indicate. 
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Changing or conflicting guidelines 
For this thesis, the BTS/SIGN 2016 guidelines for the diagnosis and management of 
asthma were followed.(4) These guidelines came into effect after the start of this PhD 
project, and superseded the earlier BTS/SIGN 2014 guidelines. One of the main 
differences between these two guidelines was the change from a five-step asthma 
management programme which included SABA prescriptions in the main steps in the 
2014 guidelines to a six-step asthma management programme in the 2016 guidelines. 
The 2016 guidelines do not include SABA in the maintenance treatment steps, but only 
as a rescue treatment. In addition, there are conflicting guidelines in the UK relating 
to the diagnosis and management of asthma. An example of a divergence in guidelines 
is the use of fractured exhaled nitric oxide (FeNo) in the diagnosis of asthma. The 
Global Initiative for Asthma (GINA) and the BTS/SIGN 2016 guidelines decided 
against the use of FeNO measurement in the diagnosis of asthma, while the National 
Institute for Health and Care Excellence (NICE) guidelines recommend the use of this 
test.(3,37,380) The difference in guidelines might appear remarkable, but is mainly a 
result of a difference in methodology. The methodology BTS/SIGN is based on critical 
appraisal of the available literature, multidisciplinary and clinically led. Its main aim 
is to provide clinically relevant recommendations. The NICE methodology looks at 
both the literature and health economic modelling, advised by a multidisciplinary 
guideline development group; as a result, it has a slightly different focus than the 
BTS/SIGN guidelines.(381) 
7.4 Recommendations for practice  
1: Asthma may be overdiagnosed in people with COPD  
The study presented in Chapter 5 of this thesis suggests that asthma is over-recorded 
in the electronic health records of COPD patients. There was no indication that the 
reverse (over-recording of COPD in asthma patients) was likely. When a patient has a 
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presumed concomitant diagnosis of asthma and COPD, reversibility testing can be 
used to verify the diagnosis of asthma. A possible reason for the excess recording of 
asthma in COPD patients could be that COPD is more conservatively diagnosed as it 
is considered a more severe disease than asthma. Another possible explanation is that 
a COPD patient can be diagnosed with asthma in the years before first being 
diagnosed with COPD, after which no further recording of asthma is made. This 
would suggest misdiagnosis of asthma, as the previous asthma diagnosis might be 
either outdated or misdiagnosed. As a result, an asthma diagnosis seems to be less 
reliable in COPD patients. Incorrect management can expose COPD patients without 
asthma to adverse effects and incur additional costs for the patient and health system, 
for example through unnecessary medication regimens (such as the usage of 
montelukast in COPD patients). 
2: Asthma patients are identifiable through EHR data 
Accurate coding and a clearer definition of asthma exacerbations or asthma attacks is 
important for both clinical care and secondary users of the data. As exacerbation 
frequency is important for clinical management, clinicians should be able to access 
information on recent asthma exacerbations easily. A standard definition of asthma 
exacerbation would help greatly with this.(24) The relatively high PPV for the 
recording of asthma in the CPRD GOLD is reassuring, and this might motivate 
clinicians and contributors to the CPRD data to keep up the work needed to record 
high-quality health data. While the general recording of asthma in CPRD GOLD is 
good, with a PPV of 86.4%, there is still some room for improvement. Possible ways 
to attain an even better PPV would be to use training or incentives for GPs to improve 
coding or to reduce the total number of non-specific Read codes. 
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3: Established asthma phenotypes are identifiable to a certain extent in 
primary care 
Clinicians should be aware that asthma phenotypes can be identified in a sizeable 
minority of asthma patients in EHR using stringent inclusion criteria, and that the 
exacerbation risk differs between patients with different phenotypes. Routine blood 
tests can be useful to categorise asthma patients according to their eosinophil counts 
as these eosinophil counts are an important piece of the puzzle when identifying these 
asthma phenotypes in primary care. However, a majority of asthma patients in 
primary care did not fit into one of the three predefined asthma phenotypes, 
indicating that a phenotype-based approach to asthma management in primary care 
is not yet attainable for all asthma patients using the measurements currently recorded 
in EHR. Possible solutions are to establish phenotypes that are more easily 
recognisable in primary care, or add additional tools and measurements in primary 
care. One of the main aims of asthma phenotyping could be the benefit to patients 
through precision medicine and the way to do this might be more attainable using a 
different approach such as the treatable traits strategy, which is discussed in the 
following subchapter. 
7.5 Recommendations for research  
1: Recommendations for future validation studies of asthma recording in other 
databases 
Identifying asthma cases in different electronic health records databases is possible 
with high sensitivity, specificity or positive predictive value by combining multiple 
data sources, or by focussing on specific test measures. Attaining high PPVs (>80%) 
for specific algorithms is possible using one of three possible reference standards: 
manual validation, comparison with a second database, or using questionnaires. The 
studies retrieved by the systematic review that test a range of case definitions show a 
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wide variation in the validity of each case definition or algorithm. This suggests that 
testing different case definitions may be important to obtain asthma definitions with 
optimal validity for the pursued study question. 
2: Asthma patients are identifiable from the CPRD GOLD 
Future epidemiological studies using the CPRD GOLD on asthma should use a 
validated definition of asthma (included in the appendix). This validated definition 
will be useful for studies using asthma as an exposure, covariate or outcome. The 
algorithm consisting of only a specific asthma code algorithm alone is the most 
practical approach to identify patients with asthma in CPRD GOLD (PPV=0.86; 95% 
CI 0.77-0.95), as asthma diagnoses were confirmed in a high percentage of patients 
with specific asthma codes. This suggests that epidemiological studies on asthma 
using the CPRD GOLD can be conducted with reasonably high validity. The findings 
of this validation study can also help inform service planning and audits involving 
asthma patients. The inclusion of airflow measurements or asthma medication in the 
algorithm to identify asthma patients in EHR did not clearly improve accuracy in the 
asthma recording validation study and severely restricted the total identifiable 
population. Recently, a new primary care database managed by the CPRD has become 
available: CPRD Aurum.(226) This database contains routinely collected data from GP 
practices using EMIS-Web (Egton Medical Information Systems electronic patient 
record system). Currently, more registered practices contribute to CPRD Aurum than 
to CPRD GOLD. As the data structure and clinical coding between CPRD Aurum and 
CPRD GOLD differs, the validity of asthma recording in CPRD GOLD is not directly 
extendable to CPRD Aurum. In the future, a validation study on asthma recording in 
CPRD Aurum may be indicated. 
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3: Identifying patients with concomitant asthma and COPD in EHR 
The findings from the study presented in Chapter 5 have implications on further 
research into concomitant asthma and COPD. Identifying potential concomitant 
asthma and COPD using electronic health records should be done cautiously. The 
prevalence of concomitant asthma and COPD in validated asthma and COPD patients 
were both around 15%. However, around half of all validated COPD patients had a 
Read code for asthma recorded, suggesting over-recording of asthma in COPD 
patients. The prevalence of COPD in validated asthma patients is similar to the 
percentage of asthma patients with a COPD code recorded. If the algorithm to identify 
both diseases consists of only a single code for each algorithm, the prevalence of 
concomitant diagnosis of asthma and COPD is likely to be overestimated.  
4: Asthma phenotyping using primary care EHR 
While it is possible to identify patients with different asthma phenotypes in primary 
care, most patients did not fit into one of three pre-specified asthma phenotypes that 
were identified in a primary care study using cluster analysis on a limited number of 
patients. The 62.7% of patients that were not included in one of the three predefined 
asthma phenotypes (benign asthma, obese non-eosinophilic asthma, and atopic 
asthma) were included in the asthma NOS group. Some of the patients included in 
this asthma NOS group could belong to one of the three predefined asthma 
phenotypes but were unable to be classified due to unrecorded or missing data, while 
some other patients could belong to other, yet unspecified phenotypes. Easier to 
define phenotypes or more complete records, including full blood counts, could help 
with the phenotyping of patient records in electronic health records. 
The rationale for the conduct of the cohort study included in Chapter 6 was that the 
classification of asthma into phenotypes could help tailor the treatment for asthma 
patients. Asthma diagnosis is still based on clinical presentation and associated lung 
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function, which are both non-specific.(375) As a result, asthma is often treated 
similarly to COPD and not optimally.(382) Precision medicine aims to define 
treatments targeted to the needs of specific patients based on genetic, biomarker, 
phenotypic, or psychosocial characteristics that differentiate these patients from 
others with a similar presentation.(351) However, many methods to classify asthma 
patients into phenotypes have been insufficient to identify patients who are likely to 
benefit from a specific treatment. In theory, phenotyping could help to inform our 
understanding of the underlying asthma endotypes, but in practice this remains 
problematic as many phenotypic characteristics can be caused by several different 
disease mechanisms.(24,383,384)  
While there has been progress on the endotyping of asthma (identifying asthma 
subgroups that share pathophysiologic processes),(383,385) how much of this explains 
the phenotypic heterogeneity of asthma remains unclear. Endotyping of asthma 
would help in the conduct of clinical trials on asthma treatment as many outcomes 
have been biased by the adoption of inclusion and exclusion criteria which can fail to 
address whether a particular asthma medication works equally well for all patients 
with the asthma syndrome.(386)  
Of note is that the phenotyping of asthma patients in electronic health records should 
not be the ultimate goal in and of itself. If the phenotyping of patients in EHR does 
not help promote precision medicine or tailoring of asthma treatment, other strategies 
that do provide a clearer theoretical base to this end will be of greater concern.  
For example, the treatable traits strategy has recently been proposed(24,351) and 
might represent a better conceptual framework towards precision medicine than 
phenotyping using primary care electronic records at this stage.(342,352,353) This 
strategy focuses asthma management on traits that are identifiable and treatable, such 
as eosinophilia or airflow limitation. This reductionist approach would use asthma 
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only as a descriptive label for a collection of symptoms without assuming any specific 
pathophysiology. Pavord et al. suggest the following treatable traits in order of 
decreasing importance and recognisability (based on earlier work by Hargreave et al.): 
Airflow limitation, airway inflammation, airway infection/impaired airway defences, 
and altered cough reflex sensitivity/efficacy.(24,155) The first treatable trait, airflow 
limitation, can be assessed using airflow measurements, while the risk of the second 
treatable trait, airway inflammation, can be assessed using biomarkers of eosinophilic 
airway inflammation such as sputum/blood eosinophils or FeNO measurements.  
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7.6 Future work  
A possible next step in this field would be a de novo cluster analysis of asthma patients 
in the CPRD GOLD. The next paragraph outlines possible methodology of this cluster 
analysis. Previous cluster analyses on primary care asthma populations have been 
conducted in smaller populations.(387,388) 
Study population 
The study period could be April 2007 to the last extraction date. Individuals would be 
eligible for inclusion from 18 year onwards, they had been registered in a UTS primary 
care practice and had a previously validated asthma code, without an upper age limit. 
Patients would enter the study cohort when they met the inclusion criteria, and the 
index date for each participant would be the first asthma diagnosis recording while 
the patient is eligible. Patients would leave the cohort on the earliest of leaving the 
primary care practice, death or last practice data collection.  
Exposure definition 
The asthma population would consist of patients with an asthma diagnosis code 
validated in the fourth chapter of this thesis. Patients with a diagnosis of COPD would 
be excluded, as asthma diagnoses in COPD patients can be less reliable in CPRD (fifth 
chapter of this thesis).  
Covariates 
Variable selection would be chosen based on clinical value, recording in the CPRD, 
and avoid variables that could introduce issues with multicollinearity. 
The covariates for generating the clusters would be defined from the CPRD GOLD, 
and include demographic characteristics, symptoms, atopy, body mass index, 
smoking status, gastro-oesophageal reflux disease, chronic rhinosinusitis, anxiety, 
depression, lung function defined by FEV1 % predicted and sex. Asthma therapy 
would be classified as defined by the BTS 2019 guidelines. 
Outcomes 
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For the evaluation and interpretation of clusters, we would use an a priori set of 
clinical outcomes, based on the rate of moderate and severe asthma exacerbations, 
socio-economic status and mortality. Exacerbations would be measured in the same 
way as the study in the sixth chapter of this PhD thesis and SES will be divided into 
quintiles. 
Statistical methods 
We would split the data into a training and test set at random and use the training 
dataset to perform statistical analyses. Multiple correspondence analysis would be 
used on all covariates, and the numerical covariates will be transformed to categorical 
variables. The data clustering (unsupervised learning) are a set of techniques to 
identify subsets by grouping by similarity. K-means and hierarchical clustering 
algorithms would be used on complete cases. Hierarchical cluster analysis using 
Ward’s method would be used to estimate the likely number of clusters in the 
population. K-clustering would be used as the main clustering technique. The stability 
and repeatability of results would be ensured by repeating the k-means clustering 
analysis at different starting points (potentially with different statistical software). 
The Euclidian distance would be used for measurement in both methods. The 
silhouette coefficient measures clustering performance (both cohesion and 
separation). Another option is to use the training dataset to generate the clusters, and 
test the reproducibility of the resulting clusters on the testing dataset. Clusters are 
considered stable if they yield a similarity greater than 75%. Descriptive statistics 
would be used to describe and compare the separate cluster populations. 
Use by general practitioners in practice 
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The classification of primary patients into different phenotypes could aid in 
identifying those patients who are most at risk of severe exacerbations. In addition, it 
could enable GPs to guide the treatment of patients with asthma, allocate asthma 
patients to secondary care if needed and adjust the frequency of asthma consultations. 
Differentiating asthma patients by phenotype in primary care would also allow the 
healthcare system to more efficiently allocate resources, by prioritising the phenotype 
group where an intervention can be the most beneficial. The use of resources in 
secondary and tertiary care for patients in phenotypes with a better prognosis could 
be limited. If this cluster analysis would produce meaningful phenotypes in primary 
care and a phenotype-based approach to asthma management would be implemented 
in primary care based on already recorded information, a further study would still be 
needed to assess the implications of the implementation. 
Handling of multiple exacerbations per patients 
Clinical interest in asthma lies in both the final outcome (death/survival time) and the 
dynamics of disease itself, as exacerbations lead to a state that is not always fully 
reversible. A standard regression model (Logistic, Cox or Poisson) may not be 
appropriate as the exacerbations are not independent of one another. Approaches to 
overcome this include marginal and multi-state models. In most marginal models the 
assumption is that all events are identical. Multi-state models can differentiate 
between different types of events, and are a stochastic process where a patients 
occupies one of several states at any time. 
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Regression analysis would be able to estimate the probability of readmission due to 
asthma. The timing of readmissions would be much harder to assess with most 
regression methodologies. Multistate models could help with modelling the process 
of readmissions. They are statistical tools in which a patient occupies one of several 
possible states.  There are multiple standard structures, where the alternating model 
or recurrent events would provide the best fit. A simple multi-state model would 
include a patient during an exacerbation and the following 2 weeks (State 1), not 
having an exacerbation (State 2), and death or loss-to-follow up (State 3). A more 
complicated multi-state model could include more different states to include the 
number of exacerbations and the readmission, with first, second, 4th exacerbation and 
first, second, nth post-exacerbation period.  
 
7.7 Overall conclusions 
It is increasingly clear that electronic health records can play an important role in the 
future of asthma research. This thesis discusses approaches to identify asthma patients 
from these records and finds that the asthma status of patient can be established in 
electronic health records with a reasonably high reliability. This thesis includes a list 
of studies which validated asthma recording and their respective test measures 
obtained through a systematic review and the results of a validation study of asthma 
recording in the CPRD GOLD database.  
As asthma and COPD share many characteristics and symptoms, the potential to 
differentiate between both diseases is of great concern to researchers aspiring to 
employ electronic health records to study these diseases. Concomitant asthma and 
COPD was present in 14.8% of validated asthma patients and in 14.5% of validated 
COPD patients. Asthma diagnoses may be less reliable in COPD patients however, as 
close to half of all COPD patients had ever received an asthma diagnostic Read code. 
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Previously suggested asthma phenotypes can, to a certain extent be distinguished in 
primary care electronic health records, but the majority of patients could not be 
classified into three predefined phenotypes with stringent inclusion criteria. There are 
two possible ways to improve the categorisation of primary care asthma patients into 
phenotypes: either by thorough recording of key variables in EHR, or by constructing 
new phenotypes that would be easier to identify in EHR. Many clinical variables used 
to phenotype patients in clinical trials are simply not available in routinely recorded 
electronic health records. The treatable traits strategy may be more likely to succeed 
in providing precision medicine for asthma patients in primary care than a phenotype-
based approach. 
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APPENDIX 
This appendix contains the code lists that were used in the conduct of the research 
included in this thesis. The appendices of the previous chapters encompass materials 
specific to those chapters.  
Included codelists: 
• Codelist 1: Definite asthma 
• Codelist 2: Possible asthma 
• Codelist 3: Asthma medication 
• Codelist 4: Oral corticosteroid codes 
• Codelist 5: Antihistamines 
• Codelist 6: COPD codes 
• Codelist 7: Atopy 
• Codelist 8: GORD 
• Codelist 9: Anxiety 
• Codelist 10: Depression 
 
Codelist 1: Definite asthma 
Medcode Read Term 
78 asthma 
81 asthma monitoring 
185 acute exacerbation of asthma 
232 asthma attack 
233 severe asthma attack 
1555 bronchial asthma 
2290 allergic asthma 
3018 mild asthma 
3366 severe asthma 
3458 occasional asthma 
3665 late onset asthma 
4442 asthma unspecified 
4606 exercise induced asthma 
4892 status asthmaticus nos 
5267 intrinsic asthma 
5627 hay fever with asthma 
5798 chronic asthmatic bronchitis 
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Medcode Read Term 
5867 exercise induced asthma 
6707 extrinsic asthma with asthma attack 
7058 emergency admission, asthma 
7146 extrinsic (atopic) asthma 
7191 asthma limiting activities 
7378 asthma management plan given 
7416 asthma disturbing sleep 
7731 pollen asthma 
8335 asthma attack nos 
8355 asthma monitored 
9018 number of asthma exacerbations in past year 
9552 change in asthma management plan 
9663 step up change in asthma management plan 
10043 asthma annual review 
10274 asthma medication review 
10487 asthma - currently active 
11370 asthma confirmed 
12987 late-onset asthma 
13064 asthma severity 
13065 moderate asthma 
13175 asthma disturbs sleep frequently 
13176 asthma follow-up 
14777 extrinsic asthma without status asthmaticus 
15248 hay fever with asthma 
16070 asthma nos 
16667 asthma control step 2 
16785 asthma control step 1 
18223 step down change in asthma management plan 
18224 asthma control step 3 
18323 intrinsic asthma with asthma attack 
19167 asthma monitoring by nurse 
19519 asthma treatment compliance unsatisfactory 
19520 asthma treatment compliance satisfactory 
19539 asthma monitoring check done 
20860 asthma control step 5 
20886 asthma control step 4 
21232 allergic asthma nec 
22752 occupational asthma 
24479 emergency asthma admission since last appointment 
24506 further asthma - drug prevent. 
24884 asthma causes daytime symptoms 1 to 2 times per week 
25181 asthma restricts exercise 
25791 asthma clinical management plan 
26501 asthma never causes daytime symptoms 
26503 asthma causes daytime symptoms most days 
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Medcode Read Term 
26504 asthma never restricts exercise 
26506 asthma severely restricts exercise 
26861 asthma sometimes restricts exercise 
27926 extrinsic asthma with status asthmaticus 
29325 intrinsic asthma without status asthmaticus 
30458 asthma monitoring by doctor 
30815 asthma causing night waking 
31167 asthma night-time symptoms 
31225 asthma causes daytime symptoms 1 to 2 times per month 
38143 asthma never disturbs sleep 
38144 asthma limits walking up hills or stairs 
38145 asthma limits walking on the flat 
38146 asthma disturbs sleep weekly 
39478 wood asthma 
39570 asthma causes night symptoms 1 to 2 times per month 
40823 brittle asthma 
41017 aspirin induced asthma 
41020 absent from work or school due to asthma 
42824 asthma daytime symptoms 
45073 intrinsic asthma nos 
45782 extrinsic asthma nos 
46529 attends asthma monitoring 
47337 asthma accident and emergency attendance since last visit 
47684 detergent asthma 
58196 intrinsic asthma with status asthmaticus 
73522 work aggravated asthma 
93353 sequoiosis (red-cedar asthma) 
93736 royal college of physicians asthma assessment 
98185 asthma control test 
99793 patient has a written asthma personal action plan 
100107 health education - asthma self management 
100397 asthma control questionnaire 
100509 under care of asthma specialist nurse 
100740 health education - structured asthma discussion 
102170 asthma review using roy colleg of physicians three questions 
102209 mini asthma quality of life questionnaire 
102301 asthma trigger - seasonal 
102341 asthma trigger - pollen 
102395 asthma causes symptoms most nights 
102400 asthma causes night time symptoms 1 to 2 times per week 
102449 asthma trigger - respiratory infection 
102713 asthma limits activities 1 to 2 times per month 
102871 asthma trigger - exercise 
102888 asthma limits activities 1 to 2 times per week 
102952 asthma trigger - warm air 
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Medcode Read Term 
103318 health education - structured patient focused asthma discuss 
103321 asthma trigger - animals 
103612 asthma never causes night symptoms 
103631 royal college physician asthma assessment 3 question score 
103813 asthma trigger - cold air 
103944 asthma trigger - airborne dust 
103945 asthma trigger - damp 
103952 asthma trigger - emotion 
103955 asthma trigger - tobacco smoke 
103998 asthma limits activities most days 
105420 asthma self-management plan review 
105674 asthma self-management plan agreed 
106805 chronic asthma with fixed airflow obstruction 
107167 number days absent from school due to asthma in past 6 month 
Codelist 2: Possible asthma 
Medcode Read Term 
719 h/o: asthma 
1208 childhood asthma 
5138 patient in asthma study 
7229 asthma prophylactic medication used 
11022 asthma trigger 
11387 refuses asthma monitoring 
11673 excepted from asthma quality indicators: patient unsuitable 
11695 excepted from asthma quality indicators: informed dissent 
13066 asthma - currently dormant 
13173 asthma not disturbing sleep 
13174 asthma not limiting activities 
16655 asthma monitoring admin. 
18141 asthma monitoring due 
18692 exception reporting: asthma quality indicators 
18763 referral to asthma clinic 
20422 asthma clinic administration 
25705 asthma monitor 3rd letter 
25706 asthma monitor 2nd letter 
25707 asthma monitor 1st letter 
25796 mixed asthma 
26496 health education - asthma 
29645 asthma control step 0 
30308 dna - did not attend asthma clinic 
30382 asthma monitoring admin.nos 
31135 asthma monitor phone invite 
35927 asthma leaflet given 
37943 asthma monitor verbal invite 
41554 asthma monitor offer default 
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Medcode Read Term 
43770 asthma society member 
92109 asthma outreach clinic 
 
Codelist 3: Asthma medication 
prodcode productname groups 
8 salbutamol 100micrograms/dose inhaler SABA 
17 salbutamol 100micrograms/dose inhaler cfc free SABA 
31 
ventolin 100microgram/inhalation inhalation powder (glaxo wellcome uk 
ltd) SABA 
38 beclometasone 100micrograms/dose inhaler ICS 
44 prednisolone 5mg gastro-resistant tablets OCS 
95 prednisolone 5mg tablets OCS 
99 becotide 100 inhaler (glaxosmithkline uk ltd) ICS 
180 phyllocontin sup THEOPH 
218 aminophylline 100 mg cap THEOPH 
235 bricanyl 250micrograms/dose inhaler (astrazeneca uk ltd) SABA 
273 theophylline 200 mg cap THEOPH 
282 salbutamol 2mg/5ml oral solution sugar free SABA 
454 pulmicort 200microgram inhaler (astrazeneca uk ltd) ICS 
465 salmeterol 25micrograms/dose inhaler LABA 
510 ventolin 5mg/ml respirator solution (glaxosmithkline uk ltd) SABA 
534 atrovent 20micrograms/dose inhaler (boehringer ingelheim ltd) SAMA 
549 serevent 25micrograms/dose inhaler (glaxosmithkline uk ltd) LABA 
555 aminophylline 225mg modified-release tablets THEOPH 
556 combivent inhaler (boehringer ingelheim ltd) SABA_SAMA 
557 prednisolone 2.5mg gastro-resistant tablets OCS 
578 prednisolone 1mg tablets OCS 
590 phyllocontin continus 225mg tablets (napp pharmaceuticals ltd) THEOPH 
622 Montelukast 4mg chewable tablets sugar free MONTELUKAST 
638 seretide 250 accuhaler (glaxosmithkline uk ltd) LABA_ICS 
665 seretide 100 accuhaler (glaxosmithkline uk ltd) LABA_ICS 
674 ventolin 2.5mg nebules (glaxosmithkline uk ltd) SABA 
696 salbutamol 8mg modified-release capsules SABA 
719 salmeterol 50micrograms/dose dry powder inhaler LABA 
746 tiotropium 18 microgram capsule LAMA 
808 Montelukast 10mg tablets MONTELUKAST 
856 ventolin 2mg/5ml syrup (glaxosmithkline uk ltd) SABA 
860 salbutamol 4mg tablets SABA 
862 salbulin inhalation powder (3m health care ltd) SABA 
863 slo-phyllin 125mg capsule (lipha pharmaceuticals ltd) THEOPH 
879 theophylline 125mg modified-release capsules THEOPH 
880 theophylline 60mg modified-release capsules THEOPH 
881 salbutamol 2mg tablets SABA 
882 salbutamol 200microgram inhalation powder capsules SABA 
883 becodisks 200microgram disc (allen & hanburys ltd) ICS 
895 beclazone 100 easi-breathe inhaler (teva uk ltd) ICS 
896 
becotide easi-breathe 100microgram/actuation pressurised inhalation 
(allen & hanburys ltd) ICS 
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prodcode productname groups 
898 
ventolin evohaler 100 100microgram/inhalation pressurised inhalation 
(glaxo wellcome uk ltd) SABA 
907 bricanyl turbohaler 500 500microgram turbohaler (astrazeneca uk ltd) SABA 
908 pulmicort 400 turbohaler (astrazeneca uk ltd) ICS 
909 budesonide 200micrograms/dose inhaler ICS 
910 
serevent diskhaler 50microgram inhalation powder (glaxo wellcome uk 
ltd) LABA 
911 
flixotide accuhaler 250 250microgram/inhalation inhalation powder (allen 
& hanburys ltd) ICS 
947 budesonide 50micrograms/actuation refill canister ICS 
955 prednisolone 5mg soluble tablets OCS 
956 pulmicort 200 turbohaler (astrazeneca uk ltd) ICS 
957 
salamol easi-breathe 100microgram/actuation pressurised inhalation 
(ivax pharmaceuticals uk ltd) SABA 
958 
ventolin easi-breathe 100microgram/actuation pressurised inhalation 
(allen & hanburys ltd) SABA 
959 budesonide 50micrograms/dose inhaler ICS 
960 pulmicort 100 turbohaler (astrazeneca uk ltd) ICS 
987 ventolin 4mg tablet (allen & hanburys ltd) SABA 
1063 prednesol 5mg tablet (sovereign medical ltd) OCS 
1087 asmasal 95micrograms/dose clickhaler (focus pharmaceuticals ltd) SABA 
1093 
salamol 100microgram/actuation inhalation powder (ivax 
pharmaceuticals uk ltd) SABA 
1097 slo-phyllin 60mg capsule (lipha pharmaceuticals ltd) THEOPH 
1100 beclazone 100 inhaler (teva uk ltd) ICS 
1236 becloforte 250micrograms/dose inhaler (glaxosmithkline uk ltd) ICS 
1242 beclometasone 250micrograms/dose inhaler ICS 
1243 beclazone 250 easi-breathe inhaler (teva uk ltd) ICS 
1258 becotide 200 inhaler (glaxosmithkline uk ltd) ICS 
1259 beclometasone 200micrograms/dose inhaler ICS 
1406 becotide 50 inhaler (glaxosmithkline uk ltd) ICS 
1409 ipratropium bromide 20micrograms/dose inhaler SAMA 
1410 ipratropium bromide 0.25mg/ml SAMA 
1411 ipratropium bromide 250micrograms/ml SAMA 
1412 
flixotide 250microgram/actuation inhalation powder (allen & hanburys 
ltd) ICS 
1423 uniphyllin continus 200mg tablets (napp pharmaceuticals ltd) THEOPH 
1424 flixotide 250microgram disc (allen & hanburys ltd) ICS 
1426 flixotide 500microgram disc (allen & hanburys ltd) ICS 
1518 
flixotide 50microgram/actuation inhalation powder (allen & hanburys 
ltd) ICS 
1537 becotide 200microgram rotacaps (glaxosmithkline uk ltd) ICS 
1551 beclazone 250 inhaler (teva uk ltd) ICS 
1552 
becloforte easi-breathe 250microgram/actuation pressurised inhalation 
(allen & hanburys ltd) ICS 
1619 terbutaline 500micrograms/dose dry powder inhaler SABA 
1620 terbutaline 250micrograms/dose inhaler SABA 
1628 terbutaline 250micrograms/actuation refill canister SABA 
1635 salbuvent 2mg/5ml oral solution (pharmacia ltd) SABA 
1642 budesonide 400micrograms/dose dry powder inhaler ICS 
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prodcode productname groups 
1676 
flixotide 125microgram/actuation inhalation powder (allen & hanburys 
ltd) ICS 
1680 pulmicort ls 50micrograms/dose inhaler (astrazeneca uk ltd) ICS 
1697 atrovent 20micrograms/dose autohaler (boehringer ingelheim ltd) SAMA 
1698 salbutamol 100micrograms/dose breath actuated inhaler SABA 
1725 beclazone 50 easi-breathe inhaler (teva uk ltd) ICS 
1727 
becotide easi-breathe 50microgram/actuation pressurised inhalation 
(allen & hanburys ltd) ICS 
1734 beclometasone 100micrograms/dose breath actuated inhaler ICS 
1741 salbutamol 100micrograms/dose breath actuated inhaler cfc free SABA 
1794 
berotec 100microgram/actuation inhalation powder (boehringer 
ingelheim ltd) SABA 
1801 ventide inhaler (glaxosmithkline uk ltd) SABA_ICS 
1832 theograd 350mg tablet (abbott laboratories ltd) THEOPH 
1833 theophylline 200mg modified-release tablets THEOPH 
1834 theophylline 400mg modified-release tablets THEOPH 
1861 aerobec 100 autohaler (meda pharmaceuticals ltd) ICS 
1882 ventodisks 200microgram/blister disc (allen & hanburys ltd) SABA 
1885 beclazone 200 inhaler (teva uk ltd) ICS 
1950 ventodisks 400microgram/blister disc (allen & hanburys ltd) SABA 
1951 becodisks 400microgram disc (allen & hanburys ltd) ICS 
1952 ventolin 400microgram rotacaps (glaxosmithkline uk ltd) SABA 
1956 pulmicort 1mg respules (astrazeneca uk ltd) ICS 
1957 ventolin 5mg nebules (glaxosmithkline uk ltd) SABA 
1959 pulmicort 0.5mg respules (astrazeneca uk ltd) ICS 
1960 volmax 8mg modified-release tablets (glaxosmithkline uk ltd) SABA 
1961 volmax 4mg modified-release tablets (glaxosmithkline uk ltd) SABA 
1974 oxis 12 turbohaler (astrazeneca uk ltd) LABA 
1975 oxis 6 turbohaler (astrazeneca uk ltd) LABA 
2020 berotec 200micrograms/dose inhaler (boehringer ingelheim ltd) SABA 
2044 prednisone 2.5 mg tab OCS 
2092 budesonide 200micrograms/dose dry powder inhaler ICS 
2124 pulmicort refil 200 mcg inh ICS 
2125 pulmicort 200microgram refill canister (astrazeneca uk ltd) ICS 
2147 theophylline 250mg modified-release capsules THEOPH 
2148 beclometasone 400microgram disc ICS 
2149 steri-neb salamol 2.5 mg inh SABA 
2152 ipratropium bromide with salbutamol 20mcg + 100mcg SABA_SAMA 
2159 aerobec 50 autohaler (meda pharmaceuticals ltd) ICS 
2160 beclometasone 50micrograms/dose breath actuated inhaler ICS 
2224 serevent 50micrograms/dose accuhaler (glaxosmithkline uk ltd) LABA 
2229 becodisks 100microgram disc (allen & hanburys ltd) ICS 
2282 fluticasone propionate 500micrograms/dose dry powder inhaler ICS 
2335 qvar 100 inhaler (teva uk ltd) ICS 
2368 prednisolone 2.5mg tablet OCS 
2390 prednisolone e/c 1 mg tab OCS 
2395 salbutamol 2 mg/5ml syr SABA 
2437 oxitropium bromide 100micrograms/dose inhaler SAMA 
2440 
flixotide accuhaler 500 500microgram/inhalation inhalation powder (allen 
& hanburys ltd) ICS 
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prodcode productname groups 
2600 beclometasone 250micrograms/dose breath actuated inhaler ICS 
2655 airomir 100micrograms/dose inhaler (teva uk ltd) SABA 
2704 prednisolone 25mg tablets OCS 
2722 duovent inhaler (boehringer ingelheim ltd) SABA_SAMA 
2723 fluticasone 25micrograms/dose inhaler ICS 
2757 slo-phyllin 250mg capsule (lipha pharmaceuticals ltd) THEOPH 
2758 bricanyl refill canister (astrazeneca uk ltd) SABA 
2799 prednisolone 10 mg tab OCS 
2850 salbutamol 400microgram inhalation powder capsules SABA 
2851 ventolin 200microgram rotacaps (glaxosmithkline uk ltd) SABA 
2862 duovent autohaler (boehringer ingelheim ltd) SABA_SAMA 
2869 salbutamol 8mg modified-release tablets SABA 
2892 becloforte 400microgram disks (glaxosmithkline uk ltd) ICS 
2893 beclometasone 200micrograms disc ICS 
2949 prednisone 5mg tablets OCS 
2951 fluticasone 250microgram/actuation pressurised inhalation ICS 
2978 salbutamol 200micrograms/dose dry powder inhaler SABA 
2992 beclazone 50 inhaler (teva uk ltd) ICS 
2994 
atrovent aerocaps 40microgram inhalation powder (boehringer ingelheim 
ltd) SAMA 
2995 nuelin sa 175mg tablets (meda pharmaceuticals ltd) THEOPH 
3018 beclometasone 50micrograms/dose inhaler ICS 
3039 oxivent 100micrograms/dose inhaler (boehringer ingelheim ltd) SAMA 
3059 prednisolone 50 mg tab OCS 
3065 bextasol inhalation powder (allen & hanburys ltd) ICS 
3075 becotide 400microgram rotacaps (glaxosmithkline uk ltd) ICS 
3119 
becloforte integra 250microgram/actuation inhaler with compact spacer 
(glaxo laboratories ltd) ICS 
3150 beclometasone 100micrograms/actuation extrafine particle cfc free inhaler ICS 
3163 salbutamol 200micrograms disc SABA 
3188 pulmicort complete 50 mcg inh ICS 
3189 salbuvent inh inh SABA 
3220 qvar 50 autohaler (teva uk ltd) ICS 
3254 salbulin 4mg tablet (3m health care ltd) SABA 
3289 flixotide 25micrograms/dose inhaler (glaxosmithkline uk ltd) ICS 
3297 salmeterol 50micrograms disc LABA 
3306 atrovent forte 40micrograms/dose inhaler (boehringer ingelheim ltd) SAMA 
3345 sintisone tablet (pharmacia ltd) OCS 
3363 becloforte 400microgram disks with diskhaler (glaxosmithkline uk ltd) ICS 
3388 theophylline 175mg modified-release tablets THEOPH 
3437 
becotide rotahaler type 4 insufflator inhalation powder (allen and 
hanburys ltd) ICS 
3442 pulmicort complete 200 mcg inh ICS 
3443 
salbutamol 100microgram/inhalation spacehaler (celltech pharma europe 
ltd) SABA 
3534 bricanyl 5mg tablets (astrazeneca uk ltd) SABA 
3546 qvar 50 inhaler (teva uk ltd) ICS 
3556 
beclometasone 50micrograms with salbutamol 100micrograms/inhalation 
inhaler SABA_ICS 
3557 prednisone 1mg tablets OCS 
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3570 budesonide 200micrograms/actuation refill canister ICS 
3584 bricanyl 1.5mg/5ml syrup (astrazeneca uk ltd) SABA 
3666 seretide 500 accuhaler (glaxosmithkline uk ltd) LABA_ICS 
3743 filair 50 inhaler (meda pharmaceuticals ltd) ICS 
3753 flixotide diskhaler-community pack 250 mcg ICS 
3758 pulmadil inhalation powder (3m health care ltd) SABA 
3763 terbutaline respules inh SABA 
3764 bricanyl respules (5mg/2ml) 2.5 mg/ml inh SABA 
3786 fenoterol 100micrograms/dose / ipratropium 40micrograms/dose inhaler SABA_SAMA 
3838 salbutamol 400mcg/beclometh.100mcg r/cap inh SABA 
3850 oxivent 100micrograms/dose autohaler (boehringer ingelheim ltd) SAMA 
3927 filair 100 inhaler (meda pharmaceuticals ltd) ICS 
3947 becotide 100microgram rotacaps (glaxosmithkline uk ltd) ICS 
3988 flixotide diskhaler-community pack 100 mcg ICS 
3989 flixotide 100microgram disc (allen & hanburys ltd) ICS 
3993 filair forte 250micrograms/dose inhaler (meda pharmaceuticals ltd) ICS 
3994 salbutamol 4mg modified-release tablets SABA 
4055 salbulin 2mg/5ml oral solution (3m health care ltd) SABA 
4131 fluticasone 100microgram disc ICS 
4132 fluticasone 125microgram/actuation pressurised inhalation ICS 
4171 ventolin 2mg tablet (allen & hanburys ltd) SABA 
4222 bricanyl 10mg/ml respirator solution (astrazeneca uk ltd) SABA 
4268 ipratropium bromide 40micrograms/dose inhaler SAMA 
4365 beclometasone 100micrograms disc ICS 
4413 qvar 100 autohaler (teva uk ltd) ICS 
4497 
ventolin accuhaler 200 200microgram/actuation inhalation powder (glaxo 
wellcome uk ltd) SABA 
4499 
aerobec 250microgram/actuation pressurised inhalation (meda 
pharmaceuticals ltd) ICS 
4514 aminophylline 350mg modified-release tablets THEOPH 
4541 bricanyl sa 7.5mg tablets (astrazeneca uk ltd) SABA 
4545 pulmicort ls 50microgram refill canister (astrazeneca uk ltd) ICS 
4593 theophylline 125mg tablets THEOPH 
4601 asmabec 100 clickhaler (focus pharmaceuticals ltd) ICS 
4665 salbulin 100micrograms/dose inhaler (3m health care ltd) SABA 
4688 fluticasone 50microgram/actuation pressurised inhalation ICS 
4759 beclometasone 100microgram inhalation powder capsules ICS 
4803 beclazone 250microgram/actuation inhalation powder (actavis uk ltd) ICS 
4842 fenoterol 100microgram/actuation inhaler SABA 
4908 ventolin rotahaler (glaxosmithkline uk ltd) SABA 
4926 
flixotide accuhaler 100 100microgram/inhalation inhalation powder (allen 
& hanburys ltd) ICS 
5143 seretide 50 evohaler (glaxosmithkline uk ltd) LABA_ICS 
5161 seretide 125 evohaler (glaxosmithkline uk ltd) LABA_ICS 
5170 salamol 100micrograms/dose inhaler cfc free (teva uk ltd) SABA 
5172 seretide 250 evohaler (glaxosmithkline uk ltd) LABA_ICS 
5185 fenoterol 200micrograms/dose inhaler SABA 
5223 fluticasone 50micrograms/dose inhaler cfc free ICS 
5261 nuelin sa 250 tablets (meda pharmaceuticals ltd) THEOPH 
5309 flixotide 50micrograms/dose evohaler (glaxosmithkline uk ltd) ICS 
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5453 uniphyllin continus 400mg tablets (napp pharmaceuticals ltd) THEOPH 
5490 deltacortril 5mg gastro-resistant tablets (alliance pharmaceuticals ltd) OCS 
5516 salamol 100micrograms/dose easi-breathe inhaler (teva uk ltd) SABA 
5521 beclometasone 200micrograms/dose dry powder inhaler ICS 
5522 beclometasone 100micrograms/dose dry powder inhaler ICS 
5551 flixotide 0.5mg/2ml nebules (glaxosmithkline uk ltd) ICS 
5558 salmeterol 50micrograms with fluticasone 500micrograms cfc free inhaler LABA_ICS 
5580 
flixotide accuhaler 50 50microgram/inhalation inhalation powder (allen & 
hanburys ltd) ICS 
5683 flixotide 250micrograms/dose evohaler (glaxosmithkline uk ltd) ICS 
5718 flixotide 125micrograms/dose evohaler (glaxosmithkline uk ltd) ICS 
5740 airomir 100micrograms/dose autohaler (teva uk ltd) SABA 
5753 salbutamol 400micrograms disc SABA 
5804 beclometasone 250micrograms/dose dry powder inhaler ICS 
5822 fluticasone 250micrograms/dose inhaler cfc free ICS 
5864 salmeterol 25micrograms with fluticasone 250micrograms cfc free inhaler LABA_ICS 
5885 fluticasone propionate 100micrograms/dose dry powder inhaler ICS 
5889 
salamol 100microgram/inhalation inhalation powder (kent 
pharmaceuticals ltd) SABA 
5913 deltacortril 2.5mg gastro-resistant tablets (alliance pharmaceuticals ltd) OCS 
5941 uniphyllin continus 300mg tablets (napp pharmaceuticals ltd) THEOPH 
5942 salmeterol 50micrograms with fluticasone 250micrograms cfc free inhaler LABA_ICS 
5957 Montelukast 5mg chewable tablets sugar free MONTELUKAST 
5975 fluticasone 125micrograms/dose inhaler cfc free ICS 
5992 beclometasone 50micrograms/dose dry powder inhaler ICS 
6050 spiriva 18 microgram capsule (boehringer ingelheim ltd) LAMA 
6081 ipratropium bromide 20micrograms/dose breath actuated inhaler SAMA 
6315 slo-phyllin 250mg capsules (merck serono ltd) THEOPH 
6325 symbicort 200/6 turbohaler (astrazeneca uk ltd) LABA_ICS 
6462 salbutamol 95micrograms/dose dry powder inhaler SABA 
6474 robinul 1mg tablet (idis world medicines) LAMA 
6512 atrovent 20micrograms/dose inhaler cfc free (boehringer ingelheim ltd) SAMA 
6522 ipratropium bromide 20micrograms/dose inhaler cfc free SAMA 
6526 formoterol 12microgram inhalation powder capsules with device LABA 
6569 salmeterol 25micrograms with fluticasone 125micrograms cfc free inhaler LABA_ICS 
6616 salmeterol 25micrograms with fluticasone 50micrograms cfc free inhaler LABA_ICS 
6746 
budesonide 400micrograms/dose / formoterol 12micrograms/dose dry 
powder inhaler LABA_ICS 
6780 symbicort 400/12 turbohaler (astrazeneca uk ltd) LABA_ICS 
6796 
budesonide 200micrograms/dose / formoterol 6micrograms/dose dry 
powder inhaler LABA_ICS 
6938 
salmeterol 50micrograms with fluticasone 100micrograms dry powder 
inhaler LABA_ICS 
6988 aminophylline hydrate 100mg modified-release tablets THEOPH 
7013 symbicort 100/6 turbohaler (astrazeneca uk ltd) LABA_ICS 
7017 salbutamol 100micrograms/dose dry powder inhaler SABA 
7088 Montelukast 4mg granules sachets sugar free MONTELUKAST 
7133 formoterol 12micrograms/dose dry powder inhaler LABA 
7192 bambuterol 10mg tablets SABA 
7218 glycopyrronium bromide 1mg tablets LAMA 
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7268 serevent 25micrograms/dose evohaler (glaxosmithkline uk ltd) LABA 
7270 salmeterol 25micrograms/dose inhaler cfc free LABA 
7452 ventolin .25 mg inj SABA 
7550 Omalizumab 150mg powder and solvent for solution for injection vials OMALIZUMAB 
7584 prednisolone 4 mg tab OCS 
7597 glycopyrronium bromide 2mg tablets LAMA 
7602 fluticasone 50microgram disc ICS 
7638 fluticasone 250microgram disc ICS 
7653 beclometasone 400microgram inhalation powder capsules ICS 
7710 prednisolone 15 mg tab OCS 
7711 terbutaline 250micrograms/dose inhaler with spacer SABA 
7724 betamethasone valerate 100micrograms/actuation inhaler ICS 
7730 theo-dur 300mg tablets (astrazeneca uk ltd) THEOPH 
7731 theo-dur 200mg tablets (astrazeneca uk ltd) THEOPH 
7732 theophylline 300mg modified-release tablets THEOPH 
7733 theophylline 250mg modified-release tablets THEOPH 
7788 budesonide 100micrograms/dose dry powder inhaler ICS 
7832 choline theophyllinate 200mg tablets THEOPH 
7841 nuelin 125mg tablets (3m health care ltd) THEOPH 
7891 fluticasone 500microgram disc ICS 
7908 robinul 2mg tablet (wyeth pharmaceuticals) LAMA 
7934 prednisone 30 mg tab OCS 
7935 
maxivent 100microgram/inhalation inhalation powder (ashbourne 
pharmaceuticals ltd) SABA 
7948 fluticasone propionate 250micrograms/dose dry powder inhaler ICS 
7953 terbutaline 1.5mg/5ml oral solution sugar free SABA 
7954 bricanyl 250micrograms/dose spacer inhaler (astrazeneca uk ltd) SABA 
8012 exirel 15mg capsule (3m health care ltd) SABA 
8056 aminophylline 100mg tablets THEOPH 
8057 aminophylline 100mg modified-release tablets THEOPH 
8111 becloforte vm 250microgram/actuation vm pack (allen & hanburys ltd) ICS 
8251 pulmicort refil 50 mg inh ICS 
8252 pirbuterol 15mg capsule SABA 
8267 sodium cromoglicate 1mg/dose / salbutamol 100micrograms/dose inhaler SABA_CROMO 
8333 ipratropium bromide 40microgram inhalation powder capsules SAMA 
8339 fenoterol hydrobromide complete unit inh SABA 
8365 moxisylyte 40mg tablets LABA 
8429 ventolin i/v 5 mg inj SABA 
8433 budesonide 100micrograms/actuation inhaler ICS 
8450 flixotide diskhaler-community pack 50 mcg ICS 
8470 aminophylline 225 mg sup THEOPH 
8504 exirel 15 mg tab SABA 
8522 terbutaline 7.5mg modified-release tablets SABA 
8572 rimiterol inhaler SABA 
8610 aminophylline 1 gm sup THEOPH 
8635 flixotide 50microgram disc (allen & hanburys ltd) ICS 
8636 ventolin s/r 8 mg spa SABA 
8653 aminophylline 360 mg sup THEOPH 
8806 phyllocontin continus 350mg tablet (napp pharmaceuticals ltd) THEOPH 
8955 theophylline 100 mg tab THEOPH 
262  
  
prodcode productname groups 
9092 theophylline 350mg modified release tablets THEOPH 
9164 fluticasone propionate 50micrograms/dose dry powder inhaler ICS 
9233 beclometasone 200microgram inhalation powder capsules ICS 
9270 
ipratropium bromide with fenoterol hydrobromide 500micrograms + 
1.25mg/4ml SABA_SAMA 
9356 becotide rotahaler insufflator inhalation powder (allen and hanburys ltd) ICS 
9384 salbutamol 4mg modified-release capsules SABA 
9477 asmabec 100microgram/actuation spacehaler (celltech pharma europe ltd) ICS 
9571 beclometasone 250micrograms/actuation vortex inhaler ICS 
9577 asmabec 50 clickhaler (focus pharmaceuticals ltd) ICS 
9599 beclazone 50microgram/actuation inhalation powder (actavis uk ltd) ICS 
9651 
asmasal 100microgram/inhalation spacehaler (celltech pharma europe 
ltd) SABA 
9658 oxitropium bromide 100micrograms/dose breath actuated inhaler SAMA 
9681 
atrovent aerohaler 40microgram inhalation powder (boehringer 
ingelheim ltd) SAMA 
9711 formoterol 6micrograms/dose dry powder inhaler LABA 
9727 prednisolone 50mg tablets OCS 
9805 salbutamol 5mg/50ml solution for infusion vials SABA 
9921 beclometasone 100micrograms/dose breath actuated inhaler cfc free ICS 
10090 beclometasone 50micrograms/actuation extrafine particle cfc free inhaler ICS 
10218 
budesonide 100micrograms/dose / formoterol 6micrograms/dose dry 
powder inhaler LABA_ICS 
10254 mometasone 400micrograms/dose dry powder inhaler ICS 
10289 aminophylline 200 mg sup THEOPH 
10321 budesonide 400microgram inhalation powder capsules ICS 
10331 nuelin 60mg/5ml liquid (3m health care ltd) THEOPH 
10353 salbuvent rondo SABA 
10360 aerocrom inhaler (castlemead healthcare ltd) SABA_CROMO 
10407 
phyllocontin paediatric continus 100mg tablets (napp pharmaceuticals 
ltd) THEOPH 
10432 theophylline 300 mg sup THEOPH 
10433 theophylline 60mg/5ml oral solution THEOPH 
10458 ventolin cr 4mg tablet (allen & hanburys ltd) SABA 
10672 opilon 40mg tablet (concord pharmaceuticals ltd) LABA 
10723 theophylline 125mg/5ml syrup THEOPH 
10744 theophylline 80 mg eli THEOPH 
10825 terbutaline 5mg tablets SABA 
10831 biophylline 125mg/5ml oral solution (lorex synthelabo ltd) THEOPH 
10858 pulmadil auto inhalation powder (3m health care ltd) SABA 
10958 salbutamol .25 mg inj SABA 
10968 
foradil 12microgram inhalation powder capsules with device (novartis 
pharmaceuticals uk ltd) LABA 
11046 ipratropium bromide with salbutamol 500micrograms + 2.5mg/2.5ml SABA_SAMA 
11149 betnelan 500microgram tablets (focus pharmaceuticals ltd) ICS 
11198 beclometasons 50 micrograms/actuation vortex inhaler ICS 
11307 
salbutamol 100micrograms/dose / beclometasone 50micrograms/dose 
inhaler SABA_ICS 
11410 
fluticasone propionate 500micrograms/dose / salmeterol 
50micrograms/dose dry powder inhaler LABA_ICS 
263  
  
prodcode productname groups 
11497 beclometasone 400micrograms/dose dry powder inhaler ICS 
11588 
fluticasone 125micrograms/dose / salmeterol 25micrograms/dose inhaler 
cfc free LABA_ICS 
11618 
fluticasone 250micrograms/dose / salmeterol 25micrograms/dose inhaler 
cfc free LABA_ICS 
11719 slo-phyllin 60mg capsules (merck serono ltd) THEOPH 
11732 beclometasone 50micrograms/dose breath actuated inhaler cfc free ICS 
11779 
ipratropium bromide 40microgram inhalation powder capsules with 
device SAMA 
11993 pro-vent 300mg capsule (wellcome medical division) THEOPH 
12042 ventolin cr 8mg tablet (allen & hanburys ltd) SABA 
12144 bambuterol 20mg tablets SABA 
12240 theophylline 300mg modified release capsules THEOPH 
12463 pirbuterol 15 mg tab SABA 
12486 
bronchodil 500microgram/dose inhalation powder (viatris 
pharmaceuticals ltd) SABA 
12563 exirel inhalation powder (3m health care ltd) SABA 
12699 pecram 225mg modified-release tablet (novartis consumer health uk ltd) THEOPH 
12808 
fenoterol 100micrograms/dose / ipratropium bromide 40micrograms/dose 
breath actuated inhaler SABA_SAMA 
12822 
salbutamol 2.5mg with ipratropium bromide 500micrograms/2.5ml unit 
dose nebuilser solution SABA_SAMA 
12909 
salbutamol 100micrograms/dose / ipratropium 20micrograms/dose 
inhaler SABA_SAMA 
12994 
fluticasone 50micrograms/dose / salmeterol 25micrograms/dose inhaler 
cfc free LABA_ICS 
13037 
pulvinal beclometasone dipropionate 200micrograms/dose dry powder 
inhaler (chiesi ltd) ICS 
13038 pulvinal salbutamol 200micrograms/dose dry powder inhaler (chiesi ltd) SABA 
13040 
fluticasone propionate 250micrograms/dose / salmeterol 
50micrograms/dose dry powder inhaler LABA_ICS 
13181 
easyhaler salbutamol sulfate 100micrograms/dose dry powder inhaler 
(orion pharma (uk) ltd) SABA 
13273 
fluticasone propionate 100micrograms/dose / salmeterol 
50micrograms/dose dry powder inhaler LABA_ICS 
13290 clenil modulite 100micrograms/dose inhaler (chiesi ltd) ICS 
13522 prednisolone 2 mg tab OCS 
13529 amnivent-225 sr tablets (ashbourne pharmaceuticals ltd) THEOPH 
13575 bambec 20mg tablets (astrazeneca uk ltd) SABA 
13615 prednisone 10 mg tab OCS 
13815 beclazone 100microgram/actuation inhalation powder (actavis uk ltd) ICS 
13996 salamol 100microgram/inhalation inhalation powder (sandoz ltd) SABA 
14294 qvar 50micrograms/dose easi-breathe inhaler (teva uk ltd) ICS 
14306 formoterol 12micrograms/dose inhaler cfc free LABA 
14321 beclometasone 200micrograms/dose inhaler cfc free ICS 
14482 bricanyl 2.5 mg inj SABA 
14524 bdp 250microgram/actuation spacehaler (celltech pharma europe ltd) ICS 
14525 salbutamol 100micrograms/inhalation vortex inhaler SABA 
14527 bambec 10mg tablets (astrazeneca uk ltd) SABA 
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14561 
salbutamol 400microgram / beclometasone 200microgram inhalation 
powder capsules SABA_ICS 
14567 asmabec 250 clickhaler (focus pharmaceuticals ltd) ICS 
14590 asmabec 250microgram/actuation spacehaler (celltech pharma europe ltd) ICS 
14700 budesonide 400micrograms/actuation inhaler ICS 
14736 
pulvinal beclometasone dipropionate 400micrograms/dose dry powder 
inhaler (chiesi ltd) ICS 
14739 norphyllin sr 225mg tablets (teva uk ltd) THEOPH 
14757 
pulvinal beclometasone dipropionate 100micrograms/dose dry powder 
inhaler (chiesi ltd) ICS 
15025 aminophylline 25 mg sup THEOPH 
15075 bronchodil 20mg tablet (viatris pharmaceuticals ltd) SABA 
15165 reproterol 500micrograms/dose inhaler SABA 
15284 slo-phyllin 125mg capsules (merck serono ltd) THEOPH 
15326 beclometasone 100micrograms/dose inhaler cfc free ICS 
15365 theophylline 10mg/5ml sf elixir THEOPH 
15409 theophylline 3 mg sol THEOPH 
15441 fenoterol hydrobromide .5 % sol SABA 
15483 bricanyl oral solution (astrazeneca uk ltd) SABA 
15706 beclometasone 100 micrograms/actuation vortex inhaler ICS 
16018 mometasone 200micrograms/dose dry powder inhaler ICS 
16054 budesonide 200micrograms/actuation breath actuated powder inhaler ICS 
16148 clenil modulite 250micrograms/dose inhaler (chiesi ltd) ICS 
16151 clenil modulite 200micrograms/dose inhaler (chiesi ltd) ICS 
16158 clenil modulite 50micrograms/dose inhaler (chiesi ltd) ICS 
16236 pirbuterol acetate inhaler SABA 
16305 flixotide 2mg/2ml nebules (glaxosmithkline uk ltd) ICS 
16577 
easyhaler salbutamol sulfate 200micrograms/dose dry powder inhaler 
(orion pharma (uk) ltd) SABA 
16584 beclometasone 50micrograms/dose inhaler cfc free ICS 
16625 ventide rotacaps (glaxosmithkline uk ltd) SABA_ICS 
16724 prednisone 50 mg tab OCS 
16994 aminophylline hydrate 350mg modified-release tablets THEOPH 
17002 aminophylline hydrate 225mg modified-release tablets THEOPH 
17140 aminophylline 200mg tablets THEOPH 
17654 
easyhaler beclometasone 200micrograms/dose dry powder inhaler (orion 
pharma (uk) ltd) ICS 
17670 
easyhaler budesonide 100micrograms/dose dry powder inhaler (orion 
pharma (uk) ltd) ICS 
17696 ventmax sr 4mg capsules (chiesi ltd) SABA 
17874 monovent 1.5mg/5ml oral solution (lagap) SABA 
17875 terbutaline with guafenesin expectorant SABA 
17901 bricanyl nebule 2.5 ml SABA 
18140 respontin 500micrograms/2ml nebules (glaxosmithkline uk ltd) SAMA 
18288 choline theophyllinate 100mg tablets THEOPH 
18308 aminophylline 100 mg sup THEOPH 
18314 aerocrom syncroner with spacer (castlemead healthcare ltd) SABA_CROMO 
18394 bdp 50microgram/actuation spacehaler (celltech pharma europe ltd) ICS 
18456 
salbutamol 200microgram / beclometasone 100microgram inhalation 
powder capsules SABA_ICS 
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18484 ventide paediatric rotacaps (glaxosmithkline uk ltd) SABA_ICS 
18537 budesonide 200microgram inhalation powder capsules ICS 
18622 salbulin 2mg tablet (3m health care ltd) SABA 
18848 qvar 100micrograms/dose easi-breathe inhaler (teva uk ltd) ICS 
18937 sabidal sr 270 270 mg tab THEOPH 
18968 salbutamol 5mg/5ml solution for infusion ampoules SABA 
18988 choline theophyllinate 62.5mg/5ml oral solution THEOPH 
19031 bdp 100microgram/actuation spacehaler (celltech pharma europe ltd) ICS 
19121 
beclometasone 100micrograms with salbutamol 200micrograms 
inhalation capsules SABA_ICS 
19141 prednisolone 5mg soluble tablets (amco) OCS 
19350 aminophylline 62.5 mg sup THEOPH 
19376 
beclometasone 200micrograms with salbutamol 400micrograms 
inhalation capsules SABA_ICS 
19389 asmabec 50microgram/actuation spacehaler (celltech pharma europe ltd) ICS 
19401 beclometasone 250micrograms/actuation inhaler and compact spacer ICS 
19642 ventolin nebules SABA 
19649 ventolin rotahaler SABA 
19653 ventolin respirator SABA 
19726 ventolin s/r SABA 
19732 cobutolin inh SABA 
19735 uniphyllin continus THEOPH 
19736 becotide susp for nebulisation ICS 
19799 tulobuterol 2mg LABA 
19805 atrovent SAMA 
20095 precortisyl forte 25mg tablet (aventis pharma) OCS 
20171 aminophylline 180 mg sup THEOPH 
20225 aminophylline 500 mg inj THEOPH 
20670 prednisolone e/c OCS 
20675 salbutamol rotahaler complete unit SABA 
20707 becotide 100 ICS 
20720 atrovent forte SAMA 
20763 becloforte ICS 
20781 salbutamol u.dose nebulising 2.5mg/2.5ml SABA 
20812 pulmicort refill ICS 
20825 
spacehaler bdp 250microgram/actuation spacehaler (celltech pharma 
europe ltd) ICS 
20838 salbuvent 2mg tablet (pharmacia ltd) SABA 
21005 beclometasone 250micrograms/dose inhaler cfc free ICS 
21102 salbutamol 2mg/5ml oral solution (lagap) SABA 
21417 prednisolone 5mg tablets (a a h pharmaceuticals ltd) OCS 
21482 beclometasone 100micrograms/dose inhaler (generics (uk) ltd) ICS 
21769 lasma 300mg tablet (pharmax ltd) THEOPH 
21833 decortisyl 5mg tablet (roussel laboratories ltd) OCS 
21859 asmaven 100microgram inhalation powder (berk pharmaceuticals ltd) SABA 
22080 aminophylline 20 ml inj THEOPH 
22225 beclomethasone /salbutamol SABA 
22313 ventmax sr 8mg capsules (chiesi ltd) SABA 
22430 
spacehaler salbutamol 100microgram/inhalation spacehaler (celltech 
pharma europe ltd) SABA 
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22467 salbutamol respirator soln SABA 
22512 salbutamol inhaler SABA 
22550 duovent SABA 
22661 pirbuterol 10mg capsule SABA 
22663 respacal 2mg tablet (ucb pharma ltd) LABA 
22669 choline theophyllinate 270 mg tab THEOPH 
22790 reproterol 10mg/ml respirator solution SABA 
23512 precortisyl 5mg tablet (hoechst marion roussel) OCS 
23567 respontin 250micrograms/1ml nebules (glaxosmithkline uk ltd) SAMA 
23572 
aminophylline sr 225mg modified-release tablet (ivax pharmaceuticals uk 
ltd) THEOPH 
23675 pulmicort l.s. refil ICS 
23688 ventolin rotacaps SABA 
23741 
novolizer budesonide 200microgram/actuation pressurised inhalation 
(meda pharmaceuticals ltd) ICS 
23787 exirel 10mg capsule (3m health care ltd) SABA 
23961 ipratropium bromide 250microgram/ml inhalation vapour (galen ltd) SAMA 
24117 aminophylline 300 mg sup THEOPH 
24207 aminophylline paed 50 mg sup THEOPH 
24219 becotide rotacaps ICS 
24380 
sodium cromoglicate 1mg/dose / salbutamol 100micrograms/dose inhaler 
with spacer SABA_CROMO 
24418 biophylline 350mg tablet (lorex synthelabo ltd) THEOPH 
24645 ventolin 5mg/5ml solution for infusion ampoules (glaxosmithkline uk ltd) SABA 
24660 betamethasone valerate ICS 
24674 biophylline 500mg tablet (lorex synthelabo ltd) THEOPH 
24716 prednisolone e/c OCS 
24898 
spacehaler bdp 100microgram/actuation spacehaler (celltech pharma 
europe ltd) ICS 
25020 ipratropium bromide (forte) SAMA 
25022 aminophylline 150 mg sup THEOPH 
25073 salbutamol SABA 
25093 theophylline s/r THEOPH 
25204 beclometasone 100micrograms/dose inhaler (a a h pharmaceuticals ltd) ICS 
25218 salbutamol cfc/free b/a SABA 
25272 precortisyl 1mg tablet (hoechst marion roussel) OCS 
25784 atimos modulite 12micrograms/dose inhaler (chiesi ltd) LABA 
25820 bronchodil 10mg/5ml oral solution (viatris pharmaceuticals ltd) SABA 
25821 exirel 7.5mg/5ml oral solution (3m health care ltd) SABA 
25829 pirbuterol 7.5mg/5ml oral solution SABA 
26063 beclometasone 100micrograms/dose inhaler (teva uk ltd) ICS 
26079 uniphyllin paediatric continus THEOPH 
26420 exirel 10 mg tab SABA 
26525 ventolin SABA 
26616 
ipratropium bromide with fenoterol hydrobromide 0micrograms + 
100micrograms/actuation SABA_SAMA 
26665 pulmicort complete ICS 
26716 airomir autohaler cfc free b/a SABA 
26829 brelomax 2mg tablet (abbott laboratories ltd) LABA 
26873 cobutolin 2mg tablet (actavis uk ltd) SABA 
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26987 bricanyl tablet (astrazeneca uk ltd) SABA 
27040 phyllocontin continus THEOPH 
27188 
easyhaler budesonide 200micrograms/dose dry powder inhaler (orion 
pharma (uk) ltd) ICS 
27505 
ipratropium bromide with fenoterol hydrobromide 40micrograms + 
100micrograms/actuation SABA_SAMA 
27525 becotide 50 ICS 
27558 choledyl THEOPH 
27573 ventolin SABA 
27583 pulmicort ICS 
27593 aminophylline 350 mg sup THEOPH 
27679 
beclometasone 100microgram/actuation pressurised inhalation (approved 
prescription services ltd) ICS 
27793 
salbutamol cyclohaler type 5 insufflator inhalation powder (bristol-myers 
squibb pharmaceuticals ltd) SABA 
27842 aminophylline 2 ml inj THEOPH 
27889 prednisolone OCS 
27915 fluticasone prop disk refill ICS 
27959 prednisolone OCS 
27962 deltastab 1mg tablet (waymade healthcare plc) OCS 
28073 
beclometasone 250microgram/actuation pressurised inhalation (approved 
prescription services ltd) ICS 
28375 prednisolone 2.5mg gastro-resistant tablets (a a h pharmaceuticals ltd) OCS 
28376 prednisolone 2.5mg gastro-resistant tablet (biorex laboratories ltd) OCS 
28508 
salbutamol 100microgram/inhalation inhalation powder (ivax 
pharmaceuticals uk ltd) SABA 
28640 
beclometasone 100microgram/actuation inhalation powder (actavis uk 
ltd) ICS 
28761 
spacehaler bdp 50microgram/actuation spacehaler (celltech pharma 
europe ltd) ICS 
28859 deltastab 5mg tablet (waymade healthcare plc) OCS 
28881 salbutamol 2mg/5ml oral solution sugar free (a a h pharmaceuticals ltd) SABA 
29138 glycopyrronium bromide 1mg/5ml oral solution LAMA 
29267 salbuvent 4mg tablet (pharmacia ltd) SABA 
29273 
aminophylline 225mg modified-release tablet (hillcross pharmaceuticals 
ltd) THEOPH 
29325 beclometasone 250micrograms/dose inhaler (generics (uk) ltd) ICS 
29333 prednisolone 5mg tablets (actavis uk ltd) OCS 
30118 salbutamol 100micrograms/dose inhaler cfc free (teva uk ltd) SABA 
30204 salbutamol 200micrograms inahalation capsules SABA 
30210 beclometasone 250micrograms/dose inhaler (teva uk ltd) ICS 
30212 salbutamol cyclohaler SABA 
30230 salbutamol 100micrograms/actuation breath actuated inhaler SABA 
30238 
beclometasone 50microgram/actuation pressurised inhalation (approved 
prescription services ltd) ICS 
30390 deltastab 2 mg tab OCS 
30596 aminophylline 225mg modified-release tablet (actavis uk ltd) THEOPH 
30649 
easyhaler budesonide 400micrograms/dose dry powder inhaler (orion 
pharma (uk) ltd) ICS 
30971 decortisyl 25 mg tab OCS 
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31082 salbuvent 5mg/ml respirator solution (pharmacia ltd) SABA 
31290 salbulin cfc free SABA 
31327 prednisolone steaglate 6.65mg tablet OCS 
31532 prednisolone 5mg gastro-resistant tablets (a a h pharmaceuticals ltd) OCS 
31758 uniphyllin continus THEOPH 
31774 beclometasone 50micrograms/dose inhaler (generics (uk) ltd) ICS 
31845 salapin 2mg/5ml syrup (pinewood healthcare) SABA 
31933 salbutamol 100micrograms/dose inhaler (a a h pharmaceuticals ltd) SABA 
32050 salbutamol 400 cyclocaps (teva uk ltd) SABA 
32102 salbutamol 4mg tablets (a a h pharmaceuticals ltd) SABA 
32461 choline theophyllinate 90 mg tab THEOPH 
32803 prednisolone 5mg gastro-resistant tablets (actavis uk ltd) OCS 
32812 numotac 10mg tablet (3m health care ltd) SABA 
32835 prednisolone 5mg tablets (wockhardt uk ltd) OCS 
32874 beclometasone 50microgram/actuation inhalation powder (actavis uk ltd) ICS 
32893 theophylline 100mg/lysine 74mg mg tab THEOPH 
33089 salbutamol 100micrograms/dose inhaler (kent pharmaceuticals ltd) SABA 
33258 beclometasone 250micrograms/dose inhaler (a a h pharmaceuticals ltd) ICS 
33373 salbutamol 200 cyclocaps (teva uk ltd) SABA 
33588 salbutamol 100micrograms/dose inhaler (generics (uk) ltd) SABA 
33691 prednisolone 5mg gastro-resistant tablet (biorex laboratories ltd) OCS 
33817 salbutamol 100micrograms/dose inhaler cfc free (actavis uk ltd) SABA 
33849 
beclometasone 100microgram/actuation inhalation powder (neo 
laboratories ltd) ICS 
33988 prednisolone 5mg tablet (co-pharma ltd) OCS 
33990 prednisolone 5mg tablet (ivax pharmaceuticals uk ltd) OCS 
34029 salbutamol 400micrograms inahalation capsules SABA 
34109 prednisolone 5 mg gastro-resistant tablet OCS 
34310 
salbutamol 100micrograms/dose inhaler cfc free (a a h pharmaceuticals 
ltd) SABA 
34311 
salbutamol 100microgram/inhalation inhalation powder (berk 
pharmaceuticals ltd) SABA 
34315 
beclometasone 250microgram/actuation inhalation powder (actavis uk 
ltd) ICS 
34393 prednisolone 5mg gastro-resistant tablets (teva uk ltd) OCS 
34404 prednisolone 1mg tablets (actavis uk ltd) OCS 
34428 
beclometasone 50microgram/actuation inhalation powder (neo 
laboratories ltd) ICS 
34452 prednisolone 1mg tablets (a a h pharmaceuticals ltd) OCS 
34461 prednisolone 2.5mg gastro-resistant tablets (actavis uk ltd) OCS 
34618 salbutamol 2mg tablets (actavis uk ltd) SABA 
34619 
salbutamol 100microgram/inhalation inhalation powder (kent 
pharmaceuticals ltd) SABA 
34631 prednisolone 1mg tablet (co-pharma ltd) OCS 
34660 prednisolone 1mg tablets (kent pharmaceuticals ltd) OCS 
34702 
salbutamol 100microgram/inhalation inhalation powder (c p 
pharmaceuticals ltd) SABA 
34739 beclometasone 50micrograms/dose inhaler (teva uk ltd) ICS 
34748 prednisolone 1mg tablets (teva uk ltd) OCS 
34781 prednisolone 5mg tablets (kent pharmaceuticals ltd) OCS 
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34794 beclometasone 200micrograms/dose inhaler (a a h pharmaceuticals ltd) ICS 
34859 
beclometasone 250microgram/actuation inhalation powder (neo 
laboratories ltd) ICS 
34914 prednisolone 1mg tablet (celltech pharma europe ltd) OCS 
34919 beclometasone 50micrograms/dose inhaler (a a h pharmaceuticals ltd) ICS 
34938 salbutamol 4mg tablets (actavis uk ltd) SABA 
34978 prednisolone 1mg tablets (wockhardt uk ltd) OCS 
34995 
spiriva 18microgram inhalation powder capsules with handihaler 
(boehringer ingelheim ltd) LAMA 
35000 
spiriva 18microgram inhalation powder capsules (boehringer ingelheim 
ltd) LAMA 
35011 tiotropium bromide 18microgram inhalation powder capsules LAMA 
35014 
tiotropium bromide 18microgram inhalation powder capsules with 
device LAMA 
35071 becodisks 200microgram (glaxosmithkline uk ltd) ICS 
35106 becodisks 100microgram with diskhaler (glaxosmithkline uk ltd) ICS 
35107 beclometasone 400microgram inhalation powder blisters with device ICS 
35113 beclometasone 200microgram inhalation powder blisters ICS 
35118 becodisks 400microgram with diskhaler (glaxosmithkline uk ltd) ICS 
35165 serevent 50microgram disks with diskhaler (glaxosmithkline uk ltd) LABA 
35225 flixotide 100microgram disks with diskhaler (glaxosmithkline uk ltd) ICS 
35288 beclometasone 400microgram inhalation powder blisters ICS 
35293 beclometasone 200microgram inhalation powder blisters with device ICS 
35299 becodisks 400microgram (glaxosmithkline uk ltd) ICS 
35374 flixotide 500microgram disks (glaxosmithkline uk ltd) ICS 
35392 flixotide 500microgram disks with diskhaler (glaxosmithkline uk ltd) ICS 
35408 becodisks 100microgram (glaxosmithkline uk ltd) ICS 
35430 becodisks 200microgram with diskhaler (glaxosmithkline uk ltd) ICS 
35461 flixotide 250microgram disks with diskhaler (glaxosmithkline uk ltd) ICS 
35503 salmeterol 50microgram inhalation powder blisters LABA 
35510 
budesonide 200micrograms/dose dry powder inhalation cartridge with 
device ICS 
35542 salmeterol 50microgram inhalation powder blisters with device LABA 
35580 beclometasone 100microgram inhalation powder blisters with device ICS 
35602 budesonide 200micrograms/dose dry powder inhalation cartridge ICS 
35611 flixotide 250microgram disks (glaxosmithkline uk ltd) ICS 
35631 
budelin novolizer 200micrograms/dose inhalation powder (meda 
pharmaceuticals ltd) ICS 
35638 
fluticasone propionate 100microgram inhalation powder blisters with 
device ICS 
35652 beclometasone 100microgram inhalation powder blisters ICS 
35700 
fluticasone propionate 500microgram inhalation powder blisters with 
device ICS 
35724 
budelin novolizer 200micrograms/dose inhalation powder refill (meda 
pharmaceuticals ltd) ICS 
35725 
formoterol easyhaler 12micrograms/dose dry powder inhaler (orion 
pharma (uk) ltd) LABA 
35772 fluticasone propionate 100microgram inhalation powder blisters ICS 
35825 serevent 50microgram disks (glaxosmithkline uk ltd) LABA 
35905 fluticasone propionate 250microgram inhalation powder blisters ICS 
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35986 flixotide 50microgram disks (glaxosmithkline uk ltd) ICS 
36021 
fluticasone propionate 50microgram inhalation powder blisters with 
device ICS 
36090 flixotide 100microgram disks (glaxosmithkline uk ltd) ICS 
36290 flixotide 50microgram disks with diskhaler (glaxosmithkline uk ltd) ICS 
36401 
fluticasone propionate 250microgram inhalation powder blisters with 
device ICS 
36462 fluticasone propionate 500microgram inhalation powder blisters ICS 
36677 reproterol 10mg/5ml oral solution SABA 
36864 
tiotropium bromide 2.5micrograms/dose solution for inhalation cartridge 
with device cfc free LAMA 
36869 
spiriva respimat 2.5micrograms/dose solution for inhalation cartridge 
with device (boehringer ingelheim ltd) LAMA 
37432 fostair 100micrograms/dose / 6micrograms/dose inhaler (chiesi ltd) LABA_ICS 
37447 fluticasone propionate 50microgram inhalation powder blisters ICS 
37470 
beclometasone 100micrograms/dose / formoterol 6micrograms/dose 
inhaler cfc free LABA_ICS 
37791 ipratropium bromide 250microgram/ml SAMA 
38079 
salbutamol 100micrograms/dose dry powder inhalation cartridge with 
device SABA 
38097 
salbutamol cyclocaps 200microgram inhalation powder (dupont 
pharmaceuticals ltd) SABA 
38120 theophylline 500mg modified release tablets THEOPH 
38136 
salbulin novolizer 100micrograms/dose inhalation powder (meda 
pharmaceuticals ltd) SABA 
38214 salbutamol 100micrograms/dose dry powder inhalation cartridge SABA 
38226 
salbulin novolizer 100micrograms/dose inhalation powder refill (meda 
pharmaceuticals ltd) SABA 
38377 glycopyrronium bromide 2mg/5ml oral solution LAMA 
38407 prednisolone 20mg tablet OCS 
38416 
salbutamol cyclocaps 400microgram inhalation powder (dupont 
pharmaceuticals ltd) SABA 
38419 terbutaline 1.5mg/5ml oral solution sugar free (a a h pharmaceuticals ltd) SABA 
38538 glycopyrronium bromide 2mg/5ml oral suspension LAMA 
39040 phyllocontin forte continus 350mg tablets (napp pharmaceuticals ltd) THEOPH 
39099 pulmicort 100micrograms/dose inhaler cfc free (astrazeneca uk ltd) ICS 
39102 budesonide 100micrograms/dose inhaler cfc free ICS 
39200 aerobec forte 250 autohaler (meda pharmaceuticals ltd) ICS 
39879 budesonide 200micrograms/dose inhaler cfc free ICS 
40057 pulmicort 200micrograms/dose inhaler cfc free (astrazeneca uk ltd) ICS 
40655 salbuvent 100microgram/actuation inhalation powder (pharmacia ltd) SABA 
41269 beclometasone 400 cyclocaps (teva uk ltd) ICS 
41412 beclometasone 400micrograms/actuation inhaler ICS 
41515 prednisolone 5mg tablets (teva uk ltd) OCS 
41548 salbutamol 2mg tablets (approved prescription services ltd) SABA 
41549 salbutamol 2mg tablet (c p pharmaceuticals ltd) SABA 
41691 salbutamol 2mg/5ml oral solution sugar free (sandoz ltd) SABA 
41745 prednisolone 25mg tablets (zentiva) OCS 
41832 monovent 1.5mg/5ml syrup (sandoz ltd) SABA 
42103 tulobuterol 1mg/5ml sugar free syrup LABA 
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42497 salbutamol 8mg tablet SABA 
42830 ventolin 100micrograms/dose evohaler (glaxosmithkline uk ltd) SABA 
42858 ventolin 200micrograms/dose accuhaler (glaxosmithkline uk ltd) SABA 
42867 terbutaline 1.5mg/5ml oral solution (sandoz ltd) SABA 
42886 bricanyl 500micrograms/dose turbohaler (astrazeneca uk ltd) SABA 
42928 flixotide 100micrograms/dose accuhaler (glaxosmithkline uk ltd) ICS 
42985 flixotide 50micrograms/dose accuhaler (glaxosmithkline uk ltd) ICS 
42994 flixotide 250micrograms/dose accuhaler (glaxosmithkline uk ltd) ICS 
43074 flixotide 500micrograms/dose accuhaler (glaxosmithkline uk ltd) ICS 
43085 bricanyl 5mg/2ml respules (astrazeneca uk ltd) SABA 
43090 atrovent 40microgram aerocaps (boehringer ingelheim ltd) SAMA 
43105 atrovent 40microgram aerocaps with aerohaler (boehringer ingelheim ltd) SAMA 
43544 prednisone 5mg tablet (knoll ltd) OCS 
43738 indacaterol 150microgram inhalation powder capsules with device LABA 
43764 opilon 40mg tablets (archimedes pharma uk ltd) LABA 
43893 
onbrez breezhaler 150microgram inhalation powder capsules with device 
(novartis pharmaceuticals uk ltd) LABA 
44064 
onbrez breezhaler 300microgram inhalation powder capsules with device 
(novartis pharmaceuticals uk ltd) LABA 
44380 prednisone 1mg modified-release tablets OCS 
44713 
salbutamol 100microgram/inhalation inhalation powder (celltech pharma 
europe ltd) SABA 
44723 prednisone 5mg modified-release tablets OCS 
44802 lodotra 5mg modified-release tablets (napp pharmaceuticals ltd) OCS 
44803 lodotra 2mg modified-release tablets (napp pharmaceuticals ltd) OCS 
45302 prednisolone 5mg tablet (biorex laboratories ltd) OCS 
45610 indacaterol 300microgram inhalation powder capsules with device LABA 
46157 beclometasone 200 cyclocaps (teva uk ltd) ICS 
46214 glycopyrronium bromide 5mg/5ml oral solution LAMA 
46551 
salbutamol 100microgram/inhalation inhalation powder (neo laboratories 
ltd) SABA 
46711 prednisone 2mg modified-release tablets OCS 
47142 prednisolone 5mg soluble tablet (amdipharm plc) OCS 
47269 glycopyrronium bromide 1mg/5ml oral suspension LAMA 
47638 neovent 25micrograms/dose inhaler cfc free (kent pharmaceuticals ltd) LABA 
47915 Omalizumab 150mg/1ml solution for injection pre-filled syringes OMALIZUMAB 
47943 
beclazone easi-breathe (roi) 100microgram/actuation pressurised 
inhalation (ivax pharmaceuticals ireland) ICS 
48340 
clenil modulite 100micrograms/dose inhaler (mawdsley-brooks & 
company ltd) ICS 
48484 theophylline 250mg/5ml oral suspension THEOPH 
48490 ventolin 100micrograms/dose evohaler (de pharmaceuticals) SABA 
48519 ventolin 100micrograms/dose evohaler (waymade healthcare plc) SABA 
48547 salamol 100micrograms/dose inhaler cfc free (arrow generics ltd) SABA 
48666 
flutiform 250micrograms/dose / 10micrograms/dose inhaler (napp 
pharmaceuticals ltd) LABA_ICS 
48709 
qvar 100micrograms/dose easi-breathe inhaler (sigma pharmaceuticals 
plc) ICS 
48739 seretide 250 evohaler (de pharmaceuticals) LABA_ICS 
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48741 
ventolin 100micrograms/dose evohaler (mawdsley-brooks & company 
ltd) SABA 
48742 ventodisks 400microgram (glaxosmithkline uk ltd) SABA 
48809 ventodisks 400microgram with diskhaler (glaxosmithkline uk ltd) SABA 
49000 seretide 250 evohaler (waymade healthcare plc) LABA_ICS 
49114 symbicort 100/6 turbohaler (sigma pharmaceuticals plc) LABA_ICS 
49227 aclidinium bromide 375micrograms/dose dry powder inhaler LAMA 
49228 eklira 322micrograms/dose genuair (almirall ltd) LAMA 
49367 
clenil modulite 50micrograms/dose inhaler (mawdsley-brooks & 
company ltd) ICS 
49368 ventodisks 200microgram with diskhaler (glaxosmithkline uk ltd) SABA 
49369 salbutamol 200microgram inhalation powder blisters SABA 
49370 ventodisks 200microgram (glaxosmithkline uk ltd) SABA 
49591 salbutamol 100micrograms/dose inhaler cfc free (sandoz ltd) SABA 
49711 pulmicort 200micrograms/dose inhaler (astrazeneca uk ltd) ICS 
49772 fluticasone 250micrograms/dose evohaler (sigma pharmaceuticals plc) ICS 
49868 
fluticasone 250micrograms/dose / formoterol 10micrograms/dose inhaler 
cfc free LABA_ICS 
50036 
flutiform 125micrograms/dose / 5micrograms/dose inhaler (napp 
pharmaceuticals ltd) LABA_ICS 
50037 pulmicort 0.5mg respules (waymade healthcare plc) ICS 
50047 glycopyrronium bromide 5mg/5ml oral solution LAMA 
50051 serevent 25micrograms/dose evohaler (waymade healthcare plc) LABA 
50103 
spiriva 18microgram inhalation powder capsules with handihaler 
(waymade healthcare plc) LAMA 
50129 qvar 100micrograms/dose easi-breathe inhaler (de pharmaceuticals) ICS 
50287 qvar 100 inhaler (de pharmaceuticals) ICS 
50292 
spiriva 18microgram inhalation powder capsules (sigma pharmaceuticals 
plc) LAMA 
50315 salbutamol 200microgram inhalation powder blisters with device SABA 
50503 
ventolin 200micrograms/dose accuhaler (mawdsley-brooks & company 
ltd) SABA 
50557 ventolin 200micrograms/dose accuhaler (lexon (uk) ltd) SABA 
50560 seretide 250 accuhaler (sigma pharmaceuticals plc) LABA_ICS 
50577 
spiriva 18microgram inhalation powder capsules with handihaler (de 
pharmaceuticals) LAMA 
50689 
flutiform 50micrograms/dose / 5micrograms/dose inhaler (napp 
pharmaceuticals ltd) LABA_ICS 
50701 becotide rotahaler (glaxosmithkline uk ltd) ICS 
50739 symbicort 400/12 turbohaler (mawdsley-brooks & company ltd) LABA_ICS 
50810 atrovent 20micrograms/dose inhaler cfc free (de pharmaceuticals) SAMA 
50886 seretide 250 evohaler (stephar (u.k.) ltd) LABA_ICS 
50945 symbicort 100/6 turbohaler (mawdsley-brooks & company ltd) LABA_ICS 
50956 ventolin 200micrograms/dose accuhaler (de pharmaceuticals) SABA 
51027 seretide 125 evohaler (de pharmaceuticals) LABA_ICS 
51151 seretide 125 evohaler (lexon (uk) ltd) LABA_ICS 
51209 
fluticasone 125micrograms/dose / formoterol 5micrograms/dose inhaler 
cfc free LABA_ICS 
51234 qvar 100 inhaler (waymade healthcare plc) ICS 
273  
  
prodcode productname groups 
51270 
fluticasone 50micrograms/dose / formoterol 5micrograms/dose inhaler cfc 
free LABA_ICS 
51394 seretide 500 accuhaler (waymade healthcare plc) LABA_ICS 
51415 qvar 50 inhaler (mawdsley-brooks & company ltd) ICS 
51430 theophylline 60mg/5ml oral suspension THEOPH 
51480 qvar 100 autohaler (de pharmaceuticals) ICS 
51570 symbicort 200/6 turbohaler (de pharmaceuticals) LABA_ICS 
51593 seretide 500 accuhaler (de pharmaceuticals) LABA_ICS 
51681 qvar 100 inhaler (sigma pharmaceuticals plc) ICS 
51753 prednisolone 1mg tablets (co-pharma ltd) OCS 
51759 symbicort 200/6 turbohaler (mawdsley-brooks & company ltd) LABA_ICS 
51815 flixotide 250micrograms/dose evohaler (waymade healthcare plc) ICS 
51861 seretide 500 accuhaler (mawdsley-brooks & company ltd) LABA_ICS 
51909 seretide 250 evohaler (necessity supplies ltd) LABA_ICS 
51967 
spiriva 18microgram inhalation powder capsules (mawdsley-brooks & 
company ltd) LAMA 
52410 bricanyl 500micrograms/dose turbohaler (necessity supplies ltd) SABA 
52543 salbutamol 400microgram inhalation powder blisters SABA 
52732 pulmicort 0.5mg respules (necessity supplies ltd) ICS 
52799 salbutamol 400microgram inhalation powder blisters with device SABA 
52806 qvar 100 autohaler (lexon (uk) ltd) ICS 
53019 ventolin 2.5mg nebules (mawdsley-brooks & company ltd) SABA 
53057 flixotide 50micrograms/dose evohaler (lexon (uk) ltd) ICS 
53230 seretide 250 accuhaler (de pharmaceuticals) LABA_ICS 
53237 symbicort 400/12 turbohaler (de pharmaceuticals) LABA_ICS 
53283 seretide 100 accuhaler (waymade healthcare plc) LABA_ICS 
53297 ventolin 200micrograms/dose accuhaler (sigma pharmaceuticals plc) SABA 
53313 prednisolone 20mg/5ml oral suspension OCS 
53336 prednisolone 25mg tablets (a a h pharmaceuticals ltd) OCS 
53480 qvar 100 autohaler (stephar (u.k.) ltd) ICS 
53491 symbicort 200/6 turbohaler (sigma pharmaceuticals plc) LABA_ICS 
53761 
glycopyrronium bromide 55microgram inhalation powder capsules with 
device LAMA 
53982 
seebri breezhaler 44microgram inhalation powder capsules with device 
(novartis pharmaceuticals uk ltd) LAMA 
54118 prednisolone 25mg/5ml oral suspension OCS 
54151 glycopyrronium bromide 600micrograms/5ml oral suspension LAMA 
54207 qvar 50 inhaler (de pharmaceuticals) ICS 
54399 qvar 100 autohaler (sigma pharmaceuticals plc) ICS 
54432 lodotra 1mg modified-release tablets (napp pharmaceuticals ltd) OCS 
54434 prednisolone 2.5mg/5ml oral suspension OCS 
54742 salmeterol 25micrograms/dose inhaler cfc free (a a h pharmaceuticals ltd) LABA 
55024 prednisolone 5mg/5ml oral solution OCS 
55480 prednisolone 2.5mg gastro-resistant tablets (alliance pharmaceuticals ltd) OCS 
55677 seretide 500 accuhaler (lexon (uk) ltd) LABA_ICS 
55794 glycopyrronium bromide 5mg/5ml oral suspension LAMA 
55795 glycopyrronium bromide 500micrograms/5ml oral suspension LAMA 
55911 glycopyrronium bromide 500micrograms/5ml oral solution LAMA 
56262 glycopyrronium bromide 200micrograms/5ml oral solution LAMA 
56462 becodisks 400microgram (waymade healthcare plc) ICS 
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56471 becodisks 200microgram (mawdsley-brooks & company ltd) ICS 
56474 flixotide 125micrograms/dose evohaler (de pharmaceuticals) ICS 
56475 flixotide 50micrograms/dose accuhaler (sigma pharmaceuticals plc) ICS 
56477 flixotide 100micrograms/dose accuhaler (waymade healthcare plc) ICS 
56478 serevent 50micrograms/dose accuhaler (de pharmaceuticals) LABA 
56482 oxis 12 turbohaler (waymade healthcare plc) LABA 
56484 flixotide 250micrograms/dose accuhaler (waymade healthcare plc) ICS 
56493 qvar 50micrograms/dose easi-breathe inhaler (sigma pharmaceuticals plc) ICS 
56498 pulmicort 200 turbohaler (waymade healthcare plc) ICS 
56499 flixotide 500micrograms/dose accuhaler (waymade healthcare plc) ICS 
56604 Montelukast 4mg chewable tablets sugar free (Actavis UK Ltd) MONTELUKAST 
56756 
Montelukast 4mg granules sachets sugar free (A A H Pharmaceuticals 
Ltd) MONTELUKAST 
56891 prednisolone 1mg tablets (waymade healthcare plc) OCS 
57249 asmavent 100micrograms/dose inhaler cfc free (kent pharmaceuticals ltd) SABA 
57524 ventolin 200micrograms/dose accuhaler (dowelhurst ltd) SABA 
57525 flixotide 250micrograms/dose accuhaler (stephar (u.k.) ltd) ICS 
57544 serevent 50micrograms/dose accuhaler (waymade healthcare plc) LABA 
57555 flixotide 125micrograms/dose evohaler (dowelhurst ltd) ICS 
57557 atrovent 20micrograms/dose inhaler cfc free (lexon (uk) ltd) SAMA 
57558 oxis 6 turbohaler (lexon (uk) ltd) LABA 
57579 flixotide 50micrograms/dose accuhaler (de pharmaceuticals) ICS 
57589 becloforte 250micrograms/dose inhaler (dowelhurst ltd) ICS 
57694 vertine 25micrograms/dose inhaler cfc free (teva uk ltd) LABA 
58000 prednisolone 5mg tablets (almus pharmaceuticals ltd) OCS 
58061 prednisone 50mg tablets OCS 
58234 prednisolone 10mg/5ml oral solution OCS 
58269 airsalb 100micrograms/dose inhaler cfc free (sandoz ltd) SABA 
58369 prednisolone 5mg tablets (boston healthcare ltd) OCS 
58384 prednisolone 1mg tablets (almus pharmaceuticals ltd) OCS 
58987 
prednisolone 5mg gastro-resistant tablets (phoenix healthcare 
distribution ltd) OCS 
59173 glycopyrronium bromide 200micrograms/5ml oral suspension LAMA 
59229 
dilacort 5mg gastro-resistant tablets (auden mckenzie (pharma division) 
ltd) OCS 
59263 Montelukast 10mg tablets (Teva UK Ltd) MONTELUKAST 
59283 
dilacort 2.5mg gastro-resistant tablets (auden mckenzie (pharma division) 
ltd) OCS 
59327 
relvar ellipta 92micrograms/dose / 22micrograms/dose dry powder 
inhaler (glaxosmithkline uk ltd) LABA_ICS 
59338 prednisolone 1mg/5ml oral solution OCS 
59409 
salbutamol 100micrograms/dose inhaler cfc free (waymade healthcare 
plc) SABA 
59439 
fluticasone furoate 92micrograms/dose / vilanterol 22micrograms/dose 
dry powder inhaler LABA_ICS 
59573 
relvar ellipta 184micrograms/dose / 22micrograms/dose dry powder 
inhaler (glaxosmithkline uk ltd) LABA_ICS 
59638 
spiriva 18microgram inhalation powder capsules with handihaler (sigma 
pharmaceuticals plc) LAMA 
59819 Montelukast 10mg tablets (Actavis UK Ltd) MONTELUKAST 
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59899 
fluticasone furoate 184micrograms/dose / vilanterol 22micrograms/dose 
dry powder inhaler LABA_ICS 
59912 prednisolone 5mg gastro-resistant tablets (waymade healthcare plc) OCS 
59968 Montelukast 5mg chewable tablets sugar free (Teva UK Ltd) MONTELUKAST 
60331 Montelukast 10mg tablets (Ranbaxy (UK) Ltd) MONTELUKAST 
60421 prednisolone 5mg tablets (co-pharma ltd) OCS 
60920 atrovent 20micrograms/dose inhaler cfc free (sigma pharmaceuticals plc) SAMA 
60923 salamol 100micrograms/dose easi-breathe inhaler (de pharmaceuticals) SABA 
60937 pulmicort 200 turbohaler (dowelhurst ltd) ICS 
61132 prednisolone 1mg tablets (boston healthcare ltd) OCS 
61162 prednisolone 5mg tablets (waymade healthcare plc) OCS 
61176 
anoro ellipta 55micrograms/dose / 22micrograms/dose dry powder 
inhaler (glaxosmithkline uk ltd) LABA_LAMA 
61280 seretide 250 accuhaler (waymade healthcare plc) LABA_ICS 
61490 
umeclidinium bromide 65micrograms/dose / vilanterol 
22micrograms/dose dry powder inhaler LABA_LAMA 
61582 
spiriva respimat 2.5micrograms/dose solution for inhalation cartridge 
with device (waymade healthcare plc) LAMA 
61591 
salbutamol 100micrograms/dose inhaler cfc free (phoenix healthcare 
distribution ltd) SABA 
61644 
fostair nexthaler 100micrograms/dose / 6micrograms/dose dry powder 
inhaler (chiesi ltd) LABA_ICS 
61664 clenil modulite 250micrograms/dose inhaler (waymade healthcare plc) ICS 
61666 
duoresp spiromax 320micrograms/dose / 9micrograms/dose dry powder 
inhaler (teva uk ltd) LABA_ICS 
61689 prednisolone 5mg soluble tablets (a a h pharmaceuticals ltd) OCS 
61782 
duoresp spiromax 160micrograms/dose / 4.5micrograms/dose dry 
powder inhaler (teva uk ltd) LABA_ICS 
61879 
incruse ellipta 55micrograms/dose dry powder inhaler (glaxosmithkline 
uk ltd) LAMA 
62030 
beclometasone 100micrograms/dose / formoterol 6micrograms/dose dry 
powder inhaler LABA_ICS 
62109 umeclidinium bromide 65micrograms/dose dry powder inhaler LAMA 
62126 seretide 100 accuhaler (de pharmaceuticals) LABA_ICS 
62410 Montelukast 10mg tablets (Alliance Healthcare (Distribution) Ltd) MONTELUKAST 
62490 Montelukast 10mg tablets (A A H Pharmaceuticals Ltd) MONTELUKAST 
63457 Montelukast 5mg chewable tablets sugar free (Accord Healthcare Ltd) MONTELUKAST 
64648 Montelukast 10mg tablets (Milpharm Ltd) MONTELUKAST 
65038 Montelukast 10mg tablets (Accord Healthcare Ltd) MONTELUKAST 
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Codelist 4: Oral corticosteroid codes 
prodcode productname 
5913 Deltacortril 2.5mg gastro-resistant tablets (Alliance Pharmaceuticals Ltd) 
5490 Deltacortril 5mg gastro-resistant tablets (Alliance Pharmaceuticals Ltd) 
27962 Deltastab 1mg Tablet (Waymade Healthcare Plc) 
28859 Deltastab 5mg Tablet (Waymade Healthcare Plc) 
59283 Dilacort 2.5mg gastro-resistant tablets (Auden McKenzie (Pharma Division) Ltd) 
59229 Dilacort 5mg gastro-resistant tablets (Auden McKenzie (Pharma Division) Ltd) 
25272 Precortisyl 1mg Tablet (Hoechst Marion Roussel) 
23512 Precortisyl 5mg Tablet (Hoechst Marion Roussel) 
20095 Precortisyl forte 25mg Tablet (Aventis Pharma) 
58234 Prednisolone 10mg/5ml oral solution 
34914 Prednisolone 1mg Tablet (Celltech Pharma Europe Ltd) 
34631 Prednisolone 1mg Tablet (Co-Pharma Ltd) 
578 Prednisolone 1mg tablets 
34452 Prednisolone 1mg tablets (A A H Pharmaceuticals Ltd) 
34404 Prednisolone 1mg tablets (Actavis UK Ltd) 
58384 Prednisolone 1mg tablets (Almus Pharmaceuticals Ltd) 
61132 Prednisolone 1mg tablets (Boston Healthcare Ltd) 
51753 Prednisolone 1mg tablets (Co-Pharma Ltd) 
34660 Prednisolone 1mg tablets (Kent Pharmaceuticals Ltd) 
34748 Prednisolone 1mg tablets (Teva UK Ltd) 
56891 Prednisolone 1mg tablets (Waymade Healthcare Plc) 
34978 Prednisolone 1mg tablets (Wockhardt UK Ltd) 
59338 Prednisolone 1mg/5ml oral solution 
28376 Prednisolone 2.5mg Gastro-resistant tablet (Biorex Laboratories Ltd) 
557 Prednisolone 2.5mg gastro-resistant tablets 
28375 Prednisolone 2.5mg gastro-resistant tablets (A A H Pharmaceuticals Ltd) 
34461 Prednisolone 2.5mg gastro-resistant tablets (Actavis UK Ltd) 
55480 Prednisolone 2.5mg gastro-resistant tablets (Alliance Pharmaceuticals Ltd) 
2368 Prednisolone 2.5mg tablet 
54434 Prednisolone 2.5mg/5ml oral suspension 
38407 Prednisolone 20mg tablet 
53313 Prednisolone 20mg/5ml oral suspension 
2704 Prednisolone 25mg tablets 
53336 Prednisolone 25mg tablets (A A H Pharmaceuticals Ltd) 
41745 Prednisolone 25mg tablets (Zentiva) 
54118 Prednisolone 25mg/5ml oral suspension 
34109 Prednisolone 5 mg gastro-resistant tablet 
9727 Prednisolone 50mg tablets 
33691 Prednisolone 5mg Gastro-resistant tablet (Biorex Laboratories Ltd) 
44 Prednisolone 5mg gastro-resistant tablets 
31532 Prednisolone 5mg gastro-resistant tablets (A A H Pharmaceuticals Ltd) 
32803 Prednisolone 5mg gastro-resistant tablets (Actavis UK Ltd) 
58987 Prednisolone 5mg gastro-resistant tablets (Phoenix Healthcare Distribution Ltd) 
34393 Prednisolone 5mg gastro-resistant tablets (Teva UK Ltd) 
59912 Prednisolone 5mg gastro-resistant tablets (Waymade Healthcare Plc) 
45302 Prednisolone 5mg Tablet (Biorex Laboratories Ltd) 
33988 Prednisolone 5mg Tablet (Co-Pharma Ltd) 
33990 Prednisolone 5mg Tablet (IVAX Pharmaceuticals UK Ltd) 
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95 Prednisolone 5mg tablets 
21417 Prednisolone 5mg tablets (A A H Pharmaceuticals Ltd) 
29333 Prednisolone 5mg tablets (Actavis UK Ltd) 
58000 Prednisolone 5mg tablets (Almus Pharmaceuticals Ltd) 
58369 Prednisolone 5mg tablets (Boston Healthcare Ltd) 
60421 Prednisolone 5mg tablets (Co-Pharma Ltd) 
34781 Prednisolone 5mg tablets (Kent Pharmaceuticals Ltd) 
41515 Prednisolone 5mg tablets (Teva UK Ltd) 
61162 Prednisolone 5mg tablets (Waymade Healthcare Plc) 
32835 Prednisolone 5mg tablets (Wockhardt UK Ltd) 
55024 Prednisolone 5mg/5ml oral solution 
1063 Prednesol 5mg Tablet (Sovereign Medical Ltd) 
47142 Prednisolone 5mg Soluble tablet (Amdipharm Plc) 
955 Prednisolone 5mg soluble tablets 
61689 Prednisolone 5mg soluble tablets (A A H Pharmaceuticals Ltd) 
19141 Prednisolone 5mg soluble tablets (AMCo) 
31327 Prednisolone steaglate 6.65mg tablet 
3345 Sintisone Tablet (Pharmacia Ltd) 
21833 Decortisyl 5mg Tablet (Roussel Laboratories Ltd) 
54432 Lodotra 1mg modified-release tablets (Napp Pharmaceuticals Ltd) 
44803 Lodotra 2mg modified-release tablets (Napp Pharmaceuticals Ltd) 
44802 Lodotra 5mg modified-release tablets (Napp Pharmaceuticals Ltd) 
44380 Prednisone 1mg modified-release tablets 
3557 Prednisone 1mg tablets 
46711 Prednisone 2mg modified-release tablets 
58061 Prednisone 50mg tablets 
44723 Prednisone 5mg modified-release tablets 
43544 Prednisone 5mg Tablet (Knoll Ltd) 
2949 Prednisone 5mg tablets 
30971 DECORTISYL 25 MG TAB 
30390 DELTASTAB 2 MG TAB 
27889 PREDNISOLONE 
27959 PREDNISOLONE 
2799 PREDNISOLONE 10 MG TAB 
7710 PREDNISOLONE 15 MG TAB 
13522 PREDNISOLONE 2 MG TAB 
7584 PREDNISOLONE 4 MG TAB 
3059 PREDNISOLONE 50 MG TAB 
20670 PREDNISOLONE E/C 
24716 PREDNISOLONE E/C 
2390 PREDNISOLONE E/C 1 MG TAB 
13615 PREDNISONE 10 MG TAB 
2044 PREDNISONE 2.5 MG TAB 
7934 PREDNISONE 30 MG TAB 
16724 PREDNISONE 50 MG TAB 
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Codelist 5: Antihistamines 
prodcode productname 
56798 Lloydspharmacy Allergy Relief 2mg/5ml syrup (Lloyds Pharmacy Ltd) 
1549 Chlorphenamine 2mg/5ml oral solution 
23054 Ephedrine HCl with Chlorphenamine 4mg with 1mg/5ml oral solution sugar free 
1436 Haymine tablets (Chemidex Pharma Ltd) 
5732 Chlorphenamine 2mg/5ml oral solution sugar free 
28967 Expulin sugar free Oral solution (Shire Pharmaceuticals Ltd) 
9815 Pseudoephedrine 30mg/5ml / Chlorphenamine 2mg/5ml oral solution sugar free 
31525 Chlorphenamine 2mg/5ml oral solution sugar free (A A H Pharmaceuticals Ltd) 
8341 Galpseud Plus linctus (Thornton & Ross Ltd) 
46914 Chlorphenamine 4mg tablets (Vantage) 
961 Piriton 2mg/5ml Oral solution (Stafford-Miller Ltd) 
43415 Chlorphenamine 50mg/5ml oral solution 
16478 Hayleve 4mg tablets (Genesis Pharmaceuticals Ltd) 
30928 Chlorphenamine 10mg/1ml solution for injection ampoules (Kyowa Kirin Ltd) 
32962 Chlorphenamine 4mg tablets (Teva UK Ltd) 
27812 Chlorphenamine 4mg tablets (Sussex Pharmaceutical Ltd) 
13956 Ephedrine hydrochloride 15mg / Chlorphenamine 10mg tablets 
32240 Chlorphenamine 4mg tablets (Actavis UK Ltd) 
36589 Pollenase Allergy 2mg/5ml syrup (E M Pharma) 
71045 Chlorphenamine 4mg tablets (Bristol Laboratories Ltd) 
34136 Chlorphenamine 12mg modified-release tablets 
4423 Dichlorphenamide 50mg tablets 
58808 Chlorphenamine 4mg tablets (Waymade Healthcare Plc) 
61263 Boots Allergy Relief Antihistamine 4mg tablets (The Boots Company Plc) 
66342 Pseudoephedrine with chlorphenamine & pholcodine oral solution sugar free 
22801 Chlorphenesin 1% powder 
23076 Allerief 2mg/5ml oral solution (Orbis Consumer Products Ltd) 
22337 Pseudoephedrine with chlorphenamine & pholcodine oral solution 
29872 Chlorphenamine 4mg tablets (A A H Pharmaceuticals Ltd) 
18490 Phenylpropanolamine 50mg / Chlorphenamine 4mg modified-release capsules 
533 Piriton 4mg Tablet (Stafford-Miller Ltd) 
21435 Contac 400 modified-release capsules (GlaxoSmithKline Consumer Healthcare) 
55536 Chlorphenamine 4mg tablets (Strides Shasun (UK) Ltd) 
16181 Tixylix Cough & Cold oral solution (Novartis Consumer Health UK Ltd) 
12062 Daranide 50mg Tablet (MSD Thomas Morson Pharmaceuticals) 
884 Chlorphenamine 4mg tablets 
43521 Chlorphenamine 4mg Tablet (Family Health) 
11985 Piriton Allergy 4mg tablets (GlaxoSmithKline Consumer Healthcare) 
23875 Alunex 4mg Tablet (M A Steinhard Ltd) 
15757 Pholcodine 2mg with chlorphenamine 1mg/5ml oral solution sugar free 
686 Piriton 4mg tablets (GlaxoSmithKline Consumer Healthcare) 
1305 Chlorphenamine 10mg/1ml solution for injection ampoules 
37093 ALLERcalm Allergy Relief 4mg tablets (Actavis UK Ltd) 
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31639 Unichem allergy relief 4mg Tablet (Unichem) 
32443 Pollenase Antihistamine 4mg tablets (E M Pharma) 
28554 Expulin children's cough sugar free Oral solution (Shire Pharmaceuticals Ltd) 
60280 Chlorphenamine 4mg tablets (Alliance Healthcare (Distribution) Ltd) 
168 Piriject 10mg/ml Injection (Link Pharmaceuticals Ltd) 
61110 Numark Antihistamine 4mg tablets (Numark Ltd) 
59556 Chlorphenamine 4mg tablets (Sigma Pharmaceuticals Plc) 
27117 Calimal 4mg tablets (Sussex Pharmaceutical Ltd) 
36522 Expulin sugar free Oral solution (Shire Pharmaceuticals Ltd) 
42009 Chlorphenamine 4mg Tablet (Genesis Medical Ltd) 
2604 Piriton 12mg Spandets (Stafford-Miller Ltd) 
26744 Expulin decongestant sugar free Oral solution (Shire Pharmaceuticals Ltd) 
629 Piriton 2mg/5ml syrup (GlaxoSmithKline Consumer Healthcare) 
70953 Chlorphenamine 4mg tablets (Kent Pharmaceuticals Ltd) 
31818 Chlorphenamine 2mg/5ml oral solution sugar free (Sandoz Ltd) 
37834 Chlorphenamine 4mg tablets (Almus Pharmaceuticals Ltd) 
70310 
Chlorphenamine 10mg/1ml solution for injection ampoules (Alliance Healthcare 
(Distribution) Ltd) 
12590 PSEUDOEPHEDRINE 30MG/CHLORPHENIRAMINE2MG 
1849 CHLORPHENIRAMINE MALEATE S/R 8 MG TAB 
27227 CHLORPHENESIN .5 % OIN 
3555 CHLORPHENIRAMINE MALEATE S/R 12 MG TAB 
52138 Chlorphenesin 0.5% ointment 
2189 Acrivastine 8mg capsules 
10087 Pseudoephedrine 60mg / Acrivastine 8mg capsules 
5671 Benadryl Allergy Relief 8mg capsules (McNeil Products Ltd) 
9782 Benadryl Allergy Relief Plus Decongestant capsules (McNeil Products Ltd) 
3525 Semprex 8mg capsules (GlaxoSmithKline UK Ltd) 
46684 Bilastine 20mg tablets 
57004 Ilaxten 20mg tablets (A. Menarini Farmaceutica Internazionale SRL) 
40150 Cetirizine 1mg/ml Oral solution (Lagap) 
39743 Cetirizine 1mg/ml Oral solution (Ratiopharm UK Ltd) 
48222 Cetirizine 10mg capsules 
45266 Cetirizine 10mg tablets (Dexcel-Pharma Ltd) 
15946 Cetirizine 10mg tablets (A A H Pharmaceuticals Ltd) 
59329 Cetirizine 10mg tablets (Alliance Healthcare (Distribution) Ltd) 
29666 Cetirizine 10mg tablets (Sandoz Ltd) 
45253 Cetirizine 10mg tablets (Sterwin Medicines) 
40783 Levocetirizine 5mg tablets (Teva UK Ltd) 
5730 Levocetirizine 5mg tablets 
43133 Cetirizine 1mg/ml oral solution sugar free (Pinewood Healthcare) 
58379 Cetirizine 10mg tablets (Chanelle Medical UK Ltd) 
29459 Cetirizine 10mg Tablet (Niche Generics Ltd) 
25782 Cetirizine 1mg/ml oral solution sugar free (Teva UK Ltd) 
56903 Cetirizine 1mg/ml oral solution sugar free (Sandoz Ltd) 
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2916 Cetirizine 1mg/ml oral solution sugar free 
61275 Cetirizine 10mg tablets (Waymade Healthcare Plc) 
55492 Cetirizine 10mg tablets (Almus Pharmaceuticals Ltd) 
59752 Cetirizine 1mg/ml oral solution sugar free (Actavis UK Ltd) 
36093 Levocetirizine 500micrograms/ml oral solution sugar free 
33709 Cetirizine 1mg/ml oral solution sugar free (A A H Pharmaceuticals Ltd) 
59210 Cetirizine 10mg tablets (Bristol Laboratories Ltd) 
34538 Cetirizine 10mg tablets (Mylan) 
45239 Cetirizine 10mg tablets (Fannin UK Ltd) 
61064 Cetirizine 1mg/ml oral solution sugar free (Waymade Healthcare Plc) 
61174 Cetirizine 10mg tablets (Wockhardt UK Ltd) 
29297 Cetirizine 10mg tablets (Teva UK Ltd) 
20886 Cetirocol 10mg tablets (Teva UK Ltd) 
70993 Cetirizine 10mg tablets (DE Pharmaceuticals) 
36284 Cetirizine 1mg/ml Oral solution (Hillcross Pharmaceuticals Ltd) 
70 Cetirizine 10mg tablets 
62117 Cetirizine 10mg tablets (Dr Reddy's Laboratories (UK) Ltd) 
41965 Cetirizine 10mg tablets (Actavis UK Ltd) 
6103 Zirtek Allergy 10mg tablets (UCB Pharma Ltd) 
22759 Zirtek Allergy Relief for Children 1mg/ml oral solution (UCB Pharma Ltd) 
57584 Zirtek 5mg/5ml oral solution (Dowelhurst Ltd) 
19174 Benadryl allergy 1mg/ml Oral solution (Pfizer Consumer Healthcare Ltd) 
45627 Pollenshield Hayfever 10mg tablets (Actavis UK Ltd) 
5901 Xyzal 5mg tablets (UCB Pharma Ltd) 
33235 Hayfever and allergy relief 10mg Tablet (Herbal Concepts Ltd) 
38307 Pollenshield Hayfever Relief 10mg tablets (Actavis UK Ltd) 
9950 Piriteze Allergy 1mg/ml syrup (GlaxoSmithKline Consumer Healthcare) 
45710 Histease allergy relief 10mg Tablet (Dr Reddy's Laboratories (UK) Ltd) 
44121 Benadryl One A Day 10mg tablets (McNeil Products Ltd) 
10047 Hayfever and allergy relief 10mg Tablet (A A H Pharmaceuticals Ltd) 
50608 Zirtek 5mg/5ml oral solution (Sigma Pharmaceuticals Plc) 
31891 Galpharm Hayfever and Allergy Relief 10mg tablets (Galpharm International Ltd) 
36828 Xyzal 0.5mg/ml oral solution (UCB Pharma Ltd) 
30508 Zirtek Allergy Relief 10mg tablets (UCB Pharma Ltd) 
10097 Benadryl One A Day Relief 10mg tablets (McNeil Products Ltd) 
6348 Piriteze Allergy 10mg tablets (GlaxoSmithKline Consumer Healthcare) 
39668 Benadryl Allergy 1mg/ml oral solution (McNeil Products Ltd) 
25783 Cetec 10mg tablets (Herbal Concepts Ltd) 
35139 Benadryl Allergy Children's 6+ 1mg/ml oral solution (McNeil Products Ltd) 
6427 Zirtek Allergy 1mg/ml oral solution (UCB Pharma Ltd) 
67658 Allacan 10mg tablets (Bristol Laboratories Ltd) 
42470 AllerTek 10mg tablets (Ratiopharm UK Ltd) 
2734 Zirtek 1mg/ml Oral solution (UCB Pharma Ltd) 
63948 Benadryl Allergy Children's 1mg/ml oral solution (McNeil Products Ltd) 
51976 Benadryl Allergy Liquid Release 10mg capsules (McNeil Products Ltd) 
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69217 Benadryl Allergy One A Day 10mg tablets (McNeil Products Ltd) 
71144 Zirtek 5mg/5ml oral solution (Waymade Healthcare Plc) 
9780 Benadryl one a day 10mg Tablet (Pfizer Consumer Healthcare Ltd) 
68007 BecoAllergy 10mg tablets (Omega Pharma Ltd) 
1443 Zirtek 10mg tablets (UCB Pharma Ltd) 
54261 Midetorin 2.5mg/5ml oral solution (Actavis UK Ltd) 
39657 Neoclarityn 2.5mg/5ml oral solution (Merck Sharp & Dohme Ltd) 
5380 Desloratadine 5mg tablets 
66466 Desloratadine 5mg tablets (Actavis UK Ltd) 
42393 Desloratadine 2.5mg/5ml oral solution sugar free 
57636 Desloratadine 5mg tablets (A A H Pharmaceuticals Ltd) 
5362 Neoclarityn 5mg tablets (Merck Sharp & Dohme Ltd) 
5934 Desloratadine 2.5mg/5ml oral solution 
5910 Neoclarityn 2.5mg/5ml syrup (Schering-Plough Ltd) 
42298 Fexofenadine 120mg tablets (A A H Pharmaceuticals Ltd) 
68650 Fexofenadine 120mg/5ml oral suspension 
2602 Fexofenadine 120mg tablets 
37785 Fexofenadine 180mg tablets (Zentiva) 
67198 Fexofenadine 180mg tablets (Actavis UK Ltd) 
69999 Fexofenadine 180mg/5ml oral solution 
60103 Fexofenadine 120mg tablets (Kent Pharmaceuticals Ltd) 
55383 Fexofenadine 180mg tablets (Alliance Healthcare (Distribution) Ltd) 
9983 Fexofenadine 30mg tablets 
62861 Fexofenadine 180mg tablets (Dr Reddy's Laboratories (UK) Ltd) 
43978 Fexofenadine 180mg tablets (A A H Pharmaceuticals Ltd) 
65780 Fexofenadine 120mg tablets (Zentiva) 
69580 Fexofenadine 180mg tablets (PLIVA Pharma Ltd) 
63109 Fexofenadine 120mg tablets (Actavis UK Ltd) 
2161 Fexofenadine 180mg tablets 
64159 Fexofenadine 120mg tablets (Mylan) 
1084 Telfast 180mg tablets (Sanofi) 
2740 Telfast 120mg tablets (Sanofi) 
49112 Telfast 120mg tablets (Lexon (UK) Ltd) 
52190 Telfast 180mg tablets (Lexon (UK) Ltd) 
17036 Telfast 30mg tablets (Sanofi) 
51673 Telfast 120mg tablets (Necessity Supplies Ltd) 
52957 Telfast 180mg tablets (Necessity Supplies Ltd) 
13700 Terfinax 120mg Tablet (Ashbourne Pharmaceuticals Ltd) 
13330 Terfinax 60mg Tablet (Ashbourne Pharmaceuticals Ltd) 
1437 Triludan Forte 120mg tablets (Hoechst Marion Roussel) 
38112 Terfenor 30mg Tablet (IVAX Pharmaceuticals UK Ltd) 
944 Terfenadine 30mg/5ml suspension 
154 Terfenadine 60mg tablets 
21818 Histafen 60mg Tablet (Berk Pharmaceuticals Ltd) 
25091 Terfenor forte 120mg Tablet (IVAX Pharmaceuticals UK Ltd) 
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44870 Aller-eze clear 60mg Tablet (Novartis Consumer Health UK Ltd) 
36715 Seldane 120mg Tablet (Hoechst Marion Roussel) 
1444 Terfenadine 120mg tablets 
1405 Triludan 30mg/5ml sugar free Oral suspension (Hoechst Marion Roussel) 
63651 Terfenadine 120mg Tablet (Approved Prescription Services Ltd) 
30397 Histafen 120mg Tablet (Berk Pharmaceuticals Ltd) 
28639 Terfenadine 60mg Tablet (Lagap) 
32749 Terfenor 60mg Tablet (IVAX Pharmaceuticals UK Ltd) 
233 Triludan 60mg Tablet (Hoechst Marion Roussel) 
3027 Terfenadine 30mg tablets 
63647 Loratadine 10mg tablets (Almus Pharmaceuticals Ltd) 
34755 Loratadine 5mg/5ml oral solution (A A H Pharmaceuticals Ltd) 
45227 Loratadine 10mg tablets (Sandoz Ltd) 
55150 Clarityn Rapide Allergy 10mg tablets (Bayer Plc) 
1077 Clarityn 5mg/5ml syrup (Schering-Plough Ltd) 
30101 Loratadine 10mg tablets (Actavis UK Ltd) 
46501 Loratadine 10mg tablets (Ranbaxy (UK) Ltd) 
34304 Loratadine 10mg tablets (Mylan) 
70041 Loratadine 10mg tablets (Alliance Healthcare (Distribution) Ltd) 
51215 Loratadine 10mg oral lyophilisates sugar free 
68597 Loratadine 5mg/5ml oral solution (Mylan) 
26707 Clarityn Allergy 5mg/5ml syrup (Bayer Plc) 
92 Loratadine 10mg tablets 
26646 Galpharm Non-Drowsy Allergy Relief 10mg tablets (Galpharm International Ltd) 
34082 Non-drowsy allergy relief 5mg/5ml Oral solution (A A H Pharmaceuticals Ltd) 
69039 Loratadine 5mg/5ml oral solution (Mawdsley-Brooks & Company Ltd) 
34752 Loratadine 10mg tablets (Zentiva) 
33893 Loratadine 10mg tablets (Teva UK Ltd) 
1015 Clarityn 10mg Tablet (Schering-Plough Ltd) 
1554 Loratadine 5mg/5ml oral solution 
34753 Loratadine 10mg tablets (A A H Pharmaceuticals Ltd) 
34262 Loratadine 5mg/5ml oral solution (Teva UK Ltd) 
31364 Non-drowsy allergy relief Tablet (A A H Pharmaceuticals Ltd) 
36201 Hay-Rite Allergy 10mg tablets (Teva UK Ltd) 
34333 Loratadine 10mg Tablet (Niche Generics Ltd) 
67296 Loratadine 5mg/5ml oral solution (Kent Pharmaceuticals Ltd) 
57547 Clarityn 5mg/5ml syrup (Waymade Healthcare Plc) 
31177 Loratadine 5mg/5ml oral solution (Actavis UK Ltd) 
20162 Clarityn Allergy 10mg tablets (Bayer Plc) 
69887 Lorapaed Allergy Relief 5mg/5ml oral solution (Pinewood Healthcare) 
4311 Mizolastine 10mg modified-release tablets 
11417 Mistamine 10mg modified-release tablets (Galderma (UK) Ltd) 
9461 Mizollen 10mg modified-release tablets (Sanofi) 
47915 Omalizumab 150mg/1ml solution for injection pre-filled syringes 
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60113 
Xolair 75mg/0.5ml solution for injection pre-filled syringes (Novartis Pharmaceuticals 
UK Ltd) 
53289 
Xolair 150mg/1ml solution for injection pre-filled syringes (Novartis Pharmaceuticals 
UK Ltd) 
7550 Omalizumab 150mg powder and solvent for solution for injection vials 
69598 Omalizumab 75mg/0.5ml solution for injection pre-filled syringes 
41287 
Xolair 150mg powder and solvent for solution for injection vials (Novartis 
Pharmaceuticals UK Ltd) 
Codelist 6: COPD codes 
medcode term 
794 Emphysema 
998 Chronic obstructive airways disease 
1001 Chronic obstructive pulmonary disease 
4084 Airways obstructn irreversible 
5710 Chronic obstructive airways disease NOS 
9520 Chronic obstructive pulmonary disease monitoring 
9876 Severe chronic obstructive pulmonary disease 
10802 Moderate chronic obstructive pulmonary disease 
10863 Mild chronic obstructive pulmonary disease 
10980 Centrilobular emphysema 
11287 Chronic obstructive pulmonary disease annual review 
12166 Other specified chronic obstructive airways disease 
14798 Emphysematous bronchitis 
18476 COPD follow-up 
18621 Chronic obstructive pulmonary disease follow-up 
18792 Chronic obstructive pulmonary disease monitoring admin 
23492 Chronic bullous emphysema NOS 
26018 Chronic obstructive pulmonary disease monitoring by nurse 
26306 Chronic bullous emphysema 
28755 Chronic obstructive pulmonary disease monitoring 1st letter 
33450 Emphysema NOS 
34202 Chronic obstructive pulmonary disease monitoring 2nd letter 
34215 Chronic obstructive pulmonary disease monitoring 3rd letter 
37247 Chronic obstructive pulmonary disease NOS 
37371 Chronic obstructive pulmonary disease monitoring due 
38074 Chronic obstructive pulmonary disease monitor phone invite 
42258 Chronic obstructive pulmonary disease monitoring verb invite 
42313 Health education - chronic obstructive pulmonary disease 
44525 Obstructive chronic bronchitis NOS 
45770 Chronic obstructive pulmonary disease disturbs sleep 
45771 Chronic obstructive pulmonary disease does not disturb sleep 
45777 Chronic obstructive pulmonary disease clini management plan 
45998 Chronic obstructive pulmonary disease monitoring by doctor 
93568 Very severe chronic obstructive pulmonary disease 
Codelist 7: GORD 
medcode readterm 
19470 reflux cough 
7577 gastric reflux 
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592 oesophagitis 
2535 reflux oesophagitis 
15054 acid reflux 
7104 gastro-oesophageal reflux with oesophagitis 
16605 oesophageal reflux with oesophagitis 
15579 peptic oesophagitis 
16450 regurgitant oesophagitis 
4614 barrett's oesophagus 
14760 oesophagitis nos 
5596 barrett's ulcer of oesophagus 
25610 oesopheal reflux without mention of oesophagitis 
1327 oesophageal reflux 
984 gastro-oesophageal reflux 
2281 acid reflux 
Codelist 8: Atopy 
medcode readterm 
175 allergic rhinitis 
230 eczema nos 
334 allergic contact dermatitis 
610 infantile eczema 
619 skin:type 1 immediate reaction 
620 allergy, unspecified 
768 desensitisation to allergens 
774 chronic rhinitis 
775 allergic rhinitis due to unspecified allergen 
788 allergic conjunctivitis 
805 chronic catarrhal rhinitis 
964 allergic rhinitis nos 
1095 discoid eczema 
1240 flexural eczema 
1243 o/e - allergic rash 
1275 allergic reaction 
1424 infected eczema 
1468 perennial rhinitis 
1674 Chronic ethmoidal sinusitis 
1741 atopic dermatitis/eczema 
1838 allergic rhinitis due to pollens 
1930 house dust mite allergy 
1973 allergic drug reaction nos 
2011 acute atopic conjunctivitis 
2257 Chronic sinusitis 
2290 allergic asthma 
2372 allergic rhinitis due to other allergens 
3162 house dust allergy 
3699 hand eczema 
3798 hay fever - unspecified allergen 
4425 egg allergy 
4433 Chronic maxillary sinusitis 
4684 discoid eczema 
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4861 cat allergy 
4882 peanut allergy 
5437 Chronic sinusitis NOS 
5869 allergic (intrinsic) eczema 
6180 atopic dermatitis nos 
6274 allergic pharyngitis 
6399 contact dermatitis and other eczemas 
6400 allergic urticaria 
7146 extrinsic (atopic) asthma 
7179 cow's milk allergy 
7309 [v]personal history of aspirin allergy 
7426 allergic contact dermatitis due drugs in contact with skin 
7530 allergic reaction to bee sting 
7796 latex allergy 
10182 nut allergy 
10546 Chronic rhinosinusitis 
10840 neurodermatitis - atopic 
11132 allergic contact dermatitis due to adhesives 
11148 allergic reaction to venom 
11306 seen by clinical allergist 
11352 h/o: aspirin allergy 
12239 h/o: multiple allergies 
12382 allergy to animal 
13223 atopic dermatitis and related conditions 
13377 dander (animal) allergy 
13378 perfume contact dermatitis 
13401 allergic reaction to insect bite 
13408 allergic reaction to wasp sting 
13409 h/o: cat allergy 
14645 chronic rhinitis nos 
14688 other chronic allergic conjunctivitis 
15163 Chronic frontal sinusitis 
15722 allergy drug side effect 
15795 allergic enteritis 
16134 hay fever - other allergen 
16556 allergic purpura 
16676 acute allergic conjunctivitis 
16685 allergic dermatitis - eyelid 
16832 contact or allergic eyelid dermatitis 
17173 Recurrent sinusitis 
18207 allergic bronchitis nec 
18572 allergic rhinosinusitis 
19862 allergy skin test positive 
20023 allergic enterocolitis 
21232 allergic asthma nec 
22763 bronchial allergy challenge 
22764 [x]exacerbation of eczema 
28589 chronic simple rhinitis 
29458 allergy test positive 
29845 allergic otitis media nos 
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medcode readterm 
30157 under care of clinical allergist 
30375 feather allergy 
30664 allergic contact dermatitis due to food in contact with skin 
33820 allergic gastritis 
33959 allergic parotitis 
35086 allergic purpura nos 
37597 chronic allergic otitis media 
38383 allergic contact dermatitis due to dyes 
39501 Chronic pansinusitis 
41618 allergic contact dermatitis due to plants, except food 
46977 allergic alveolitis and pneumonitis nos 
47599 [x]other allergic rhinitis 
48703 Chronic sphenoidal sinusitis 
49548 Other chronic sinusitis 
53095 allergic alveolitis and pneumonitis nos 
53414 allergic eosinophilia 
54375 Other chronic sinusitis NOS 
59742 [x]allergic contact dermatitis due to other agents 
62442 allergic extrinsic alveolitis nos 
63733 [X]Other chronic sinusitis 
63780 acute allergic sanguinous otitis media 
70788 acute allergic serous otitis media 
72240 allergic arthritis of multiple sites 
72490 [x]other seasonal allergic rhinitis 
73453 [x]personal history of allergy to other antibiotic agents 
73749 allergic arthritis of other specified site 
73880 [x] adverse reaction to antiallergic and antiemetic drugs 
91301 [v]personal history of vitamin d3 allergy 
94213 oral allergy syndrome 
95938 dog allergy 
104056 acute allergic mucoid otitis media 
105338 allergen specific ige antibody level 
108904 Atopy 
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Codelist 9: Anxiety 
medcode readterm 
131 Anxiousness 
462 Panic attack 
514 Tension - nervous 
636 Anxiety states 
655 Anxiety with depression 
791 Nervous breakdown 
962 [X]Anxiety neurosis 
1582 Nervous exhaustion 
1758 Chronic anxiety 
2509 [D]Nervousness 
2524 Worried 
3076 Agoraphobia with panic attacks 
3328 General nervous symptoms 
4069 Panic disorder 
4081 [X]Panic state 
4534 Anxiety state NOS 
4634 Recurrent anxiety 
4659 Generalised anxiety disorder 
5385 [X]Other anxiety disorders 
5902 Anxiousness - symptom 
6221 Separation anxiety disorder 
6408 [X]Panic attack 
6939 Anxiety state unspecified 
7749 [X]Mild anxiety depression 
7999 Anxiety counselling 
8205 [X]Panic disorder [episodic paroxysmal anxiety] 
8424 [X]Anxious [avoidant] personality disorder 
8725 O/E - nervous 
10344 [X]Generalized anxiety disorder 
10390 Fear of death 
10723 [D]Nervous tension 
11890 C/O - panic attack 
11913 [X]Mixed anxiety and depressive disorder 
11940 Acute panic state due to acute stress reaction 
12838 Agoraphobia without mention of panic attacks 
13124 O/E - anxious 
14890 [X]Panic disorder with agoraphobia 
16729 [X]Agoraphobia without history of panic disorder 
17687 [X]Dream anxiety disorder 
19000 O/E - panic attack 
20089 General nervous symptom NOS 
20163 Apprehension 
23838 [X]Anxiety disorder, unspecified 
24066 [X]Other specified anxiety disorders 
25638 [X]Anxiety NOS 
26331 O/E - fearful mood 
28167 [X]Anxiety hysteria 
28381 Alleviating anxiety 
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28925 Referral for guided self-help for anxiety 
29608  
34064 [X]Phobic anxiety disorder, unspecified 
35825 [X]Anxiety reaction 
38155 O/E - afraid 
40431 Cries easily 
44321 [X]Other mixed anxiety disorders 
50191 [X]Anxiety state 
56924 Adjustment reaction with anxious mood 
93401 Anxious 
101422 Feeling low or worried 
Codelist 10: Depression 
medcode readterm 
2716 H/O: depression 
1996 Depressed 
4824 C/O - feeling depressed 
9796 Symptoms of depression 
10438 Depressive symptoms 
19439 Depression resolved 
18702 Postnatal depression counselling 
44848 Depression management programme 
30483 Patient given advice about management of depression 
12399 Depression annual review 
12122 Depression medication review 
30405 Depression interim review 
42931 On depression register 
44936 Removed from depression register 
48970 Exception reporting: depression quality indicators 
28970 Excepted from depression quality indicators: Patient unsuita 
43239 Excepted from depression quality indicators: Informed dissen 
30583 Depression - enhanced services administration 
65435 Depression - enhanced service completed 
96995 On full dose long term treatment depression - enh serv admin 
51258 Depression monitoring administration 
71009 Depression monitoring first letter 
72966 Depression monitoring second letter 
91105 Depression monitoring third letter 
88644 Depression monitoring verbal invite 
85852 Depression monitoring telephone invite 
2560 Depressive psychoses 
10610 Single major depressive episode 
5879 Agitated depression 
6546 Endogenous depression first episode 
6950 Endogenous depression first episode 
595 Endogenous depression 
34390 Single major depressive episode, unspecified 
16506 Single major depressive episode, mild 
15155 Single major depressive episode, moderate 
15219 Single major depressive episode, severe, without psychosis 
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32159 Single major depressive episode, severe, with psychosis 
43324 Single major depressive episode, partial or unspec remission 
57409 Single major depressive episode, in full remission 
7011 Single major depressive episode NOS 
15099 Recurrent major depressive episode 
6932 Endogenous depression - recurrent 
35671 Recurrent major depressive episodes, unspecified 
29342 Recurrent major depressive episodes, mild 
14709 Recurrent major depressive episodes, moderate 
25697 Recurrent major depressive episodes, severe, no psychosis 
24171 Recurrent major depressive episodes, severe, with psychosis 
56273 Recurrent major depressive episodes,partial/unspec remission 
55384 Recurrent major depressive episodes, in full remission 
6482 Recurrent depression 
25563 Recurrent major depressive episode NOS 
9183 Masked depression 
8478 Reactive depressive psychosis 
17770 Psychotic reactive depression 
1055 Agitated depression 
655 Anxiety with depression 
1131 Neurotic depression reactive type 
2639 Postnatal depression 
10455 Depressive personality disorder 
1533 Brief depressive reaction 
36246 Brief depressive reaction NOS 
16632 Prolonged depressive reaction 
324 Depressive disorder NEC 
2972 Postviral depression 
4323 Chronic depression 
20785 [X]Post-schizophrenic depression 
11055 [X]Schizoaffective disorder, depressive type 
35274 [X]Schizoaffective psychosis, depressive type 
41022 [X]Schizophreniform psychosis, depressive type 
4639 [X]Depressive episode 
9055 [X]Single episode of depressive reaction 
18510 [X]Single episode of psychogenic depression 
7604 [X]Single episode of reactive depression 
11717 [X]Mild depressive episode 
9211 [X]Moderate depressive episode 
9667 [X]Severe depressive episode without psychotic symptoms 
41989 [X]Single episode agitated depressn w'out psychotic symptoms 
22806 [X]Single episode major depression w'out psychotic symptoms 
59386 [X]Single episode vital depression w'out psychotic symptoms 
12099 [X]Severe depressive episode with psychotic symptoms 
24117 [X]Single episode of major depression and psychotic symptoms 
52678 [X]Single episode of psychogenic depressive psychosis 
24112 [X]Single episode of psychotic depression 
28863 [X]Single episode of reactive depressive psychosis 
10667 [X]Mild depression 
98346 [X]Major depression, mild 
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98252 [X]Major depression, moderately severe 
98414 [X]Major depression, severe without psychotic symptoms 
98417 [X]Major depression, severe with psychotic symptoms 
101054 [X]Single major depr ep, severe with psych, psych in remiss 
101153 [X]Recurr major depr ep, severe with psych, psych in remiss 
6854 [X]Other depressive episodes 
10720 [X]Atypical depression 
56609 [X]Single episode of masked depression NOS 
2970 [X]Depressive episode, unspecified 
543 [X]Depression NOS 
3291 [X]Depressive disorder NOS 
28248 [X]Prolonged single episode of reactive depression 
5987 [X] Reactive depression NOS 
3292 [X]Recurrent depressive disorder 
8851 [X]Recurrent episodes of depressive reaction 
19696 [X]Recurrent episodes of psychogenic depression 
8902 [X]Recurrent episodes of reactive depression 
28756 [X]Seasonal depressive disorder 
8826 [X]SAD - Seasonal affective disorder 
29784 [X]Recurrent depressive disorder, current episode mild 
29520 [X]Recurrent depressive disorder, current episode moderate 
33469 [X]Recurr depress disorder cur epi severe without psyc sympt 
11329 [X]Endogenous depression without psychotic symptoms 
11252 [X]Major depression, recurrent without psychotic symptoms 
29451 [X]Manic-depress psychosis,depressd,no psychotic symptoms 
73991 [X]Vital depression, recurrent without psychotic symptoms 
47009 [X]Recurrent depress disorder cur epi severe with psyc symp 
23731 [X]Endogenous depression with psychotic symptoms 
28677 [X]Manic-depress psychosis,depressed type+psychotic symptoms 
32941 [X]Recurr severe episodes/major depression+psychotic symptom 
31757 [X]Recurr severe episodes/psychogenic depressive psychosis 
16861 [X]Recurrent severe episodes of psychotic depression 
37764 [X]Recurrent severe episodes/reactive depressive psychosis 
22116 [X]Recurrent depressive disorder, currently in remission 
47731 [X]Other recurrent depressive disorders 
44300 [X]Recurrent depressive disorder, unspecified 
36616 [X]Monopolar depression NOS 
8584 [X]Depressive neurosis 
10290 [X]Depressive personality disorder 
7737 [X]Neurotic depression 
15220 [X]Persistant anxiety depression 
19054 [X]Recurrent brief depressive episodes 
11913 [X]Mixed anxiety and depressive disorder 
7749 [X]Mild anxiety depression 
13307 [X]Postnatal depression NOS 
4979 [X]Postpartum depression NOS 
32845 [X]Depressive conduct disorder 
 
 
